66th ASH Annual Meeting: Author Index A

A M, M.

1052 - Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia Α: Final Results from a Phase 1 Clinical Trial

A, M.

2150 - Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis – Need for Dose Intensification
4879 - EASIX_d0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis

A Safdar, O.

2008 - Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory Multiple Myeloma – a Meta-Analysis

Aakko, S.

1560 - Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
4265 - Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study

Aalbers, A.

3906 - Comprehensive Analysis of Diagnosis, Treatment and Outcome in a Retrospective Cohort of HES Patients in the South-West of the Netherlands between 2000-2020

Aamer, H.

2196 - Relieving Restriction in Resting CD8+ T Cells Increases Gene Transfer and Improves Tumor Killing after Transduction with CD8-Targeted CD19CAR Fusosome

Aarnink, A.

927 - Predictive Modeling of Hematopoietic Stem Cell Transplant Outcomes: Discovering the Role of Immunogenetic Features through Machine Learning Models

Aarons, D.

3799 - Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry

Aass, K. R.

4686 - Predictive Biosignature and Risk Scoring for Bone Disease in Multiple Myeloma

Ababneh, H.

5112 - Outcomes of Salvage Radiotherapy in Relapsed/Refractory Large B-Cell Lymphoma Patients Following CAR T-Cell Therapy Failure: A Multicenter Pooled Analysis

Abad, J.

2266 - The Mediating Effects of Racial and Social Health Disparities on Cancer Urgent Care Outcomes: An Urban Cancer Center Experience

Abadi, U.

866 - Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study
5124 - Epcoritamab for Relapsed/Refractory B Cell Lymphoma – the Israeli Real-World Experience of a Compassionate Use Program

Abadir, E.

4257 - WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Abagnale, D. P.

2463 - Advancing Diagnostic Accuracy and Lowering Idiopathic Erythrocytosis Rates through Next-Generation Sequencing

Abal García, R.

3593 - Automated Image Analysis Pipeline for Standardized Processing, Segmentation, and Feature Extraction in Diffuse Large B-Cell Lymphoma Histological Slides: Towards Enhanced Prediction of Immunotherapy Response and Risk Stratification
3606 - Smartcytoflow: A Machine Learning Decision Support System for Flow Cytometry Analysis in Non-Hodgkin Lymphoma Diagnosis and Screening

Abalo, K. D.

1623 - Plasma Proteomic Profiling Identifies Prognostic Biomarkers in Mantle Cell Lymphoma
1638 - Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy
2995 - Rule-Based Machine Learning Analysis of the Blood Proteome Identifies MCL Patients with High Risk of Early Disease Progression

Abankwah, D. N. Y.

2499 - Effectiveness of Hydroxyurea in Patients with Sickle Cell Disease in Ghana: A Population-Level, Healthcare Facilities–Based Study

Abasaeed, R.

4862 - Baseline Salivary Microbiota Predicts Severe Oral Mucositis after Allogeneic Hematopoietic Cell Transplantation
4880 - Differential Impact of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning on Supragingival Plaque Microbiota and Oral Mucositis after Allogeneic Transplantation

Abassi, N.

2536 - Deep Cellular and Molecular Characterization Reveal a Distinct Phenotype and Metabolic Signature of Human Senescent CD8⁺ T Cells: Implication for Cancer Cellular Therapy

Abate, S.

3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada

Abayasiriwardana, K.

358 - Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific Antibody Therapy and Leads to Durable Remission of Vk*MYC Multiple Myeloma

Abayomi, K.

667 - Multiple Myeloma Progression Is Accelerated By Microenvironmental-Derived Fatty Acid Binding Proteins 4 and 5 (FABP4/FABP5) in a Murine Model

Abaza, Y.

353 - Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
447 - Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
737 - Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients
1425 - Clinical and Molecular Characterization of TP53-Mutant Acute Lymphoblastic Leukemia
1487 - Leukemia Physician’s Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia
1787 - Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors
2801 - Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study
2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3225 - Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)
4282 - Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction
5174 - Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
2907.1 - A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Abba, M.

2670 - Primary Hematopoietic Cells of Vexas Patients Are Highly Sensitive to Treatment with TAK-243 and Pevonedistat
4143 - The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient’s NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CD123+ Leukemic Stem and Progenitor Cells in AML and MDS

Abbas, H. A.

Abbasi Sureshjani, S.

108 - Deep Learning Predicts Risk of Large B-Cell Lymphoma Progression upon R-CHOP Therapy from Baseline Histology

Abbazio, C.

4615 - Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up

Abbonante, V.

1165 - Silk Bone Marrow Niches to Model Fibrosis and Altered Megakaryopoiesis in Myeloproliferative Neoplasms
1169 - Altered Calcium Signaling Via STIM1 Drives Aberrant Megakaryopoiesis and Myelofibrosis

Abbott, D.

969 - Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
3803 - Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)
4259 - Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia
4266 - Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia

Abbott, N.

1993 - Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

Abbou, S. D.

3108 - Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study

Abboud, C. N.

224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Abboud, M. R.

179 - Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks

Abboud, R.

224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis

Abdalla, E.

5158 - Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Abdallah, A. O.

Abdallah, H.

1217 - Accuracy of a Bleeding Assessment Tool in Predicting the Diagnosis of an Inherited Bleeding Disorder: Systematic Review and Meta-Analysis

Abdallah, K.

1911 - Assessing the Efficacy and Safety of Reduced Dexamethasone Duration in Newly Diagnosed AL Amyloidosis Versus Standard Therapy

Abdallah, M.

- Time Management in Clinical and Research: There are only 24 Hours in a Day or Everyone Needs a System

Abdallah, N.

704 - Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
5143 - AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis
- Clinical Frailty Assessments and Biomarkers of Biological Aging

Abdallahi Lefdil, Z.

405 - The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC
3757 - Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT
5148 - Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Abdel Rahman, Z.

1260 - Evaluation of Risk Assessment Models for Predicting Venous Thromboembolic Events in Cancer Patients Using Implanted Central Venous Access Devices
2277 - Characteristics and Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A 14-Year Experience in a Limited Resource Setting
3797 - Genetic Profiling and Risk Stratification of Acute Myeloid Leukemia (AML): Comparative Analysis of the Jordanian AML Cohort (JAMLC) to the German-Austrian AML Study Group (AMLSG)
4465 - Dose-Adjusted EPOCH-R Is Superior to R-CHOP in Frontline Treatment of Mediastinal Large B-Cell Lymphoma

Abdel-Razeq, H.

1260 - Evaluation of Risk Assessment Models for Predicting Venous Thromboembolic Events in Cancer Patients Using Implanted Central Venous Access Devices
4465 - Dose-Adjusted EPOCH-R Is Superior to R-CHOP in Frontline Treatment of Mediastinal Large B-Cell Lymphoma

Abdel-Razeq, N.

111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1672 - Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study

Abdel-Wahab, O.

343 - Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms
371 - Development of CAR T Cells Targeting U5 snRNP200 for the Treatment of Acute Myeloid and B-Lymphoid Leukemias
637 - Cross-Talk between Leukemic Blasts and T Cells Drives Targetable T Cell Dysfunction in the AML Tumor Microenvironment
817 - Single-Cell Spatial Transcriptomics Identifies Lymphoid Aggregates with Location-Specific Alterations of Adaptive Immune Cells in Human MDS Bone Marrow
950 - Systematic Evaluation of GAPs and Gefs Identifies ARHGAP45 As a Targetable Leukemia-Specific Dependency
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1604 - Transcriptomic and Epigenomic Landscape of Hairy Cell Leukemia at Single-Cell Resolution
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
2070 - CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
3215 - Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies
4772 - Mitochondrial Augmentation of Hematopoietic Stem and Progenitor Cells As a New Therapeutic Approach for Myelodysplasia
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Abdelaziz, N.

3495 - CMV Reactivation Kinetics in Patients Undergoing Haploidentical Stem Cell Transplantation Using Low-Dose Post-Transplant Cyclophosphamide: A Single Center Experience

Abdelbaky, S. B.

2922 - A Rapid Diagnostic Assay to Detect a DNA Methylation Signature of Menin Inhibitor Response in Acute Myeloid Leukemia

Abdelfattah, N.

4461 - Use of Doxorubicin-Containing Regimens Is Not Associated with Hemolytic Complications in Severely G6PD Deficient Patients with Lymphoma

Abdelghani, E.

5199 - Motivations and Experiences of Physicians Who Pursued Hemostasis and Thrombosis Fellowship - a Survey Study

Abdelghany, S.

3495 - CMV Reactivation Kinetics in Patients Undergoing Haploidentical Stem Cell Transplantation Using Low-Dose Post-Transplant Cyclophosphamide: A Single Center Experience

Abdelhak, A.

4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Abdelhakeem, A.

4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Abdelhakim, H.

2141 - Impact of Conditioning Intensity on Outcomes after Allogeneic Related Donor HCT with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Acute Leukemia and Myelodysplastic Syndromes
3505 - Pattern, Incidence, and Outcomes of Invasive Fungal Infections after Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
3801 - Molecular Features of Acute Myeloid Leukemia in Hispanics: An Analysis from the Marrow Consortium
4065 - Immune Checkpoint Inhibitors Reverse the Mesenchymal Stromal Cell-Mediated Immunosuppression in Acute Myeloid Leukemia Microenvironment
4256 - Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
4860 - Impact of Conditioning Intensity on Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Patients with Acute Leukemia and Myelodysplastic Syndromes
5030 - The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Abdelhay, A.

2619 - Characterization of Bleeding in Thrombotic Thrombocytopenic Purpura Treated without Caplacizumab
2620 - Fetal and Maternal Morbidity in Pregnant Patients with Thrombotic Thrombocytopenic Purpura: A Nationwide Analysis
3912 - Hemophagocytic Lymphohistiocytosis in Pregnancy, a Systematic Review of Case Reports and Case Series

Abdelmagid, M.

244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
1797 - The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates
1798 - Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
3169 - Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts
3176 - Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Abdelmessieh, P.

2091 - Comparative Analysis of Dexamethasone-Enhanced Pre-Medication in Motixafortide-Induced Hematopoietic Stem Cell Mobilization for Multiple Myeloma: A Retrospective Study
2165 - Effects of Post-Transplant Cyclophosphamide on Outcomes of Allogeneic Stem Cell Transplant Are Different between Older and Younger Adult Patients: A Single Institutional Experience

Abdelmessieh, P.

1573 - Epigenetic Adaptation Promotes Cellular Resilience in Senescence-like AML Cells

Abdelmohsen, L.

294 - Higher Hemoglobin Level Correlates with Increased Tissue Oxygenation in a Comprehensive Profile of Hemorheology in Sickle Cell Disease
3876 - Dynamic Cerebral Autoregulation and Blood Pressure Oscillations Reveal the Severity of Autoregulatory Dysfunction in Sickle Cell Disease
3879 - Assessing the Impact of Cognitive Load on Resting State Tissue Oxygen Saturation in Adult Patients with Sickle Cell Disease

Abdelrahman, S.

233 - CDK9 Is a Vulnerability in GATA-3 Driven and MCL-1 Independent T-Cell Lymphomas

Abdelwahed, I.

3495 - CMV Reactivation Kinetics in Patients Undergoing Haploidentical Stem Cell Transplantation Using Low-Dose Post-Transplant Cyclophosphamide: A Single Center Experience

Abdi, Z.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Abdollahi, P.

4730 - Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Abdou, M. N.

3610 - Novel Plasma Cell-Free RNA-Based Liquid Biopsy Approach for CLL

Abdukadir, A.

2790 - EVOLVE205, a Highly Potent 2:1 CD20-Targeted CD2 Co-Stimulatory T Cell Engager Engineered for the Treatment of B Cell Malignancies and B Cell Autoimmune Diseases

Abdul Hay, M.

4602 - A Retrospective Cohort Study Evaluating Outcomes of Higher Risk MDS Treated with Hypomethylating Agents with or without Venetoclax Using International Working Group 2023 Response Criteria

Abdul Rahman, A.

4568 - Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)

Abdul-Hay, M.

212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
1440 - Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort

Abdul-Mumin, A.

392 - Determinants of Linkage to Care in a New Newborn Screening Care Program for Sickle Cell Disease in Ghana, West Africa

Abdulelah, A. A.

2421 - The Burden of Leukemia in the United States from 1990 to 2021

Abdulgawad, A.

2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access
3496 - Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation

Abdulhaleem, M.

4493 - Real World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Abdulhaq, H.

5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Abdulkarim, S.

4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Abdulla, F.

2482 - Bruton Tyrosine Kinase Inhibitor Rilzabrutinib Reduces Vaso-Occlusion and Markers of Inflammation and Adhesion in Transgenic Mice with Sickle Cell Disease
3866 - Oral Administration of Nitrous Oxide Reduces Acute Vaso-Occlusive Pain in Mice with Sickle Cell Disease

Abdullah, A.

3931 - Post-Injury Treatment with Rapid Intraosseous Injection of Lyophilized Synthetic Platelets Enhances Survival, Hemostasis, and Hemodynamics in a Rat Model of Liver Laceration

Abdullah, H. A.

2541 - The Quiet Defenders: Immunoglobulin Levels As Predictors of Mortality in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

Abdulmalik, O.

412 - A Novel Genome-Scale CRISPR-Cas12a Screen Identifies Ptpa As a Fetal Hemoglobin Regulator Via BCL11A

Abdulmalik, O.

173 - A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease – In Vivo Efficacy of Ilx-002 in Humanized Mice

Abdulsalam, A.

1599 - CD38-SADA, a Self-Assembling and Dis-Assembling Bispecific Fusion Protein for Two-Step Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma

Abdulsalam, M. M.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Abe, J. I.

4055 - Fetal-Derived B-1 Cells Can Reduce Atherosclerotic Progression in the Clonal Hematopoiesis Condition

Abe, M.

1884 - Steric Hindrance By APRIL in Binding of BCMA-Directed Bispecific Antibodies: A Novel Refractory Mechanism of BCMA-Directed Immunotherapies in Multiple Myeloma
4683 - Development of a Novel and Rapid Diagnostic Technique for Cardiac Amyloidosis Using Raman Spectroscopy

Abe, M.

1297 - Alpha 2-Adrenergic Agonist As a Novel Microenvironment-Directed Agent for Acute Myeloid Leukemia Via Notch Signaling Inhibition

Abe, T.

3988 - Treatment with a Novel Small Molecule Dual Factor IIa/Xa Inhibitor Protects Against Coagulopathy and Organ Dysfunction in a Baboon Model of Staphylococcus Aureus Sepsis

Abe, Y.

741 - Spatially Resolved Single-Cell Transcriptomics of T Cells in Follicular Lymphoma Reveals Distinct Immune Ecosystems

ABE, Y.

3292 - Single-Center Retrospective Analysis of Autologous Stem Cell Transplantation for Patients with Systemic Light Chain Amyloidosis

Abedi, M.

382 - Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies
694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
963 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes
1503 - Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia
2085 - A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3458 - Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence
4837 - Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)
4845 - Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Abedin, S.

212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
1039 - Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
2878 - A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4258 - Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy
5173 - CNS Status at Diagnosis Can Identify Acute Myeloid Leukemia Patients with Poor Induction Outcomes
2907.1 - A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02
3514.1 - OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Abedpour, N.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Abedu, P. M.

2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Abel, G.

448 - Frailty and Long-Term Survival Among Older Adults with Blood Cancers
792 - Impact of Fee-for-Service Versus Managed Care Medicare Insurance on the Quality of End-of-Life Care Among Older Adults with Blood Cancers
1831 - Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
4597 - Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes
5073 - Assessing the Contribution of Duffy Null Phenotype to Disparities in Eligibility Criteria for Clinical Trials for Newly-Diagnosed Colorectal Cancer
5171 - Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group
5205 - Moral Distress and Burnout Among Hematologists in Mexico: Results of a National Survey

Abel, L.

2216 - Proposed Use of the Microfluidic Impedance Red Cell Assay (MIRCA) to Identify Individuals with Sickle Cell Disease in Need of Second Line Therapies
5006 - Lapses in Appointment Attendance Among Children with Sickle Cell Disease in the First Five Years of Life

Abella, E.

1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Abelman, D. D.

3338 - Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma

Abelson, S.

1954 - Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study

Abelson, S.

2770 - Preclinical Activity of RAS(ON) Multi-Selective Inhibitor RMC-7977 and Therapeutic Combinations in AML with Signaling Mutations

Aberdeen, A.

2227 - AI-Driven Quantitation of Blast Cells and Vessel Density in Bone Marrow Biopsies Highlights Limitations of Manual Assessment

Åberg, M.

2212 - Mapping the Spatial Proteome of Individual Leukemia Cells Undergoing Fludarabine Treatment

Abeyakoon, C.

1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy

Abeyakoon, C.

571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Abeykoon, J. P.

613 - Assessment of Classical Hematologists and Hematology-Focused Fellowship Programs at NCI-Designated Cancer Centers: Implications for Addressing Workforce Shortages and Enhancing Mentorship Opportunities
2747 - Cyclin D1 Overexpression in Mantle Cell Lymphoma Causes Cellular Dependence on Microhomology-Mediated End-Joining
3181 - Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms
3910 - High Prevalence of Concomitant Autoimmunity in Patients with Rosai-Dorfman Disease
4563 - Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis
4564 - Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses

Abhyankar, S.

5033 - Continuity of Care for Patients with Chronic Lymphocytic Leukemia: An Analysis of Real-World Data
5114 - Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States

Abhyankar, S.

68 - Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
389 - Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients
3503 - Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis
3517 - Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
4823 - Inb-100: Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma Delta T Cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide
5030 - The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART

Abi Rached, R.

4526 - Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study

Abid, D.

536 - HEXIM1 Regulates Early Erythropoiesis and Participates in Multiple Complexes in Erythroid Cells

Abidi, S. A.

2008 - Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory Multiple Myeloma – a Meta-Analysis

Abildgaard, N.

3343 - Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study

Abillar-Wright, J.

1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Abío Calvete, M.

1131 - Non-Invasive Prenatal Diagnosis of Sickle Cell Disease in Spain

Abirached, J.

4817 - Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine

Abkowitz, J. L.

1293 - iPSC Reprogramming Identifies the Role of Cryptic Drivers in Preleukemic Clonal Evolution
4209 - Extended Follow-up of Dose-Adjusted EPOCH (DA-EPOCH) Plus Inotuzumab Ozogamicin (InO) in Adults with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Safe and Effective Salvage Therapy
- Role of Heme and Iron in Effective and Ineffective Erythropoiesis

Abla, F.

3909 - Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Abla, O.

3909 - Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Able, M.

1392 - Potent Activity of Duocarmyin- and Mmaf-Conjugated FLT3-Directed Antibody-Drug Conjugates Towards Acute Myeloid Leukemia Stem Cells in Vitro and In Vivo

Aboaid, H.

2390 - Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections (URTIs) and Venous Thromboembolism (VTE) in Patients with Multiple Myeloma Treated with Isatuximab

Abobarin-Aofolaju, O.

2343 - Medicaid Expansion and Cancer-Specific Survival Among Individuals with Acute Lymphoblastic Leukemia
2371 - Exploring the Intersectionality of Marital Status and Sex on Survival Outcomes in Non-Hodgkin’s Lymphoma

Abodunrin, F.

2343 - Medicaid Expansion and Cancer-Specific Survival Among Individuals with Acute Lymphoblastic Leukemia
2371 - Exploring the Intersectionality of Marital Status and Sex on Survival Outcomes in Non-Hodgkin’s Lymphoma

Aboismail, E.

3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
1674.3 - Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Abonour, R.

768 - Multiomics Data Integration in the Complete Myeloma Genome Reveals Frequent Centromeric Rearrangements and Their Epigenomic Consequences
1882 - Phylogenetic Analysis Reveals Distinct Evolutionary Patterns in Multiple Myeloma Patient Derived Xenografts
4644 - Reconstructing Catastrophic Chromothripsis Events Using Multiomic Data Reveals Their Functional Impact in Multiple Myeloma
4657 - Subclone-Aware Prognosis across Stages of Myeloma Progression and Course of Treatment

Aboobacker, F. N.

1052 - Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia Α: Final Results from a Phase 1 Clinical Trial

Aboreden, N.

537 - LDB1 Establishes Multi-Enhancer Networks to Regulate Erythroid Gene Expression
2740 - Defining Oncogenic Transcriptional Networks Regulated By LDB1 in T-Cell Acute Lymphoblastic Leukemia

Abosabie, S. A.

1228 - Phenotypic and Transcriptomic Profiling of MPN Endothelium

Abou Baker, N.

2246 - Pain Management in Patients with Sickle Cell Disease through an Inpatient Sickle Cell Disease Consult Service

Abou Chahla, W.

2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)

Abou Dalle, I.

851 - Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party
4945 - Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study

Abou El-Hasan, O.

3495 - CMV Reactivation Kinetics in Patients Undergoing Haploidentical Stem Cell Transplantation Using Low-Dose Post-Transplant Cyclophosphamide: A Single Center Experience

Abou Mourad, Y.

2919 - Survival Outcomes for Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) in a Real-World, Retrospective Cohort Receiving Intensive Chemotherapy

Abou Zeid, H. K.

1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis

Abou-Ismail, M. Y.

1227 - Clonal Persistence of Anti-PF4 Antibodies in VITT Represents an MGTS-like State
2619 - Characterization of Bleeding in Thrombotic Thrombocytopenic Purpura Treated without Caplacizumab

Abou-Ismail, M. Y.

2617 - Can Machine Learning Supplant the Plasmic Score in Improving the Early Diagnosis of Thrombotic Thrombocytopenic Purpura?

Abou-Jawde, R.

2367 - Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort

Aboualizadeh, F.

4995 - Single-Cell Proteogenomic Analysis of Clonal Evolution in Patient-Derived Xenograft Models of AML Treated with IDH Inhibitors

Abouelhoda, M.

4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population

Aboukameel, A.

2768 - Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia

Aboulafia, D.

3638 - Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar

Aboulafia, D. M.

573 - Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Abouqateb, M.

2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
3540 - Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party

Abousaida, B.

5170e - Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Abousoud, J.

4976 - Blood Preservation Workflows for Single Cell Technologies Using Off-the-Shelf Reagents

Abouzeid, A.

2785 - LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

Abow, A.

4995 - Single-Cell Proteogenomic Analysis of Clonal Evolution in Patient-Derived Xenograft Models of AML Treated with IDH Inhibitors

Abowali, H.

5170g - Multiple Myeloma (MM) Clinical Characteristics, Prognostic Factors and Survival in Adolescents and Young Adults (AYA)

Abraha, S.

1221 - Evaluation of Pharmacokinetics, Efficacy and Safety of a New Human Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency

Abraham, A.

647 - Rationalization of Anti-PD-1 Therapy Using Receptor Occupancy Data to Guide Drug Dosing – a Single Arm Phase II Trial Using Immunomodulation in Relapsed/Refractory Hodgkin Lymphoma
1052 - Factor VIII Expression from a Novel F8 Transgene through a Lentiviral Vector Transduced CD34+ Autologous Hematopoietic Stem Cells for Gene Therapy of Severe Hemophilia Α: Final Results from a Phase 1 Clinical Trial
2090 - Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)
2150 - Lower Mycophenolic Acid Exposure in Patients Undergoing Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide/ Cyclosporine a-Based GvHD Prophylaxis – Need for Dose Intensification
2585 - Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study
3048 - Dose Optimization of Check-Point Inhibitors: A Comparison of Standard Dose and Low Dose Nivolumab in Relapsed/Refractory Hodgkin Lymphoma
4879 - EASIX_d0 Predicts Early Transplant-Related Mortality in Patients Undergoing Haploidentical Transplantation with Post-Transplant Cyclophosphamide-Mycophenolate Mofetil-Based GvHD Prophylaxis

Abraham, C.

87 - Human IFN-α2- and PD-L1-Modified T Cells (αp-T cells) Inhibit Graft-Versus-Host Disease but Retain Anti-Leukemia Activity
2039 - Reprogramming T Cell EZH2 to Counteract CAR T Cell Dysfunction during Tumor Control
3430 - Inhibiting Tumor Cell CDK9 Reprograms Cell Death Pathways to Enhance Efficacy of CAR T Cell Therapy

Abraham, I.

2423 - Association of Neighborhood Crime with AML Molecular Subtypes and Survival
3794 - Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Abraham, L.

4806 - A Regulated Cytokine Engineering Strategy to Augment in Vitro and In Vivo persistence of Allogeneic iPSC Derived CD8 T-Cells

Abraham, R. M.

5024 - Haemophilia Rapid Card Test in Community Outreach Initiatives: Insights from a Single Centre in Kerala

Abraham, V.

4278 - Quantum-First: Deep-Dive Analysis of FMS-like Tyrosine Kinase 3–Internal Tandem Duplication (FLT3-ITD) Detection Methods Utilized for Enrollment and Longitudinal MRD Detection in Newly Diagnosed (nd) Patients (pts) with FLT3-ITD–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

Abraham-Miranda, J.

896 - Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma

Abrahamse-Testroote, M.

1013 - Improved Efficacy with Response- and MRD-Guided Ibrutinib–Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/Next STEP Phase 2 Trial

Abrahamsen, I. W.

4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Abrahamsson, J.

322 - Comparison of the WHO and ICC Classifications of Cytogenetic Abnormalities in Childhood Acute Myeloid Leukemia
323 - Measurable Residual Disease Monitoring during Treatment for Pediatric Acute Myeloid Leukemia in First Relapse Predicts Outcome
2809 - Allopurinol Add-on Treatment - Promising Approach to Opitimize Maintenance Therapy for Acute Lymphoblastic Leukemia in Children
2954 - Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with RUNX1::RUNX1T1
4994 - Ultra-Deep Sequencing and Single Cell Multi-Omics Characterize Measurable Residual Disease and Identify Therapy-Survived Clone in Pediatric Acute Myeloid Leukemia

Abrahao, R.

2360 - Identifying Disparities in Autologous Hematopoietic Cell Transplantation (autoHCT) Utilization for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in California

Abramashvili, M.

2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Abramova, R.

4198 - A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
4288.1 - A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Trial in Progress

Abramova, V.

3782 - Efficacy of Isa-Pom-Dex Therapy in Double Refractory Multiple Myeloma (MM) Patients in Real Clinical Practice

Abrams, C. S.

1753 - Pitpβ Loss Ameliorates Jak2 V617F-Induced Myeloproliferative Neoplasms (MPN) in Mice

Abrams, S. I.

4678 - Differences in Immune Cell Populations between Individuals with or without MGUS

Abramson, J. S.

72 - Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study
400 - Comparison between Vulnerable Elders Survey-13 and Comprehensive Geriatric Assessment in Predicting Clinical Outcomes in Aggressive Lymphomas
459 - A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
460 - Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
1669 - Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade
1729 - Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
3125 - Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3130 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up
4361 - Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma
4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up
5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study
3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Abreu, G. A.

5161 - Multiple Lines of Therapy and Progression to Next Lines in Multiple Myeloma Patients: Real-World Studies in Argentina (TOTEMM-A) and Brazil (TOTEMM-B)

Abreu, M.

4377 - Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy
4506 - Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

Abrisqueta Costa, P.

471 - Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
3009 - Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma
3109 - Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience
4478 - A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Abrisqueta, P.

1698 - Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo
1715 - Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study
4403 - Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study
4422 - Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?

Abro, E. U.

51 - Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

Abruzzese, E.

242 - Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study
995 - FATE and Role of Peripheral Blood CD26+ Leukemia STEM CELLS at Diagnosis in Chronic Myeloid Leukemia Patients: FINAL Results of Prospective Flowers Study
1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy
2435 - The Impact of Ponatinib on Pregnancy Outcomes
3158 - ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
4530 - Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study
4532 - Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study
4539 - Results of the Molecular Response Evaluation and TKI Dose Adjustment in Chronic Myeloid Leukemia Patients in Prospective Study of Reduction and Discontinuation Treatment of TKI (READIT)

Absar, N.

3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Abu Abed, N.

4465 - Dose-Adjusted EPOCH-R Is Superior to R-CHOP in Frontline Treatment of Mediastinal Large B-Cell Lymphoma

Abu Haimed, A.

3618 - Lower Emergency Severity Index Assignment Results in Faster Time to First Analgesia in Patients with Sickle Cell Disease

Abu Jazar, H.

2277 - Characteristics and Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A 14-Year Experience in a Limited Resource Setting

Abu Shanab, L.

3797 - Genetic Profiling and Risk Stratification of Acute Myeloid Leukemia (AML): Comparative Analysis of the Jordanian AML Cohort (JAMLC) to the German-Austrian AML Study Group (AMLSG)

Abu-Farsakh, Y.

1473 - Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
1488 - A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience
2848 - Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience
2862 - Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study
2868 - Outcomes of Blast-Phase MPN and JAK2, MPL, and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2, MPL, and CALR Genes: A Propensity Score-Adjusted Cohort Study
4248 - Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study
4249 - Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience
4297 - The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Abu-Shihab, Y.

2921 - BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML

Abu-Zeinah, G.

1761 - MPN Fitness: A Single-Cell, Single-Tube Measurement of the Pathobiology of MPNs
1764 - Hematopoietic Bias Drives Lymphopenia in Myeloproliferative Neoplasms
1784 - Outcomes Are Similar for Combination Interferon and Ruxolitinib Versus Ruxolitinib in Myelofibrosis: A Propensity-Score Matched Study
3172 - Advanced Pulmonary Hypertension Shortens Survival in Polycythemia Vera
3190 - DNMT3A Mutations Do Not Affect Treatment Response or Outcomes for Patients with Polycythemia Vera Treated with Interferon Alpha
3600 - Deep Learning Predicts JAK2, Calr TET2, and ASXL1 directly from Whole Slide Marrow Images
3613 - Correlating Image-Level Nucleomorphologic Features with Molecular Subtypes of Myeloproliferative Neoplasms
4558 - Validating the MPN Personalized Risk Calculator in 475 Patients with Polycythemia Vera
4568 - Ropeginterferon Alfa-2b (ROPEG) and Peginterferon Alfa-2a (PEG) at Low Dose with Response-Based Titration (LDRT) Have Comparable Efficacy and Tolerability in Polycythemia Vera (PV)
3191.1 - HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

Abuamsha, H.

1473 - Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
1488 - A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience
2848 - Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience
2862 - Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study
2868 - Outcomes of Blast-Phase MPN and JAK2, MPL, and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2, MPL, and CALR Genes: A Propensity Score-Adjusted Cohort Study
4248 - Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study
4249 - Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience
4297 - The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Abuasab, T.

3727 - Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Hodgkin Lymphoma in a Safety-Net Health System
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Abufara, A.

4465 - Dose-Adjusted EPOCH-R Is Superior to R-CHOP in Frontline Treatment of Mediastinal Large B-Cell Lymphoma

Abuhelwa, Z.

4589 - The Argument for Targeted Therapy in IDH1 Mutated Myelodysplastic Syndromes (MDS): Poor Outcomes Post-Hypomethylating Agent Failure in Higher Risk MDS and Reduced Leukemia Free Survival in Lower Risk MDS
4692 - Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy

Abuhelwa, Z.

2004 - Predictive Markers for Outcomes after Disease Progression Post BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma

Abuin Blanco, A.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia
5148 - Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Abunasser, M.

1260 - Evaluation of Risk Assessment Models for Predicting Venous Thromboembolic Events in Cancer Patients Using Implanted Central Venous Access Devices

Acedo Dominguez, N.

2555 - Early Treatment Use of Fostamatinib for Immune Thrombocytopenia (ITP): Efficacy and Safety As Second/Third ITP Treatment Lines in Clinical Practice in Spain

Acera Gómez, M.

405 - The Impact of Frailty on Outcomes and Quality of Life in Allogeneic Hematopoietic Cell Transplantation: Summary of Results from a Collaborative Prospective Study Conducted on Behalf of the Geth-TC
5148 - Frailty and Outcomes in Multiple Myeloma Patients Eligible for Autologous Hematopoietic Cell Transplantation: A Prospective Study of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)

Acevedo-Calado, M.

767 - Single-Cell Multi-Omic Profiling of Patients with BCMA-Targeted Therapy Identifies Molecular and Cellular Factors Associated with Responsiveness and Treatment Effects
1584 - Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis
3272 - Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma
4640 - Elucidation of Molecular Mechanisms of Iberdomide and Mezigdomide Resistance in Cell Line Models of Multiple Myeloma
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Acha, P.

666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Acha, P.

879 - Unveiling ZMAT2 and SMARCD3 As Therapeutic Targets to Mitigate Aberrant Hematopoiesis in MDS
2709 - Association of Clonal Hematopoiesis and Dysgranulopoiesis with Germline ETV6 Carriers without Hematological Malignancies
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

Acharya, C.

3258 - Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment
4658 - Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis

Acharya, S.

1216 - Athn 10 – Novel Variants in Persons with Rare Coagulation Disorders across Hemophilia Treatment Centers in the United States
1223 - Use of Low Dose Tranexamic Acid in Patients with Bleeding Disorders
4015 - Systematic Review of Pediatric Venous Thromboembolism Associated with Inferior Vena Cava (IVC) Anomalies

Achebe, M. O.

162 - Cost-Effectiveness of Universal Duffy Testing at 9-12 Months: An Effort Towards Equity in Interpreting Absolute Neutrophil Counts (ANC)
2531 - Multinational Assessment of Absolute Neutrophil Counts and White Blood Cell Counts Among Healthy Individuals with the Duffy Null Phenotype or Genotype
- How Inappropriate Reference Ranges Can Propagate Systemic Racism
- Implications for Ongoing Clinical Research in SCD and Drug Development

Achenbach, S.

397 - Prevalence, Genetic Predispositions and Clinical Consequences of Non-CLL-Type MBL: Screening in 10,330 Individuals

Achille, A.

1906 - De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression
1995 - Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study
4645 - The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma

Achrekar, A. R.

852 - Machine Learning Identifies Gene Mutations and Variant Allele Fractions That Refine the 2022 European Leukemianet Risk Stratification for Acute Myeloid Leukemia
1550 - Prognostic Significance of Wilms’ Tumor 1 Gene Mutations in Acute Myeloid Leukemia: Risk Stratification and Survival Outcomes
2931 - Double Trouble: Composite Mutations in Driver Genes in Acute Myeloid Leukemia (AML)
2953 - Leukemic Stem Cell Measurable Residual Disease (LSC MRD) Status Is a Better Predictor of Relapse Than Multiparametric Flowcytometric Analysis in Acute Myeloid Leukemia Patients
4290 - Mutational Landscape and Factors Affecting Prognosis in Acute Myeloid Leukaemia (AML) with RUNX1::RUNX1T1
4310 - Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia (AML)

Achter, E.

3783 - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval

Ackbarali, S.

5087 - Challenges in PNH and CAD Management Revealed through Educational Interventions over Three Years

Ackbarali, T.

3662 - Systems-Based Care Improvements to Optimize BTK Inhibitors in Chronic Lymphocytic Leukemia Vary in the Community Setting
5087 - Challenges in PNH and CAD Management Revealed through Educational Interventions over Three Years

Acker, J.

- Canada Blood Banking Perspective on Stored Red Blood Cell Quality and Its Assessment

Ackerman, B.

3763 - Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma

Acosta Fleitas, C.

598 - HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Acosta Maldonado, B. L.

4452 - Extranodal NK/T-Cell Lymphoma in Latin America: A Retrospective Multinational Analysis of Clinical Features, Therapeutic Approaches and Outcomes from the Latin American Group of Lymphoproliferative Disorders (GELL)
5205 - Moral Distress and Burnout Among Hematologists in Mexico: Results of a National Survey

Acosta Medina, A. A.

4563 - Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis
4564 - Efficacy of Small Molecule Kinase Inhibitors in Histiocytic Neoplasms with Non-BRAFV600E Mutations: Concordance of Pre-Clinical Predictions to Clinical Responses

Acs, K.

1548 - Efficacy of the Peptide Drug Conjugates Melflufen and OPDC3 in Venetoclax Resistant Acute Myeloid Leukemia

Acs, K.

4648 - Deciphering Variability in Light Chain Amyloidosis and Amyloidosis with Co-Occurring Multiple Myeloma By Single-Cell RNA Sequencing

Acuña, P.

2569 - B-Cell Distribution in Immune Thrombocytopenia and Its Relation to Ageing
3977 - Concizumab As a Possible Treatment for Bleeding Disordersof Unknown Cause

Acuña-Cruz, E.

2874 - A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)

Acúrcio, R. C.

4664 - Characterizing the Multiple Myeloma Bone Marrow Microenvironment at the Single-Cell Level in a Preclinical Model

Adabala, J.

2261 - Routine Screening of African American Males in Hematology Oncology Clinic for G6PD Deficiency: A Prospective Comparative Study of a Pharmacogenomic Panel Versus Standard Enzyme Assay

Adabra, S.

5107 - Barriers to CAR-T Therapy Adoption: Comparing Access in Academic and Community Settings in the US

Adachi, A.

4515 - Cbl^Q367P Cooperates with Loss of Tet2 to Drive a Cnl-like Disease Via the NF-Kb Pathway

Adachi, S.

4537 - Growth Retardation and Adult Height in Children with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Adalsteinsson, V.

2031 - Early MRD Detection after CAR-T Associated with Poor Outcome in Patients with Large B-Cell Lymphoma

Adam, J.

1120 - Transcriptomic Profiling Supports the Phenotypic Classification of Stable-State Sickle Cell Disease Patients

Adamczewska-Wawrzynowicz, K.

1462 - Chromothripsis Is Enriched at Relapse of Childhood B-Cell Precursor Acute Lymphoblastic Leukemia and Cooccurs with Loss of Function of TP53 and RB1 Genes

Adami, D.

4975 - Autonomous Region-of-Interest Detection, Cell Segmentation and Cell Classification in Bone Marrow Cytomorphology Using Deep Learning

Adamia, S.

4817 - Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine

Adamo, A.

421 - Tolerance of Whole Genome Duplication in Megakaryocytes, and Consequences for Their Genome Integrity
2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Adams, B.

982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Adams, B.

4905 - Abatacept and Post Transplant Cyclophosphamide Based Regimen for Graft Versus Host Disease Prevention in High-Risk Stem Cell Transplantation from Unrelated Donor Is Safe and Feasible, with Low Non- Relapse Mortality

Adams, C.

4510 - Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Adams, D.

4980 - Novel Machine Learning Approaches Tailored to Protein Configuration Predict Drug Vulnerabilities in Myeloid Neoplasia

Adams, M.

1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Adams, M.

3969 - Strategies for Increasing Racial and Ethnic Diversity in Hemophilia Clinical Trials and Their Outcomes

Adams, P.

383 - Memory T-Cell Add Back and Prophylactic blinatumomab Post Tcrαβ Depleted Haploidentical Transplantation Results in Promising Outcomes in Pediatric Patients with High-Risk Acute Leukemia
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia

Adams, R.

4620 - Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

Adams, R.

1802 - Efficacy and Tolerability of Trametinib in Adults with Histiocytic Neoplasms

Adams, S.

2202 - In Utero mRNA Lipid Nanoparticle Delivery in a Murine Model of Fanconi Anemia
4069 - Metabolic Rewiring of AML-Experienced Hematopoietic Stem and Progenitor Cells

Adams, S.

550 - T Cell Clonality in Paediatric Immune Thrombocytopenia
2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia

Adamson, A.

4033 - Characterization of a Colony Stimulating Factor Receptor (CSF1R) Upstream Regulatory Element in Haematopoiesis

Adamson, B.

2367 - Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort

Addada, J.

3085 - Excellent Outcomes with Brentuximab-Nivolumab for Relapsed/ Refractory Primary Mediastinal B-Cell Lymphoma in the Real-World Setting

Ade, C. P.

3287 - Novel NOTCH1 Effector NFIL3 Is a Therapeutic Target to Combat Drug Resistance and Improve Patient Outcomes in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma

Ade-Odunlade, D.

522 - Enhanced Artificial Intelligence (AI)-Driven Prediction of Vaso-Occlusive Crises in Sickle Cell Disease: Precision through Advanced Machine-Learning Frameworks and Digital Remote Monitoring

Adedokun, B.

526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
527 - Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Adegbite, B. O.

4735 - Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Adegunsoye, A.

2502 - Triaging Acute Chest Syndrome Clinical Decision-Making Using Bedside SaO₂/FiO₂ Ratio

Adekola, K.

6 - Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study
110 - Representation of Minorities in Therapeutic Clinical Trials – a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)

Adélaïde, J.

1378 - Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study

Adelaja, A.

2600 - Primary Care Screening for Von Willebrand Disease in African American Adolescents with Heavy Menstrual Bleeding
3710 - Measuring the Utility of the Adolescent Menstrual Bleeding Questionnaire (aMBQ) in a Culturally Diverse Adolescent Population

Adell, K.

3924.1 - Trials in Progress: A Phase 3 Study to Investigate Efficacy, Safety, and Tolerability of Mavorixafor in Participants with Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders

Adelman, K.

540 - STAT5 Facilitates Terminal Erythroid Maturation in Concert with the Integrator Complex

Adelmann, H.

100 - Safety and Efficacy of the Glucagon-like Peptide 2 (GLP-2) Analog Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease (aGvHD) in Combination with Best Available Therapy: Results from a Multicenter, Randomized, Single-Blind, Proof-of-Concept, Phase 2 Stargaze Trial

Adema, V.

50 - A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4⁺ T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy
153 - Pharmacological Targeting of the Heme-Regulated Inhibitor Kinase Overcomes Ineffective Erythropoiesis in Patients with Myelodysplastic Syndromes with Ringed Sideroblasts and Sickle Cell Disease

Ademokun, C.

2457 - Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results
2497 - Combined Red Cell and Plasma Exchange Is Associated with Reduced Mortality of Fat Embolism Syndrome in Sickle Cell Disease

Adeniran, L.

1265 - Cardiovascular Outcome of Heart Failure Patients with Iron Deficiency Anemia Who Received Iron Infusion Vs Red Blood Cell Transfusion: Analysis from a Nationwide Trinetx Database

Adeoye, T.

2343 - Medicaid Expansion and Cancer-Specific Survival Among Individuals with Acute Lymphoblastic Leukemia
2371 - Exploring the Intersectionality of Marital Status and Sex on Survival Outcomes in Non-Hodgkin’s Lymphoma

Ades, L.

351 - Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
737 - Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients
1839 - Enasidenib (ENA) Monotherapy in Patients with IDH2 mutated Myelodysplastic Syndrome (MDS), the Ideal Phase 2 Study By the GFM and Emsco Groups
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
3174 - DNA Methylation Profiling Reveals Multiple Hits in MAPK Pathway in Triple Negative MDS/MPN with SF3B1 Mutation and Thrombocytosis
3222 - A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study
4311 - IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AML
4316 - Prognostic Significance of Monocytic-like Phenotype in AML Patients Treated with Venetoclax and Azacytidine
4513 - JAK Inhibition Results in Aggressive Cutaneous Squamous Cell Carcinoma through MAPK Pathway Activation and Shapes the Tumor Immune Microenvironment to Create Novel Therapeutic Opportunities

Adesina, O.

1127 - Identification of Clinical Sub-Phenotypes of Sickle Cell Disease Using Latent Class Analysis
3900 - Low Bone Density Associates with Severe Outcomes in Young Adults with Sickle Cell Disease
- Adult Classical Hematology

Adewale, O.

3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis

Adeyemo, T. A.

178 - A Phase 1b/2 Study of the Efficacy and Safety of Combination Hydroxyurea and Dose-Escalated Erythropoietin for Treatment of Anemia in Sickle Cell Disease (ACHiEvE-SCD)

Adeyeye, J.

4964 - Development of Humanized Antibodies Against Vasoactive Intestinal Polypeptide for Increased T Cell Anti-Leukemia Activity

Adhikari, S.

416 - CEBPA Regulates Molecular Kinetics of RNA Polymerase I in Myeloid Progenitors

Adhikary, S.

4193 - Impact of Disease Burden, CAR-T Expansion, and Mononuclear Cell Recovery on Overall Response and Duration of Response in Zuma-3 Pivotal Study

Adil, S. N.

3324 - Impact of Pre-Transplant Depth of Response on Outcomes in Patients with Multiple Myeloma: A Report on Behalf of Pakistan Blood and Marrow Transplant Group

Adili, R.

182 - An Important Role for P-Selectin in Thrombotic Microangiopathy
184 - HDL and HDL-Mimetic Nanoparticles Prevent Induced TTP and Interrupt the Course of Ongoing Episodes of the Disease
3864 - Erythrocytes from Sickle Cell Mice Activate the Endothelium and Blood Cells and Induce Vaso-Occlusion When Transfused into ADAMTS13-Deficient Mice: Role of Lipid Degradation

Adintori, P.

259 - Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical Gvhd Models
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
4943 - Dietary Sucrose Exacerbates Antibiotic-Induced Microbiome Injury in Allo-HCT

Adiyodi, J.

1802 - Efficacy and Tolerability of Trametinib in Adults with Histiocytic Neoplasms

Adjinkpang, S.

392 - Determinants of Linkage to Care in a New Newborn Screening Care Program for Sickle Cell Disease in Ghana, West Africa

Adkins, S.

4506 - Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

Adkins, T.

291 - Integrative Strong Body and Mind Training for Sickle Cell Disease (I-STRONG)—an Interdisciplinary, Multicomponent Treatment Approach for Pediatric Chronic SCD Pain

Adlowitz, D. G.

2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages

Admiak, M.

4034 - The Pro-Mobilizing Effects of UDP-Glucose—P2Y14 Purinergic Receptor Signaling Are Explained By Promoting Membrane Lipid Raft Formation to Optimize Hspcs' Responsiveness to Chemoattractants—a Potential Strategy to Optimize Hematopoietic Transplantation and Improve Transplant Outcomes

Adnan-Awad, S.

1780 - Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

Adnot, S.

2511 - Evaluation of Sleep Apnea in Adult Sickle Cell Disease; About 107 SS and Sβ°Thal Patients

Adolph, L.

2957 - High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies

Adomakoh, Y. D.

606 - An e-Health Pain Assessment Tool Incorporating Animations and Images Is Feasible and Useful for Patients in a Ghanaian Sickle Cell Disease Cohort

Adrianzen Herrera, D.

702 - Impact of Thrombosis and Bleeding on Survival of Older People with Myelodysplastic Syndromes (MDS): A Population Analysis
5180 - Erythropoietin Stimulating Agents and Risk of Cardiovascular Events in Older Patients with Myelodysplastic Syndromes

Adroja, S.

1716 - Primary Vitreoretinal Lymphoma with or without Intracranial Involvement: A Single Center Experience
5131 - Statins May Improve Outcomes and Toxicities in Patients Undergoing CD19-Specific CAR T-Cell Therapy for Aggressive B-Cell Lymphomas

Adu, E.

290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project

Adu, Y.

3771 - Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma (MM) Patients: Real-World Learnings from a Large, Prospective Study

Adubi, O.

2343 - Medicaid Expansion and Cancer-Specific Survival Among Individuals with Acute Lymphoblastic Leukemia
2371 - Exploring the Intersectionality of Marital Status and Sex on Survival Outcomes in Non-Hodgkin’s Lymphoma

Adusumalli, S.

2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Advani, A. S.

308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
1473 - Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
1488 - A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience
1777 - Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study
1840 - PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study
2414 - Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024
2848 - Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience
2862 - Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study
2868 - Outcomes of Blast-Phase MPN and JAK2, MPL, and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2, MPL, and CALR Genes: A Propensity Score-Adjusted Cohort Study
3153 - Impact of Non-ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia
4184 - The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
4221 - Impact of TP53 Mutation on Survival Outcomes in Acute Lymphoblastic Leukemia at a Tertiary Center
4248 - Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study
4249 - Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience
4297 - The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience
4838 - BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic Anti‑CD7 CAR-T-Cells

Advani, R. H.

570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
1664 - Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy
3045 - Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results
3068 - Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma
4369 - Comprehensive Characterization of the Cell States and Ecosystems in Classic Hodgkin Lymphoma Using Single-Cell RNA-Seq, Digital Deconvolution, and Machine Learning
4425 - Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)
4431 - Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD) for Classical Hodgkin Lymphoma (CHL) in the Real-World Setting
1718.1 - SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)
- When Should We Use It? The Role of Brentuximab Vedotin in 2024

Aerts, G.

3664 - Remote Patient Monitoring for Early Detection of Cytokine Release Syndrome in Myeloma Patients: A Comparative Study between Standard Care and Remote Monitoring

Afaq, Y.

3791 - CAR-T Therapy Showdown: Comparative Efficacy and Safety of of Ide-Cel (Idecabtagene vicleucel) and Cilta-Cel (Ciltacabtagene Autoleucel) in Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Study
5160 - Risk of Infection: Real-World Analysis of (Ide-cel) Idecabtagene Vicleucel and (Cilta-cel) Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Afari-Dwamena, N. A.

1204 - ATHN Transcends Hemophilia Natural History Arm: Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia A and B

Affer, M.

4333 - Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML

Afghahi, A.

3808 - Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2

Afonja, O.

4955 - Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial

Afonso, C.

4718 - Predicting Caregiver Burden in Multiple Myeloma: Insights from the Carmma Study Using Machine Learning Models

Afonso, M.

2256 - Relationship between Frequency of Treatment Administration, Adherence to Treatment, and Quality of Life in Patients with Hemophilia a or Hemophilia B, with or without Inhibitors: A Real-World Survey
2262 - Real-World Analysis of Healthcare Resource Utilization in Patients with Hemophilia a and B with or without Inhibitors Using Data from Disease Specific Programmes™
2314 - Unmet Needs in People with Hemophilia Receiving Prophylaxis Treatment: A Real-World Survey

Afonso, R.

1125 - First-Year Outcomes of Newborn Sickle Cell Disease Screening in an Angolan Hospital

Afonso, S.

4718 - Predicting Caregiver Burden in Multiple Myeloma: Insights from the Carmma Study Using Machine Learning Models

Afram, G.

1024 - Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
3320 - Outcomes of Relapsed and Refractory Multiple Myeloma with the Evolving Standard of Care

Afranie-Sakyi, J. A.

2249 - Screening for Cognitive Impairment and Depression in Sickle Cell Disease: How Are We Doing?
2442 - Buprenorphine Knowledge and Attitudes Among Sickle Cell Disease Providers
3628 - Buprenorphine & Sickle Cell: How Pediatric and Adult Providers Differ in Prescribing Habits and Evolving Pain Management Styles
5009 - Implementation of American Society of Hematology (ASH) Neuro-Related Guidelines at a Sickle Cell Center: How Are We Doing?

Afriat, A.

4 - Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Afridi, S.

4244 - Does Time Matter from Diagnosis to Induction in Acute Myeloid Leukemia?

Afrin, M.

3536 - Spatial Characterization of Molecular Pathways Suggests the Dysregulation of LGR5 Expressing Fibroblasts in Patients with sclerodermatous Chronic Graft-Vs-Host Disease

Afrin, N.

4705 - Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma

Afrough, A.

861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
933 - Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
5170e - Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Afrough, A.

936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
3370 - First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
3792h - Upfront Use of Anti-CD38 Monoclonal Antibodies Is Associated with Improvement in Renal Failure in Multiple Myeloma: A Flatiron Real World Analysis from 2010 to 2023
4712 - Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Afshar-Kharghan, V.

3926 - Large Scale Manufacturing of GMP Grade Cord Blood Derived Megakaryocytes for Chemotherapy Induced Thrombocytopenia

Aftandilian, C.

531 - Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)
2846 - GWAS Identifies Pharmacogenetic Markers Associated with Premedication-Related Pegaspargase Hypersensitivity and Toxicities in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma
4204 - A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia

Afzal, A.

814 - Elimination of Modifiable Risk Factors for Anticoagulant-Related Bleeding in Patients with Cancer Reduces the Probability of Bleeding
5091 - Association of Anticoagulant Therapy with Bleeding in Patients with Chronic Liver Disease: A Case-Cross over Study Using the National Veterans Health Administration Database

Afzal, S.

3334 - Absolute Risk of Multiple Myeloma Is Quite Modest in Individuals with Incidentally Discovered Vertebral Fractures: A Prospective Cohort Study of 9,065 CT-Scanned Danish General Population Individuals with Independent Validation in a UK General Population Cohort

Agadzhanian, N.

1412 - Targeting β-Catenin Protein Degradation in Refractory B-Cell Malignancies
4125 - Identification of High-Efficiency β-Catenin Protein Degradation As Critical Vulnerability in B-Cell Malignancies
4164 - Identification of Nuclear NAD+ Salvage As a Therapeutic Vulnerability in B-Lymphoid Malignancies

Agarwal, A.

860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1649 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study

Agarwal, A.

2774 - Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia

Agarwal, A.

198 - CD74 Signaling Regulates Inflammatory Stress to Drive Defective Hematopoiesis and Fitness Advantage of Progenitors in RUNX1-Familial Platelet Disorder

Agarwal, G.

1909 - A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data

Agarwal, M.

16 - Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)
4181 - Kinetics of Blast Clearance in Cerebrospinal Fluid (CSF) Detected on Flow Cytometric Immunophenotyping (FCM), but Negative By Cytopathology in Newly Diagnosed Acute Lymphoblastic Leukemia Patients

Agarwal, N.

69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
911 - CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma

Agarwal, N.

2115 - A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy
2131 - A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

Agarwal, R.

2015 - Evaluation of Bone Marrow in Fanconi Anemia Patients Treated with Briquilimab Antibody-Based Conditioning and TCRαβ⁺ T-Cell/CD19⁺ B-Cell Depleted Haploidentical Grafts
3525 - T-allo10 Immunotherapy Results in Enhanced Early Immune Reconstitution and Reduced GvHD with Excellent Clinical Outcomes Post Αβ-Depleted HSCT in Pediatric and Young Adult Hematologic Malignancy Patients

Agarwal, S.

4433 - Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Agarwal, S.

297 - Development and Validation of a Risk Assessment Model for Venous Thromboembolism in the Pediatric Intensive Care Unit
1256 - Venous Thromboembolism in Individuals with Sickle Cell Disease- a Retrospective Review of This Understudied Problem
2600 - Primary Care Screening for Von Willebrand Disease in African American Adolescents with Heavy Menstrual Bleeding
5199 - Motivations and Experiences of Physicians Who Pursued Hemostasis and Thrombosis Fellowship - a Survey Study

Agarwal, S.

443 - Engineered Telomerase RNA Component (eTERC), a Potential Lncrna Medicine to Extend Replicative Lifespan and Telomere Length in Dyskeratosis Congenita Patient Stem Cells
4971 - Targeting Metabolism to Restore Hematopoiesis in Inherited Bone Marrow Failure Syndromes: Preclinical Insights from Zebrafish Models

Agarwal, Y.

5059 - Analysis of Factors Influencing Enrollment Success in Hematology Malignancy Cancer Clinical Trials (2008-2023)

Agasti, S.

807 - The Ectopyrase CD73 Is a Critical Checkpoint in Thromboinflammation

Agatep, B.

3728 - Duration of Therapy in Patients with Waldenström Macroglobulinemia Undergoing Dose Reductions of First-Line Ibrutinib: A Real-World Analysis

Agathangelidis, A.

975 - Structural and Functional Analysis of the Clonotypic B Cell Receptor Immunoglobulin in Splenic Marginal Zone Lymphoma: Ontogenetic and Therapeutic Implications

Agathocleous, M.

436 - The Role of Canonical Glycolytic Endpoints in the Development and Function of Hematopoietic Stem and Progenitor Cells
1280 - The Cell-Type-Specific Essentiality of the Tricarboxylic Acid (TCA) Cycle in the Hematopoietic System

Agathon, D.

1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
3575 - Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec
3577 - Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety

Agbadiba, E. C.

4425 - Concomitant Use of Antibiotics During Immune Checkpoint Inhibitor (CPI)-Based Salvage Therapy Does Not Impact Post-ASCT Outcomes in Patients with Relapsed/Refractory Hodgkin Lymphoma (RRHL)

Agbedia, O.

- Targeting Aggressive NK-Cell Leukemia and Other CD94-Expressing NK/T-Cell Lymphoproliferative Disorders with CAR T-Cell Therapy

Agbor-Enoh, S.

648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders

Agbuduwe, C.

1960 - Automated Body Composition Analyses Reveal Significant Associations with Mortality in Myeloma Patients Following Immunotherapy with Bispecific Antibodies

Agdamag, A.

2660 - Gut Microbiota Promote Chronic Inflammation in Jak2^V617F Mice

Age Kos, I.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Agersborg, S.

1946 - Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)
3316 - Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)
4295 - Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)
4367 - Establishing Lymphoma Type-Specific Cytokine Signatures Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)

Aggarwal, B.

350 - Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent–Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial

Aggarwal, N.

4094 - T Lymphopenia and Aged Immune System Characterize Immunodeficiency in Adult Patients with Telomere Biology Disorders

Aggarwal, P.

2407 - Cytomegalovirus Infections Following CAR T-Cell Therapy: A Systematic Review and Meta-Analysis

Aggarwal, R.

878 - TGF-β1-SMAD2 Axis Regulates Hematopoiesis and β-Globin Gene Expression Via Super-Enhancer Associated Chromatin Reorganization
3200 - Environmental Pollution Is Associated with Higher Risk MDS in a Diverse Urban Cohort and Triggers Inflammation in a Murine Models

Agha, A.

2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Aghaallaei, N.

4967 - Modulating G-CSFR Signaling Using De Novo Designed Cytokines

Aghanya, V.

4432 - Anthracycline Exposure and Breast Cancer Risk in Female Hodgkin Lymphoma Survivors

Agirre, X.

670 - An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited
1889 - Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses

Agirrezabal, I.

2582 - Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a

Agis, H.

1967 - Real World Efficacies of First Line Treatments in Non-Transplant-Eligible Newly Diagnosed (ND-NTE) Multiple Myeloma (MM) Patients: A Challenge to Maia ? an Analysis from the Austrian Myeloma Registry (AMR)
3328 - An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Agius, M. P.

155 - Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Agius, P.

247 - Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
4740 - Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)

Agius, R.

4609 - Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Agnarsson, B.

1015 - Differential Detection of Clonal Bone Marrow Plasma Cells in IgA Vs. IgG Monoclonal Gammopathy of Undetermined Significance and Its Association with Disease Progression

Agnelli, L.

4656 - Single Cell Transcriptomics on Bone Marrow Biopsies Unveils Peculiar Bone Microenvironment Cell Subtypes and Highlights Alterations Correlated with High-Risk Features in Precursor Monoclonal Gammopathies and Multiple Myeloma Patients

Agostinelli, C.

1620 - Impaired rRNA Synthesis Contributes to BCL-2 Induced Chemoresistance in Diffuse Large B-Cell Lymphoma

Agostinho, D.

796 - Post-Partum Hemorrhage in Sub-Saharan Africa: A Prospective, Multi-Faceted Intervention Study in Metropolitan Mozambique

Agrawal, A.

1661 - Safeguarding Lungs: Evaluating Pneumocystis Pneumonia Prophylaxis in Lymphoma Patients Receiving Rituximab-Inclusive Therapies

Agrawal, A.

4639 - Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia

Agrawal, A. K.

2846 - GWAS Identifies Pharmacogenetic Markers Associated with Premedication-Related Pegaspargase Hypersensitivity and Toxicities in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma

Agrawal, N.

3154 - Response Adapted Dasatinib De-Escalation Strategy Compared to Upfront Low-Dose Dasatinib: A Prospective Cohort Study

Agrawal, N.

1765 - Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Agrawal, S.

1640 - Waldenström Macroglobulinemia: A Retrospective Survival Analysis Study from SEER Database

Agrawal, S. P.

4931 - Impact of Cannabis Use on Clinical Outcomes in Bone Marrow Transplant Patients: A Nationwide Analysis
4951 - Ulcerative Colitis and Adverse Outcomes in Hematopoietic Stem Cell Transplantation: A Nationwide Analysis

Agrawal Singh, S.

190 - Delayed Trp53 Activation Protects Dnmt3a-Mutant Haematopoietic Stem Cells from Inflammatory Attrition
722 - Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation

Agrawal, V.

729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
966 - CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study
1440 - Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort
2278 - Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Agreiter, C.

881 - Ly6C⁺ Inflammatory Monocytes Create a Leukemia-Initiating Niche

Agrippa, O.

522 - Enhanced Artificial Intelligence (AI)-Driven Prediction of Vaso-Occlusive Crises in Sickle Cell Disease: Precision through Advanced Machine-Learning Frameworks and Digital Remote Monitoring
2339 - Feasibility of Advanced Remote Health Monitoring in Waldenstrom Macroglobulinemia: Integrating Wearable Technology and Digital Quality of Life Tracking
4557 - Mympnvoice – a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms
5071 - Comparison of Sickle Cell Disease Patient Experiences in Developed and Developing Countries: Insights from UK and India Patient Cohorts
5072 - A Virtual Hospital Approach in Sickle Cell Disease | Remote Biometric, Quality of Life, and Hospitalisations Monitoring

Agten, S.

2603 - Citrullination in the C-Terminus of Tissue Factor Pathway Inhibitor-Alpha Impairs the Inhibition of Factor V Activation, and the Synergy with Protein S in Factor Xa Inactivation

Aguayo-Hiraldo, P.

380 - Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Agudelo, C.

1943 - Prognostic Impact of Measurable Residual Disease Evaluated By Next Generation Flow and PET-CT in Clinical Practice at Fundación Santa Fe De Bogotá Hospital, Colombia

Aguero, P.

616 - Efficacy of a Concise Training Curriculum for the Joint and Activity Damage Exam (J.A.D.E) to Facilitate International Harmonization of Musculoskeletal Ultrasound in Hemophilia
3965 - Assessment of Annual Rate Changes of Intraarticular Tissue Measurements in Hemophilic Joints Experiencing Acute Bleeding Using the Joint Activity Damage Exam (JADE) Ultrasound Protocol

Aguet, F.

4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Aguiar, E.

2894 - Improved Real-World Outcomes of Patients with Acute Promyelocytic Leukemia Treated with First-Line Arsenic Trioxide in Specialized Centers in Portugal through a 24/7 Phone-Based Referral: A Study from the Portuguese Acute Leukemia Group

Aguilar, C.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Aguilar, J.

842 - Clinical and Molecular Characteristics of RAS and RAS-like Mutational Signature in Acute Myeloid Leukemia
1540 - Clonal Evolution of TP53 Configurations with Treatment Predict Prognosis in Myeloid Neoplasms
4254 - Longitudinal Sequencing to Investigate Clonal Evolution in Myeloid Neoplasms

Aguilar, J. J.

2768 - Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia

Aguilar, O. A.

4646 - CD48: Friend or Foe in NK-Cell Immunosurveillance of Multiple Myeloma?

Aguilar-Martinez, P.

794 - uRADAR: European Patients Referral Frame to Improve Access to New Drugs and Therapies in Ultra-Rare Anemia Disorders and Severe Hereditary Spherocytosis

Aguilar-Meseguer, E.

3850 - Homozygous C282Y Hereditary Hemochromatosis: Evolution and Prognosis in a Cohort of Patients Followed up over 30 Years

Aguilar-Monserrate, G.

3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

Aguilar-Navarro, A.

2678 - Chemotherapy-Induced Bone Defects Stem from Skeletal Progenitor Dysfunction

Aguilera, C.

4390 - Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Aguinaga, K.

118 - The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe

Aguinaga, L.

351 - Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study
4316 - Prognostic Significance of Monocytic-like Phenotype in AML Patients Treated with Venetoclax and Azacytidine

Aguirre Arrizabalaga, M. A.

713 - Avespa Study: Effectiveness and Safety of Avatrombopag in Immune Thrombocytopenia (ITP). a Real-World Study of the Spanish ITP Group (GEPTI)

Aguirre, C.

3463 - Alloreactive Vs IL15 Ex Vivo Stimulated Natural Killer Cells As Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Acute Leukemia: A Phase I/II Clinical Trial

Aguirre, L. E.

1508 - Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia
1845 - Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 (SF3B1^del5q): Outcomes and Response to Treatment
2947 - The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia – an International Multicenter Cohort Study
4267 - Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes
5175 - Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy

Aguirre, L. E.

4281 - Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities

Aguirre, M. A.

1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis

Aguirre Muñoz, V. Y.

3946 - Iron Deficiency in Immune Thrombocytopenia: Are We Doing Enough?
4189 - Vincristine Dose Adjustments in Acute Lymphoblastic Leukemia: Impact on Treatment Outcomes and Neuropathy

Aguirre-Ghiso, J. A.

4137 - Targeting PERK Arm of Unfolded Protein Response Helps to Eliminate Therapy-Induced Residual Senescent-like Acute Myeloid Leukemia Cells

Aguirre-Ruiz, P.

1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies
1889 - Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses

Aguliar, A.

5128 - Mortality after Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

Agullo, C.

365 - Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial
4694 - Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma

Agullo, C.

489 - Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis

Ahearne, M.

3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
4445 - Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study

Ahire, D.

4512 - Role of HMGA2 Overexpression Caused By Specific Genetic HMGA2 Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients
4520 - High-Resolution Chromosomal Microarrays Reveals Exon-Level Deletion in Chromosome 12q14.3 in Patients with Myeloproliferative Neoplasms

Ahlgren, L.

2769 - Unraveling How Treatment Shapes Clonal Evolution and Resistance in Murine KMT2A-Rearranged Leukemia with Subclonal Kras^G12D

Ahlgrimm, M.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Ahlman, M.

2958 - Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study

Ahlstrom, J. M.

283 - National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma
706 - Patient-Centered Care in Hematology: How Side Effect Severity Influences Decision-Making Autonomy in Relapsed Refractory Multiple Myeloma
3786 - Satisfaction and Experiences with Talquetamab: Results from Qualitative Patient and Physician Research
5143 - AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis
5144 - First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

Ahmad, E.

1130 - Trends and Disparities in Sickle Cell Disease-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database
3947 - Trends and Disparities in Idiopathic Thrombocytopenic Purpura-Related Mortality in the United States: A Retrospective Study over Two Decades
5103 - Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database

Ahmad, I.

1502 - UM171 Cord Blood Transplantation for TP53 Mutated and EVI1 Rearranged Myelodysplasia/Acute Myeloid Leukemia
4916 - Long Term Follow up of UM171 Expanded Cord Blood Transplantation Patients Does Not Reveal Any Late Toxicity

Ahmad, M.

1022 - Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light‑Chain (AL) Amyloidosis
4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Ahmad, O.

3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Ahmad, R. U.

2008 - Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory Multiple Myeloma – a Meta-Analysis

Ahmad, S.

3791 - CAR-T Therapy Showdown: Comparative Efficacy and Safety of of Ide-Cel (Idecabtagene vicleucel) and Cilta-Cel (Ciltacabtagene Autoleucel) in Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Study
5160 - Risk of Infection: Real-World Analysis of (Ide-cel) Idecabtagene Vicleucel and (Cilta-cel) Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Ahmad, S.

1130 - Trends and Disparities in Sickle Cell Disease-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database
5103 - Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database

Ahmad-Fakri, A. Z.

1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)

Ahmadi, T.

773 - Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
2998 - Epcoritamab Induces in Vitro-Derived Terminally Differentiated Exhausted T Cells to Kill B Cells

Ahmann, G.

3269 - A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

Ahmed, A. A.

1677 - Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Ahmed, A.

2920 - Distinct Phenotypes of Myeloid Neoplasia Associated with Truncating C-CBL Mutations
3199 - Could Somatic Gene Rescue Explain Frequency of Compound Heterozygous and Concurrent Receptor Tyrosine Kinase Mutations in Hematological Diseases?
4084 - An Immunogenetic Perspective on Bone Marrow Failure Syndromes: The KIR-HLA System
4085 - Counterpoising Immune Pressure and Privilege: Paroxysmal Nocturnal Hemoglobinuria Evolutionary Dynamics

Ahmed, A.

1688 - Low-Count T-/NK-Large Granular Lymphocytic Leukemia: A Nosologically Distinct Disease Subtype at the Crossroads between Lymphoproliferation, Autoimmunity and Immunodeficiency

Ahmed, A.

3884 - Hindsight 20/20: The Role of Hemoglobin F in Sickle Cell Retinopathy

Ahmed, A. Z.

3181 - Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms
3910 - High Prevalence of Concomitant Autoimmunity in Patients with Rosai-Dorfman Disease
3911 - Evaluating Treatment-Related Outcomes in the Era of Targeted Therapy for Rosai Dorman and Erdheim Chester Disease

Ahmed, A.

1802 - Efficacy and Tolerability of Trametinib in Adults with Histiocytic Neoplasms

Ahmed, E. N.

3017 - Cardiac Safety Profiles of First-Generation Vs. Second-Generation BTK Inhibitors: A Meta-Analysis

Ahmed, F.

4720 - Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution

Ahmed, H.

3283 - A CD38xCD28 Costimulatory Bispecific Antibody Demonstrates Potent Preclinical Combinatorial Activity with a BCMAxCD3 T Cell-Engager

Ahmed, I.

3105 - Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma
4477 - Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study

Ahmed, J.

2846 - GWAS Identifies Pharmacogenetic Markers Associated with Premedication-Related Pegaspargase Hypersensitivity and Toxicities in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma

Ahmed, K.

2245 - Understanding the Experiences of Caregivers for Children Five Years and Above Living with Sickle Cell Diseases in Kaduna, Nigeria

Ahmed, M.

824 - Immunotherapy of Acute Myeloid Leukemia Enabled By Targeting of Pan-Cancer Molecular Patterns with a Novel Trispecific T Cell Engager

Ahmed, M.

2541 - The Quiet Defenders: Immunoglobulin Levels As Predictors of Mortality in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

Ahmed, M.

1573 - Epigenetic Adaptation Promotes Cellular Resilience in Senescence-like AML Cells

Ahmed, N.

526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
2288 - The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024)
4936 - Correlates of Patient-Reported Outcomes Following Allogeneic Unrelated Donor Hematopoietic Stem Cell Transplantation

Ahmed, N.

71 - Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)
389 - Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients
935 - Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin’s Lymphoma
1965 - Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study
2009 - A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment
2350 - Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)
2404 - Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities—a Multicenter Study
2411b - Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial
2411g - Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma
3317 - Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis
4503 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium
4742 - Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
5030 - The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART
5040 - Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns
5045 - Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma
5162 - Social Determinants of Health (SDOH) and Access to CART for Multiple Myeloma
5163 - Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma
5170d - Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients
5170e - Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Ahmed, P.

3324 - Impact of Pre-Transplant Depth of Response on Outcomes in Patients with Multiple Myeloma: A Report on Behalf of Pakistan Blood and Marrow Transplant Group

Ahmed, R.

3235 - PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy

Ahmed, R.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Ahmed, R.

3078 - Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment
3154 - Response Adapted Dasatinib De-Escalation Strategy Compared to Upfront Low-Dose Dasatinib: A Prospective Cohort Study

Ahmed, R.

2637 - Rapido: Results from a UK-Wide Audit of 2477 Patients Who Received a Reversal Agent for a Direct Oral Anticoagulant

Ahmed, R.

1051 - Ex Vivo Lentiviral Hematopoietic Stem Cell (HSC) Gene Therapy May Represent a Curative Therapy for the Life-Threatening Inborn Error of Immunity Severe Combined Immunodeficiency Due to Adenosine Deaminase (ADA) Deficiency (ADA-SCID)

Ahmed, S.

3976 - Safety and Outcome of Early Start of Emicizumab in Neonates and Infants with Severe Hemophilia Α, a Real-World Experience

Ahmed, S. Y.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients

Ahmed, S.

2291 - Using the Serious Illness Conversation Guide (SICG) in Patients with Hematological Malignancies As a Tool to Address Their Perspectives on Palliative Care
3670 - The Serious Illness Conversation Guide Is Meaningful to Patients with Hematologic Malignancies and Impacts Death in Acute Care

Ahmed, S.

Ahmed, S.

3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Ahmed, S.

1130 - Trends and Disparities in Sickle Cell Disease-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database
5103 - Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database

Ahmed, S.

3947 - Trends and Disparities in Idiopathic Thrombocytopenic Purpura-Related Mortality in the United States: A Retrospective Study over Two Decades

Ahmed, S. O.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients
4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Ahmed, S. O.

4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population

Ahmed, T.

3600 - Deep Learning Predicts JAK2, Calr TET2, and ASXL1 directly from Whole Slide Marrow Images
3613 - Correlating Image-Level Nucleomorphologic Features with Molecular Subtypes of Myeloproliferative Neoplasms

Ahmed, U.

3324 - Impact of Pre-Transplant Depth of Response on Outcomes in Patients with Multiple Myeloma: A Report on Behalf of Pakistan Blood and Marrow Transplant Group

Ahmedna, T.

828 - CCRL2 As a Novel Target in Acute Erythroid Leukemia

Ahn, A.

1468 - Measurable Residual Disease in Adult B Lymphoblastic Leukemia: A Study of Concordance between Multiparametric Flow Cytometry, Next-Generation Sequencing of Immunoglobulin Gene Rearrangements, and Quantitative PCR

Ahn, C.

4234 - Should “Medically Fit” Older Patients with Acute Myeloid Leukemia (AML) Continue to Receive Intensive Chemotherapy in the Venetoclax (VEN) Era?
5096 - Enrollment in Clinical Trials Demonstrates Benefit for Low Income DLBCL Patients; A Retrospective National Cancer Database (NCDB) Analysis

Ahn, D. E.

4001 - Caplacizumab in Immune-Mediated Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Literature Review and Meta-Analyses of Clinical Trials and Observational Studies

Ahn, E.

21 - “Platelet Fatigue” during Cold Storage
1269 - Reduction of Lactate Production By Phospholipase C Inhibition in Cold Stored Platelets
1391 - The Arginine Methyltransferase PRMT5 Regulates Maintenance and TKI Resistance of Self-Renewing FLT3-ITD AML LSC

Ahn, H. S.

424 - Mechanistic Insights and Clinical Implications of the Thrombotic Risks of a Highly Prevalent GRK5 Variant Affecting Platelets

Ahn, I. E.

583 - Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy
587 - Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1669 - Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
1874 - A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
4611 - Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients
4617 - Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Ahn, J. S.

778 - Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD
1495 - PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML
2897 - Intensity-Adjusted Salvage Chemotherapy Plus FLT3-Inhibitor Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia with Mutated FLT3-ITD/TKD (SAPPHIRE-G)
4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

Ahn, J.

4892 - Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/Ptcy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia

Ahn, J.

4020 - Real-World Validation of the Khorana Risk Score in Predicting Thrombosis for Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

Ahn, K. H.

3942 - Impact of Platelet Transfusion and Bleeding Risk Stratification in Patients with Immune Thrombocytopenia before Procedures: A Nationwide Population-Based Cohort Study

Ahn, K. J.

1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL

Ahn, M.

3591 - ASTX295 a Novel Potent MDM2 Antagonist Induces More Than One Mechanism of Programmed Cell Death (PCD) in Lymphoid Malignancies

Ahn, S.

247 - Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
591 - NF-Kb Pathway Activation Driven By TRAF3 Loss Mediates Resistance to Anti-BCMA T-Cell Based Therapies in Multiple Myeloma
1892 - Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma
1899 - Timing Antigenic Escape in Multiple Myeloma Treated with T-Cell Redirecting Immunotherapies
4642 - Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma
4651 - BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Ahsan, A.

496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study

Ahsan, B.

3324 - Impact of Pre-Transplant Depth of Response on Outcomes in Patients with Multiple Myeloma: A Report on Behalf of Pakistan Blood and Marrow Transplant Group

Ahuja, K.

4402 - Second Primary Malignancies in Marginal Zone Lymphoma Survivors
4420 - Second Primary Malignancies in Hairy Cell Leukemia Survivors

Ahuja, S.

295 - Efficacy and Safety of Apixaban for Pediatric Patients Requiring Anticoagulation for Treatment of Venous Thromboembolism
2335 - Anaphylaxis Associated with Calaspargase in Pediatric Patients with Acute Lymphoblastic Leukemia

Ahumada, A.

2113 - Predictive Value of Liver Sitffness Measurement for Early Diagnosis of Veno-Occlusive Disease and Final Stem-Cell Outcomes

Ai, H.

2822 - Single-Cell RNA-Sequencing Identifies TCF1 and BCL11B Upregulation As Predictors of Blinatumomab Efficacy in B-Cell Acute Lymphoblastic Leukemia Patients

Ai, J.

5194 - Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results

Ai, W.

3042.3 - Combination of Glofitamab with Pirtobrutinib in BTK Inhibitor (BTKi)-Naive or Btki-Intolerant Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

Ai, Y.

1387 - An Orally Active Pan-BCR::ABL1 Degrader Tgrx-3247 Potently Targets a Wide Spectrum of Orthosteric, Allosteric and Compound Mutations Resistant to TKI Therapies
4176 - Tgrx-678 Penetrates Blood-Brain Barrier and Exhibits Preclinical Anti-Tumor Activity in Murine Ph+ CNS Leukemia and ALL Models

Aiello, J.

2383 - A Patient Perspective on Actionable Steps to Address Disparities in Healthcare Among US Patients with Multiple Myeloma
3381.3 - A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Aifantis, I.

207 - Enhancing Macrophage Mediated Phagocytosis in AML: The Complementary Mechanisms of Venetoclax and Azacitidine Combination Therapy
951 - CRISPR/RfxCas13d Screening Identifies the Long Non-Coding RNA (LncRNA) Nfyc-AS1 As a Molecular Vulnerability in Acute Myeloid Leukemia (AML)
954 - A Protein-Coding Circular RNA That Regulates DNA Damage Response in BCR::ABL-Positive Leukemias
4130 - Isoform-Level Long Noncoding RNA Dependencies in Multiple Myeloma
4170 - PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Aigner, M.

684 - Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease
4835 - Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma – a Single-Center Experience

Aigner, S.

1221 - Evaluation of Pharmacokinetics, Efficacy and Safety of a New Human Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency

Aikawa, S.

366 - Soluble B-Cell Maturation Antigen Levels for Disease Monitoring in Oligo- and Non-Secretory Relapsed Multiple Myeloma
3035 - Serum BCMA Is a Better Reflector of Tumor Volume Than IgM in the Induction Period of Waldenström Macroglobulinemia
3313 - Soluble BCMA As a Surrogate Biomarker for Tumor Burden in Multiple Myeloma: Correlations with Various Biomarkers and Treatment Responses

Ailawadhi, D.

3771 - Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma (MM) Patients: Real-World Learnings from a Large, Prospective Study

Ailawadhi, S.

861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)
1022 - Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light‑Chain (AL) Amyloidosis
1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
2265 - Prospective Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Attributes and Factors Affecting Patient Shared Decision-Making in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in the United States (USA)
2271 - Reducing Time Toxicity for Anti-B-Cell Maturation Antigen (BCMA) Bispecific Treatment: Evidence from Pivotal Single-Arm Trial Data on Teclistamab, Elranatamab, and Linvoseltamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
2381 - Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA
3366 - Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC^TM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
3658 - Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies across Diverse Clinical Landscapes: An International Prospective Study
3763 - Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma
3771 - Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma (MM) Patients: Real-World Learnings from a Large, Prospective Study
3790 - Disparities in Multiple Myeloma (MM): Race/Ethnicity-Specific Sociodemographic and Economic Factors That May Drive Patient Decisions to Refuse Treatment
4614 - Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax
4723 - Early Mortality in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Sociodemographic and Economic Factors Contributing to the Disparity
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee
3309.1 - A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
3381.3 - A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Aina-Mumuney, A.

2328 - Practice Patterns and Clinical Outcomes of Thromboprophylaxis during Pregnancy

Ainciburu, M.

879 - Unveiling ZMAT2 and SMARCD3 As Therapeutic Targets to Mitigate Aberrant Hematopoiesis in MDS

Ainley, L.

669 - Tumour-Intrinsic Features Shape T-Cell Differentiation through Myeloma Disease Evolution
1017 - Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Aiolfi, R.

1230 - Enhanced Thrombotic Susceptibility, Endotheliopathy, and Abnormal Cognitive Behavior for up to 5 Months after Sars-Cov-2 Infection in a Mouse Model of Long COVID

Airaud, F.

3842 - Hereditary Erythrocytosis: Results from Europe's Largest Idiopathic Erythrocytosis Database

Airewele, G.

3878 - Identifying Clinical and Socioeconomic Factors Associated with Neuropsychological Impairment in Pediatric Patients with Sickle Cell Disease

Aisner, D.

969 - Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Aitken, R.

1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada

Aittokallio, T.

913 - Comprehensive Drug Profiling and CRISPR Screening Reveal Essential Pathways for NK Cell Cytotoxicity

Aiuti, A.

4050 - Poisoning of Healthy Hematopoiesis Is an Unanticipated Mechanism Driving Clonal Dominance in Vexas Syndrome

Aivasovsky, I.

181 - TMEM16E and TMEM16F Regulate the Generation and Procoagulant Activity of Extracellular Vesicles during Endothelial Cell Inflammation

Aiyeolemi, A.

5201 - Impact of an Educational Intervention on Emergency Department Residents' Knowledge and Perceptions of Sickle Cell Disease: A Pilot Study

Aizawa, K.

338 - Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

Ajayi, A.

1256 - Venous Thromboembolism in Individuals with Sickle Cell Disease- a Retrospective Review of This Understudied Problem

Ajazi, R.

4929 - Return to Work after Allogeneic HSCT: Further Insights in the Patients-Related Predictive Factors (The SOPRALLO Project)

Ajib, S.

3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Ajiboye, S.

1268 - Standardized Prophylactic Platelet Transfusion Dose for Infants Decreases Platelet Exposure without Increasing Bleeding or Transfusion Frequency

Ajjamada, L.

1783 - Distinguishing Germline from Acquired Pathogenic CSF3R Variants: Key Diagnostic Features and Clinical Implications

Ajmal, M.

1119 - Beyond the Binary: Analysis of Sickle Cell Disease Crisis Hospitalizations in the Transgender Population in United States: National Inpatient Data Base Study from 2012-2020
1128 - Beyond the Binary: Analysis of Sickle Cell Disease Crisis Hospitalizations in the Transgender Population in United States

Ajufo, H.

15 - Non-Driver Genomic Alterations and Venous Thromboembolism in Myeloproliferative Neoplasms
2632 - Bleeding in Lung Cancer Patients Receiving Therapeutic Anticoagulation While Being Treated with VEGF and EGFR Inhibitors

Akahoshi, Y.

380 - Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd
384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

Akard, L.

4738 - MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma

Akard, L. P.

4858 - An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with G-CSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Akashi, K.

454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
2081 - Pre-CAR-T GTE Scoring of Electroencephalogram Abnormalities As Predictive Biomarkers for Icans

Akashi, K.

1312 - Efficacy and Safety of Cyclosporine Monotherapy for Patients with Non-Severe Aplastic Anemia Not Requiring Transfusions: Results from a Prospective Multicenter Phase II Study
2225 - A Novel and Highly-Specific qRT-PCR System for Mutant NPM1 MRD Detection
2689 - Efficacy and Safety of Eltrombopag Added to Rabbit Anti-Human Thymocyte Globulin+Cyclosporine in Aplastic Anemia: Results from a Prospective Multicenter Phase II Study
4475 - A Multicenter, Prospective, Observational Study of Pola-R-CHP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (POLASTAR): A Preliminary Analysis

Akay, O. M.

1663 - Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

Akbar, A.

1252 - Superior Safety and Efficacy of Doacs over Warfarin in Obese Patients: A Propensity-Matched Cohort Study

Akbar, M.

3885 - OEF Measured with Diffuse Optical Spectroscopies As a Biomarker of Silent Stroke in Pediatric Sickle Cell Anemia

Akbar, U. A.

1252 - Superior Safety and Efficacy of Doacs over Warfarin in Obese Patients: A Propensity-Matched Cohort Study

Akbari, A.

1080 - A Single Mutation in the SENP1 Region Regulates the Excessive Erythropoiesis in the Andes

Akbari-Moghaddam, M.

547 - Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicentre Cohort Study

Akbilgic, O.

5064 - Towards Remote Monitoring of Sickle Cell Disease for Heart Failure: A Single Lead ECG-AI Model

Akel, S. M.

383 - Memory T-Cell Add Back and Prophylactic blinatumomab Post Tcrαβ Depleted Haploidentical Transplantation Results in Promising Outcomes in Pediatric Patients with High-Risk Acute Leukemia
2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia
2100.1 - Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease

Akens, M.

2678 - Chemotherapy-Induced Bone Defects Stem from Skeletal Progenitor Dysfunction

Akerman, M.

371 - Development of CAR T Cells Targeting U5 snRNP200 for the Treatment of Acute Myeloid and B-Lymphoid Leukemias

Akhtar, O. S.

81 - 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702
254 - Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial
- Moderator Introduction and Session 3 Initial Audience Voting

Akilov, O.

3056 - Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule
4453.1 - First-in-Human Phase 1a Clinical Trial of the Investigational New Drug ST-001, a Novel Nano-Phospholipid Dispersion Formulation of Fenretinide, in Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Akin, C.

4556 - Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis

Akinsanya, O. J. D.

178 - A Phase 1b/2 Study of the Efficacy and Safety of Combination Hydroxyurea and Dose-Escalated Erythropoietin for Treatment of Anemia in Sickle Cell Disease (ACHiEvE-SCD)

Akintobi, T.

291 - Integrative Strong Body and Mind Training for Sickle Cell Disease (I-STRONG)—an Interdisciplinary, Multicomponent Treatment Approach for Pediatric Chronic SCD Pain

Akinyemi, O. A.

2343 - Medicaid Expansion and Cancer-Specific Survival Among Individuals with Acute Lymphoblastic Leukemia
2371 - Exploring the Intersectionality of Marital Status and Sex on Survival Outcomes in Non-Hodgkin’s Lymphoma

Akinyemiju, T. F.

2295 - Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Akiyama, H.

1400 - Targeting Lipid Droplet Biogenesis to Enhance Ferroptosis in Acute Myeloid Leukemia
2765 - Molecular Interactions between Mitochondrial Ferroptosis and Apoptosis Pathways in Acute Myeloid Leukemia

Akizuki, K.

1805 - Impact of Cooperating Myeloid Gene Mutations on Disease Progression and Survival in Japanese MPN Patients: A Multicenter Study

Akkad, N.

4348 - Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients
4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma
4396 - Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy

Akoto, N. A.

5176 - National Trends and Disparities in Sepsis-Related Mortality in Adults with Hematological Cancers, 1999-2020

Akpan, I.

2850 - The Burden of Cardiovascular-Related Mortality in Early-Onset Acute Myeloid Leukemia

Akpuogu, L.

5000 - Joint Sickle Cell-Gynecology Clinic Improves Access to Reproductive Health

Akram, A.

4670 - Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Patients with Light-Chain Amyloidosis: A Systematic Review and Meta-Analysis

Akram, N.

4932 - Outcomes with Venetoclax and Hypomethylating Agents in Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis

Akram, U.

1130 - Trends and Disparities in Sickle Cell Disease-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database
3947 - Trends and Disparities in Idiopathic Thrombocytopenic Purpura-Related Mortality in the United States: A Retrospective Study over Two Decades
5103 - Trends and Disparities in Acute Lymphoblastic Leukemia-Related Mortality in the United States from 1999 to 2020: Insights from the CDC Wonder Database

Aksoylar, H. I.

123 - Loss of LDH-a Accelerated CD8⁺ T Memory Cell Differentiation but Impairs Anti-Tumor Responses

Aktas-Samur, A.

764 - PKMYT1 Kinase Is an Actionable Synthetically Lethal Target for Del17p Myeloma
1018 - Differentiating between MM like Smoldering Myeloma (SMM) and Non-Progressor SMM
3268 - A Novel Ribonuclease Targeting Small Molecule RNA-Degrader (MYC-RiboTAC) Overcomes MYC Dependency in Multiple Myeloma
4130 - Isoform-Level Long Noncoding RNA Dependencies in Multiple Myeloma

Akyol, A.

869 - Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
3123.3 - Trial in Progress: Phase 1/2 Study of Cereblon-Modulating Agent Golcadomide (BMS-986369/CC-99282) in Relapsed or Refractory (R/R) T-Cell Lymphomas (TCLs) (GOLSEEK-3)

Al Abdulaali, M.

1121 - Newborn Screening Program (NBS) for Early Detection of Sickle Cell Disease and G6PD: The Saudi Experience

Al Ali, N. H.

Al Baghdadi, T.

1831 - Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS)
3123.2 - S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Al Deeban, B.

762 - Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation
2980 - Integration of [¹⁸f]FDG-PET Radiomics with Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed DLBCL Patients

Al Essa, W.

404 - The Prognostic Value for Survival of Self-Reported Fatigue in Patients with Newly Diagnosed Myelodysplastic Syndromes: An International Prospective Observational Study By the Gimema
2980 - Integration of [¹⁸f]FDG-PET Radiomics with Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed DLBCL Patients

Al Hadidi, S.

254 - Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)
256 - Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
1904 - The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
1937 - Identification of Risk Factors for Myeloma Progression in African American Patients
2405 - Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
3789 - Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma
4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis
4676 - Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression
4713 - Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
4729 - Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages
5170c - Secondary Cancers Among Patients with Multiple Myeloma: A 15-Year Analysis of a Population-Based Cohort in Ontario, Canada

Al Khraisat, L.

2647 - Platelet Quality and Function Variability across Collection Platforms and during Storage: Findings from the Ongoing Chilled Platelet Study in Vitro (CHIPSiv)

Al Malki, M. M.

729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
775 - Multidimensional Analysis of Relapsed Bone Marrow Reveals Cold Immune Microenvironment Post-TMLI in Acute Leukemia Transplant Patients
924 - TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial
1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
1043 - Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)
2878 - A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3393 - Tissue-Specific Myeloablative Conditioning with Total Marrow Irradiation Enhances Gut Microbiome Diversity and Mitigates Gvhd: A Novel Therapeutic Approach
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
4257 - WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
4264 - Phase 1 Trial of Navitoclax/Venetoclax/Decitabine Combination in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4924 - Social Vulnerability Is an Important Predictor of Cardiovascular Disease Risk after Allogeneic Hematopoietic Cell Transplantation
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
3514.1 - OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Al Mansour, M.

465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Al Masud, A.

2496 - Results from a Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tebapivat (AG-946) in Patients with Sickle Cell Disease

Al Nawakil, C.

3241 - Prognosis of the IGLV3-21^R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort
3256 - Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Al Raizah, A.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease
2627 - Comparison of Riete and Some Scores for Predicting Cancer in Unprovoked Thrombosis

Al Sagheer, T.

1672 - Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study
3091 - CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL) – a Multicenter Retrospective Study

Al Saleh, A. S.

2627 - Comparison of Riete and Some Scores for Predicting Cancer in Unprovoked Thrombosis

Al Ta’ani, O.

2421 - The Burden of Leukemia in the United States from 1990 to 2021

Al Tabaa, Y.

4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Al Zahrani, M.

176 - Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
778 - Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD
2184 - Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party
2627 - Comparison of Riete and Some Scores for Predicting Cancer in Unprovoked Thrombosis
4930 - Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

Al Zaki, A.

3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
3428 - Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy
4506 - Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma
4508 - Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma
5127 - Utility of PET/CT Imaging in Predicting Outcomes of Patients with Lymphoid Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis from a Single Tertiary Center
1674.3 - Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Al-Agil, M.

1284 - DNMT3A-Mutant Clonal Haematopoiesis Is Associated with Worse Recovery after ST-Elevation Myocardial Infarction Via Increased Inflammation

Al-Ahmari, A.

595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Al-Akioui Sanz, K.

3463 - Alloreactive Vs IL15 Ex Vivo Stimulated Natural Killer Cells As Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Acute Leukemia: A Phase I/II Clinical Trial

Al-ali, F.

4461 - Use of Doxorubicin-Containing Regimens Is Not Associated with Hemolytic Complications in Severely G6PD Deficient Patients with Lymphoma

Al-Ali, H. K.

406 - Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival – an Analysis By the German Study Group for MPN (GSG-MPN)
482 - Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial
483 - Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis
1000 - Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis
1090 - Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)
1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
4546 - Clinical Outcomes in Patients with Myelofibrosis Treated with Ruxolitinib and Anemia-Supporting Medications
1808.2 - POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Al-Ali, R. W.

59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial
2950 - Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Al-Atrash, G.

1837 - Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies
4841 - Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies

Al-Bazaz, M.

3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

Al-Behaisi, S.

1135 - Characterizing People with Sickle Cell Disease Who Share Attitudes Regarding Clinical Trial Participation: Findings from the Global LISTEN Survey
1137 - How People with Sickle Cell Disease Rate Motivators is Associated with the Likelihood of Wanting to Participate in a Clinical Trial: Findings from the Global LISTEN Survey

Al-Bitar, F.

2125 - Association between Malnutrition and Inpatient Mortality in Hematopoietic Stem Cell Transplant (HSCT) Population: A Nationwide Inpatient Sample (NIS) Database Analysis
2421 - The Burden of Leukemia in the United States from 1990 to 2021

Al-Ghafry, M.

4015 - Systematic Review of Pediatric Venous Thromboembolism Associated with Inferior Vena Cava (IVC) Anomalies

Al-Hadaddin, R.

3797 - Genetic Profiling and Risk Stratification of Acute Myeloid Leukemia (AML): Comparative Analysis of the Jordanian AML Cohort (JAMLC) to the German-Austrian AML Study Group (AMLSG)

Al-Hadidi, S.

2277 - Characteristics and Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A 14-Year Experience in a Limited Resource Setting
3781 - Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
4726 - Impact of Additional Chromosome 1q Copies on Multiple Myeloma Survival Outcomes

Al-Hamaly, M.

154 - Large-Scale In Vivo Zebrafish Drug Screen Uncovers Novel Insights into Leukemia Stem Cell Biology

Al-Hattab, E.

784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience

Al-Jadiry, M. F.

2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Al-Jaghbeer, M. J.

1260 - Evaluation of Risk Assessment Models for Predicting Venous Thromboembolic Events in Cancer Patients Using Implanted Central Venous Access Devices

Al-Janadi, A.

4434.1 - CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial

Al-Kadhimi, Z.

2808 - Effect of Lumbar Puncture Timing on Neurotoxicity with Blinatumomab Therapy in a Real-World Cohort of Acute Lymphoblastic Leukemia (ALL)

Al-Kali, A.

244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
440 - Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
1798 - Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials
1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
1823 - Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
1827 - Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform
2667 - A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations
2771 - Preclinical Evaluation of Stx-0712, a CCR2 Cytotoxicity Targeting Chimera (CCR2-CyTAC) for the Treatment of Chronic Myelomonocytic Leukemia
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
2869 - Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41^MT Germline Predisposition Syndrome
3197 - Targeting Aberrant DLK1 Re-Expression in ASXL1-Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Al-Mansour, Z. A.

224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Al-Mashhadi, A.

650 - Identifying Trial-Eligible High- and High-Intermediate Risk Patients with Diffuse Large B-Cell Lymphoma Using Prognostic Models: A Real-Life Comparative Analysis of IPI, aaIPI and NCCN-IPI from Danish Study Group

Al-Mousawi, A.

3201 - Oral Vitamin C Supplementation Modulates Inflammatory Cytokines in Clonal Cytopenia of Undetermined Significance and Low-Risk Myeloid Malignancies: Results from EVI-2 Trial

Al-Rabi, K.

664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
4465 - Dose-Adjusted EPOCH-R Is Superior to R-CHOP in Frontline Treatment of Mediastinal Large B-Cell Lymphoma

Al-Rwashdeh, M.

4465 - Dose-Adjusted EPOCH-R Is Superior to R-CHOP in Frontline Treatment of Mediastinal Large B-Cell Lymphoma

Al-Samkari, H.

278 - Characterizing the Healthcare Resource Utilization and Costs of Hereditary Hemorrhagic Telangiectasia (HHT)
409 - ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
553 - A Randomized, Placebo-Controlled, Multicenter Proof-of-Concept (POC) Study to Assess the Safety and Efficacy of the Novel Allosteric AKT Inhibitor, VAD044, in Adults with Hereditary Hemorrhagic Telangiectasia (HHT)
558 - Long-Term Safety and Effectiveness of Pomalidomide for Bleeding in Hereditary Hemorrhagic Telangiectasia
1180 - Direct Glycoprotein-Specific Platelet Autoantibodies Detected in a Majority of Patients with Chemotherapy-Induced Thrombocytopenia
2252 - Risk Factors for Bleeding after Recent Medical Hospitalization: The Medical Inpatient Thrombosis and Hemostasis Study (MITH)
2457 - Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results
2496 - Results from a Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tebapivat (AG-946) in Patients with Sickle Cell Disease
2570.1 - Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)
- Adult Classical Hematology

Al-Sarayfi, D.

2984 - Unveiling Transformation Mechanisms of Nodal Marginal Zone Lymphoma Using a Multi-Omics Approach

Al-Sawaf, O.

761 - Polyfunctional Effector PD-1⁺ CD8⁺ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models
1859 - Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial
3250 - Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)
4613 - Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Al-Shahrour, F.

872 - Mutation-Specific Differences in the Relationship between Obesity and Clonal Hematopoiesis, with a Focus on JAK2^V617F and MPN Prevention

Al-Shaibani, E.

4273 - FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience
4930 - Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

Alabdly, M. J.

2531 - Multinational Assessment of Absolute Neutrophil Counts and White Blood Cell Counts Among Healthy Individuals with the Duffy Null Phenotype or Genotype

Alachkar, H.

2845 - Metabolomic Profiling of Asparaginase-Induced Hepatotoxicity in Pediatric Acute Lymphoblastic Leukemia

Aladjidi, N.

548 - Adolescents and Young Adults with Secondary Chronic Immune Thrombocytopenia: A Switzerland/France Collaboration Project

Alaez, C.

4549 - Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms

Alagar, M.

1115 - A Novel Oral Prodrug AN233 Induces Fetal Hemoglobin Expression in Sickle Cell Disease Mice and Baboons

Alagbe, A. E.

3861 - Inhibition of Purine Nucleoside Phosphorylase Is a Promising Anti-Sickling Approach for Sickle Cell Disease

Alahmadi, A.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients

Alahmari, A.

176 - Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients
2136 - Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
2184 - Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party
4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Alahmari, B.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alahmary, A.

2627 - Comparison of Riete and Some Scores for Predicting Cancer in Unprovoked Thrombosis

Alajangi, R.

2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK

Alakwe, S.

910 - A Clonally Expanded Nodal T Cell Population Diagnosed As T Cell Lymphoma after CAR-T Therapy

Alalouf, O.

1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Alam, R.

514 - Prime Editing Enables Precise and Efficient Single Amino Acid Substitutions to Shield CD34+ Hematopoietic Stem Cells from Anti-CD117 Antibody-Based Conditioning

Alameh, M. G.

2202 - In Utero mRNA Lipid Nanoparticle Delivery in a Murine Model of Fanconi Anemia

Alamer, A.

4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Álamo Moreno, J. R.

1034 - CART Cell Therapy Targeting CD84 Alone or in Combination with CD19 for the Treatment of B-Cell Malignancies

Alamoush, A.

2277 - Characteristics and Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A 14-Year Experience in a Limited Resource Setting
3797 - Genetic Profiling and Risk Stratification of Acute Myeloid Leukemia (AML): Comparative Analysis of the Jordanian AML Cohort (JAMLC) to the German-Austrian AML Study Group (AMLSG)

Alanazi, T.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alao, O.

5110 - Association of Race, Ethnicity, and Social Deprivation on the Incidence and Severity of Adverse Events in Induction in Children with Acute Lymphoblastic Leukemia

Alaoui, A. Y.

2781 - The Cyclin-G Associated Kinase (GAK) Is a Critical Targetable Dependency for Successful Mitosis By Diffuse Large B-Cell Lymphomas Linked to Retinoblastoma Loss of Function
3276 - Replication Stress Induces Hyper-Apobec Mutagenesis in Multiple Myeloma

Alapat, D. V.

1156 - The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease
1904 - The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans
4729 - Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Alapi, H.

3239 - Development of a Machine Learning–Based Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating BTK Inhibitor Therapy

Alarcon Tomas, A.

1698 - Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo

Alarcón Tomás, A.

1715 - Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study
3757 - Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT

Alasbali, R.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients

Alaskar, A.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alaskar, A.

2627 - Comparison of Riete and Some Scores for Predicting Cancer in Unprovoked Thrombosis

Alassaad, L.

2508 - Parameters Associated with Improved Peripheral Oxygen Extraction in Sickle Cell Patients Treated with Voxelotor
3890 - Protection Against Coronary Atherosclerosis in High Cardiovascular Risk Sickle Cell Disease Patients: A Beneficial Role of Intravascular Hemolysis?

Alati, C.

835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Alatrash, G.

208 - CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo
346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant
506 - Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial
736 - Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
2810 - Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
4818 - Cord-Derived Invariant Natural Killer T Cells As Novel Cell Therapy to Improve the Outcome of Hematopoietic Stem Cell Transplantation

Alavi, A.

513 - Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises

Alayash, A. I.

3871 - Mechanism-Based Treatable Targets for Organ Damage and Pain in Sickle Cell Disease

Albabtain, A.

4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Albalawi, F.

1121 - Newborn Screening Program (NBS) for Early Detection of Sickle Cell Disease and G6PD: The Saudi Experience

Albano, F.

3155 - CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major molecular response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Albano, L.

4050 - Poisoning of Healthy Hematopoiesis Is an Unanticipated Mechanism Driving Clonal Dominance in Vexas Syndrome

Albayrak, Ö.

2665 - Clonal Endotheliopoiesis in Patients with Carotid Atherosclerosis

Alberge, J. B.

488 - Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma
492 - Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies
1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
3279 - Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Alberich Jorda, M.

1563 - ACSL4-Associated Lipid Metabolism Is a Distinct Therapeutic Vulnerability in KMT2A-Rearranged Acute Myeloid Leukemia

Alberio, L.

1120 - Transcriptomic Profiling Supports the Phenotypic Classification of Stable-State Sickle Cell Disease Patients

Albero, R.

1371 - The SOX11 Interactome Reveals the SOX11:SMARCA4 Complex As a Driver of Oncogenic Transcriptional Programs in Mantle Cell Lymphoma

Albert, M. H.

3563 - Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial
5079 - Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Albert, S.

1912 - Incidence and Prevalence of Clinically Detected Smoldering Multiple Myeloma Among the General Population

Alberti, J.

3360 - Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Alberts, N. M.

1065 - Sickle Cell Disease-Related Worry and Associations with Healthcare Utilization in Youth with Sickle Cell Disease
3688 - Health-Related Communication in Adolescents and Young Adults with Sickle Cell Disease

Albertsson-Lindblad, A.

1638 - Survival in Mantle Cell Lymphoma Patients with a Second Primary Malignancy
3014 - Timing of Disease Progression and Impact on Survival in Mantle Cell Lymphoma: A Novel Illness-Death Model Study from the Swedish Mclcomplete Project

Albi, E.

762 - Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Albici, A. M.

2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

Albiez, J. J.

1199 - Preclinical Evaluation of NXT007 Using in Vitro and In Vivo Models of Hemostasis and Thrombosis

Albiol, N.

2084 - The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)
3232 - Patients with Chronic Lymphocytic and Non-Hematologic Autoimmune Disorders Show Distinctive Clinical and Immune Alterations in Th17 and Treg Cells
3757 - Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT

Albitar, M.

1946 - Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)
3316 - Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)
4295 - Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)
4367 - Establishing Lymphoma Type-Specific Cytokine Signatures Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)

Albitar, M.

2923 - Immune and Myeloid Differentiation Shape Transcriptome to Discriminate Evolutionary Stages of Cellular Transformation
4687 - Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Albliwi, M.

1473 - Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
1488 - A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience
2848 - Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience
2862 - Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study
2868 - Outcomes of Blast-Phase MPN and JAK2, MPL, and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2, MPL, and CALR Genes: A Propensity Score-Adjusted Cohort Study
4248 - Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study
4249 - Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience
4297 - The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Albo Lopez, C.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)

Albrici, G.

2142 - Improvement of Survival By Use of New Tecniques of Manipulation after Haploidentical Hematopoietic Stem Cell Transplantation: Report of 230 Transplants in Paediatric Patients with Primary Immunodeficiencies and Oncological Diseases

Albuja Altamirano, M. F.

- Incidence of Thrombotic and Bleeding Complications in Patients with Cancer Undergoing Lower Extremity Arthroplasty, an Administrative Database Study

Albuquerque De Melo, M.

2752 - Molecular Mechanisms Associated with Autophagy Inhibition to Overcome Resistance to FLT3 Inhibitors
4518 - Synergistic Effect of Tamoxifen and Ruxolitinib Combination in Reducing Disease Burden in Myeloproliferative Neoplasms

Albuquerque, D.

1109 - Cereblon-Based Compounds for Induction of HbF
3868 - Novel Selective HDAC1/2 Inhibitor 2-Aminobenzamide Derivative Potently Induces Fetal Hemoglobin

Alcaide, S. O.

867 - Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

Alcala Peña, M. M.

2411e - Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis

Alcalay, Sr., M.

1541 - Genomic Landscape and Clonal Hematopoiesis Dynamics in Patients with Ovarian Cancer during PARP Inhibitors Treatment: Preliminary Results of a Prospective Longitudinal Study

Alcalde Mellado, P.

1183 - Use of Steroids in Subjects with ITP in Spain: Duration and Toxicity
2096 - Assessing CAR-T Cell Product Quality: The Crucial Role of Metabolic and Persistence Analysis after Antigen Stimulation
3948 - Investigating the Effectiveness and Safety of Combining Thrombopoietin Receptor Agonist and Immunosuppressant Drugs for Patients with Multirefractory Immune Thrombocytopenia after Second-Line Monotherapy Treatments

Alcazer, V.

1321 - Efficacy and Safety of Pegcetacoplan in PNH Patients with Extra-Vascular Hemolysis Under Anti-C5: The Real-Life Experience of the National French Reference Center

Alchidiac, J.

474 - Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Alcoceba, M.

4390 - Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Alcoceba, M.

4478 - A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Alcorn, A.

2056 - Developing Novel Cell Therapy Strategies to Convert Macrophage Programming and Induce Synergistic, Multicellular Immunity Against AML

Aldebert, C.

633 - The Role of an Inflammatory Phenotype in Driving Clonal Evolution in B-Acute Lymphoblastic Leukemia

Aldecoa, K. A. T.

3652 - Comparison of Healthcare Utilization in Patients Undergoing CAR T-Cell Therapy for Multiple Myeloma and Lymphoma

Alderfer, M. A.

605 - Empowering Adolescents and Young Adults with Sickle Cell Disease: Development of a Shared Decision-Making Toolkit for Disease-Modifying Therapies
3627 - Development of an Age-Appropriate, Multi-Media Educational Digital Hub for Adolescents with Sickle Cell Trait
5008 - Sctalk: A Pilot Trial Using Implementation Science to Improve Documentation and Disclosure of Sickle Cell Trait during Infancy

Alderuccio, J. P.

337 - Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma
571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
1622 - Epcoritamab with R-CHOP Overcomes Poor Risk Features of High Total Metabolic Tumor Volume in High-Risk Large B-Cell Lymphoma
2981 - Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response
3032 - Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma - Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study
3091 - CD20xCD3 Bispecific Antibodies As Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL) – a Multicenter Retrospective Study
3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
4423 - Association of Body Composition Factors and Toxicity in Patients with Advanced Stage Hodgkin Lymphoma Receiving BV-AVD
1674.2 - PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Aldoaiji, N.

1121 - Newborn Screening Program (NBS) for Early Detection of Sickle Cell Disease and G6PD: The Saudi Experience

Aldosari, K.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Aldoss, I.

211 - Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
966 - CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study
1043 - Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)
1425 - Clinical and Molecular Characterization of TP53-Mutant Acute Lymphoblastic Leukemia
2278 - Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible
2821 - Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study
2825 - Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
3450 - WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival
4264 - Phase 1 Trial of Navitoclax/Venetoclax/Decitabine Combination in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Alduaij, W.

742 - A Novel Genetics-Based Classification of Advanced Follicular Lymphoma Identifies Prognostic Subgroups Following Bendamustine-Rituximab Immunochemotherapy
5095 - Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras

Alecu, I.

4971 - Targeting Metabolism to Restore Hematopoiesis in Inherited Bone Marrow Failure Syndromes: Preclinical Insights from Zebrafish Models

Aleem, A.

2423 - Association of Neighborhood Crime with AML Molecular Subtypes and Survival

Alegre, A.

1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Aleissa, M.

3500 - BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study

Alekseeva, A.

3332 - The Impact of Circulating Plasma Cells on Overall Survival (OS) in Patients with Newly Diagnosed Multiple Myeloma (MM) - Results of a Multicenter Study

Alekseeva, E.

4341 - Comprehensive Analysis of Malignant B-Cell Receptors Provides Insights into B-Cell Lymphoma Pathogenesis

Aleman, A.

357 - Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab
589 - BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies
3259 - Improving Anti-BCMA CAR-T Functionality with Novel Celmods in Multiple Myeloma
3329 - Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation
4654 - Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients
4691 - Monovalent XBB1.5 Vaccination Augments Humoral and Cellular Immunity to Novel Sars-Cov-2 Variants in Immunocompromised Patients with Multiple Myeloma

Aleman, S.

4634 - Severity of COVID-19 in Individuals with Chronic Lymphocytic Leukemia throughout the Pandemic in Sweden: A Nationwide Multiple Register Cohort Study Conducted from 2020 to 2023

Alemi, H.

Alemu, L.

32 - Longitudinal Contribution of Distinct Hematopoietic Clones during Marrow Recovery in Immune Aplastic Anemia
34 - T Cell Receptor Clonal Dynamics and Hematopoietic Recovery after Immunotherapy in Severe Aplastic Anemia
4056 - Single-Cell Multi-Omics Analysis Reveals Dysfunctional Features of the Immune Responses in Vexas Syndrome

Alemu, L.

439 - Danazol Treatment for Telomere Biology Disorders: Long-Term Results of a Phase I/II Study

Alencar, A. J.

110 - Representation of Minorities in Therapeutic Clinical Trials – a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)
337 - Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma
884 - Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study
2802 - Impact of Ph-like Gene Signatures on Clinical Outcomes in Adult B-ALL Patients in Resource-Constrained Settings
2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results
3032 - Limited Duration Loncastuximab Tesirine Induces a High Rate of Complete Responses in Patients with Relapsed/Refractory Marginal Zone Lymphoma - Report of First Planned Interim Futility Analysis of a Multicenter Phase II Study
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4628 - A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
4502.4 - Trial in Progress – Alliance A051901 – Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Aleo, E.

4656 - Single Cell Transcriptomics on Bone Marrow Biopsies Unveils Peculiar Bone Microenvironment Cell Subtypes and Highlights Alterations Correlated with High-Risk Features in Precursor Monoclonal Gammopathies and Multiple Myeloma Patients

Alese, T. T.

1226 - “Endothelialized” Hemostasis-on-a-Chip Reveals Rapid Platelet Recruitment By Locally Concentrated Ultra-Large Von Willebrand Factor (VWF) Release from Endothelial Cells Surpasses Plasma and Platelet VWF in Initiating Hemostasis

Alevizopoulos, V. I.

1163 - Long-Term Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Patients with Progressive Systemic Sclerosis

Alex, A.

4099 - Leukemia-Mutated Proteins PHF6 and PHIP Form a Repressive Chromatin Complex That Suppresses AML Stemness

Alexander, K.

166 - Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia

Alexander, N.

3437 - Natural Killer and Gamma Delta T Cells Derived from Engineered Induced Pluripotent Stem Cells Have Potent Preclinical Activity to Treat B Cell-Mediated Autoimmune Diseases

Alexander, S.

4470 - Prior History of Severe Infection in Children, Adolescents and Young Adults with Lymphoma As Proxy for Inborn Errors of Immunity: Prevalence and Impact on Post-Lymphoma Outcomes

Alexander, S. C.

514 - Prime Editing Enables Precise and Efficient Single Amino Acid Substitutions to Shield CD34+ Hematopoietic Stem Cells from Anti-CD117 Antibody-Based Conditioning

Alexander-Shani, R.

894 - Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis
1030 - Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma

Alexandersen, T.

4730 - Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Alexandrov, L.

1363 - Defining the Roles of Base Deaminase and Splicing Deregulation in Pediatric B-Cell Acute Lymphoblastic Leukemia Stem Cell Persistence

Alexandru, R.

333 - CD70 Deregulation in Follicular Lymphoma at Diagnosis Is Associated with Relapse and Opens New Avenues for Dual CD19-CD70 CAR-T Therapy

Alexe, G.

205 - Posttranslational Changes in Histone Modification Driven By USP48 Loss Increase Sensitivity to Hypomethylating Agents in Acute Myeloid Leukemia
626 - Riboflavin Drives Nucleotide Biosynthesis and Iron-Sulfur Metabolism to Promote Acute Myeloid Leukemia
2717 - ADAR1 Is a Vulnerability in TP53-Mutant Acute Myeloid Leukemia

Alexis, K.

1504.3 - Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3-ITD–Negative Acute Myeloid Leukemia

Alfa Cisse, O.

171 - IMA001 Is a Novel Therapeutic Molecule That Reduces Sickling and Hemolytic Anemia Markers in a Sickle Cell Disease Mouse Model
1103 - IMA001 Is a Novel Therapeutic Molecule That Improves Hematological Parameters during Vaso-Occlusion in Sickle Cell Disease In Vivo

Alfaham, M. S.

4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population

Alfar, H. R.

3954 - Elevated Microclots with Low D-Dimer As an Indicator of Impaired Plasmin Generation in Patients with Viral Infections

Alfar, R.

2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study

Alfar, R.

2277 - Characteristics and Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A 14-Year Experience in a Limited Resource Setting
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Alfaro, E.

2841 - Impact of Late Relapses in the Outcome of Childhood Acute Lymphoblastic Leukemia IKZF1del and IKZF1plus: An Update Findings Previously Reported

Alfaro Moya, T.

687 - Survival and Engraftment Post Allogeneic Hematopoietic Stem Cell Transplantation: ABO Mismatch Matters in RIC
4883 - Tolerability and Efficacy of Post-Transplant Cyclophosphamide in Older Adults Undergoing Matched Sibling Donor Allogeneic Transplantation: A Retrospective Analysis
4896 - Monocytes Matter: Impact of Monocyte Recovery on Allogeneic Hematopoietic Stem Cell Transplant Outcomes with Post-Transplantation Cyclophosphamide As Graft Versus Host Disease Prophylaxis

Alfaro, T.

2183 - Expanding the Donor Pool, the Number of Antigen Mismatches Has No Impact in the Outcomes of Haploidentical Stem Cell Transplantation with Peripheral Blood Stem Cells and Dual T Cell Depletion

Alfattah, H.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients

Alfayez, M.

4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Alfert, A.

2832 - Recurrent Molecular Variants, Clonal Evolution and Clinical Relevance in T-Cell Lymphoblastic Neoplasia Comparing Lymphoma and Leukemia Samples Derived from Children and Adults

Alfieri, R.

4050 - Poisoning of Healthy Hematopoiesis Is an Unanticipated Mechanism Driving Clonal Dominance in Vexas Syndrome

Alfonso, M.

1672 - Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study

Alfraih, F. A.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients
4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Algarotti, A.

2106 - Early Mixed Lymphoid Chimerism in Acute Myeloid Leukemia Patients Undergoing Allogeneic Transplantation after a Myeloablative Busulfan-Based Conditioning Regimen
2186 - Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Retrospective Multicenter Analysis on 285 Procedures Performed between 2000 and 2020
2192 - Effective Cytoreductive Treatment before Allogeneic Hematopoietic Stem Cell Transplantation May Improve the Outcome of Patients with Blast Phase Myelofibrosis

Algarra, J. L.

319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)

Algeri, M.

512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
2126 - Evidence-Based Choice of Conditioning Regimen for Hematopoietic Stem Cell Transplantation (HSCT) in Acute Leukemia: The Italian Cellular Therapy and Stem Cell Transplant Group (GITMO) Guidelines
3561 - Outcomes of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia Given Blinatumomab As Last Consolidation Treatment before Allogeneic Hematopoietic Cell Transplantation
4834 - Phase I/II Clinical Trial on CD19-Chimeric Antigen Receptor (CAR) T Cells Generated with an Automated Process, from Fresh Apheresis, and Reinfused As Fresh Drug Product for Pediatric/Young Adult Patients with Relapsed/Refractory (r/r) B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Alghamdi, I.

1121 - Newborn Screening Program (NBS) for Early Detection of Sickle Cell Disease and G6PD: The Saudi Experience

Alhaddad, M.

2789 - A Novel Approach Combining Type II JAK Inhibitor Chz-868 with Nutrient Restriction to Augment Cell Death in Philadelphia like Acute Lymphoblastic Leukemia

Alhaj Moustafa, M.

111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1637 - Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
1672 - Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study
2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes
3181 - Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Alhajahjeh, A.

788 - Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia

Alhamad, K.

3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis

Alhamrouni, J.

2500 - Voxelotor Impact after 6 Months on Blood Rheology in Patients with Sickle Cell Disease
2506 - Improvement in Kidney Function after 6 Months of Voxelotor in Sickle Cell Disease Patients
2508 - Parameters Associated with Improved Peripheral Oxygen Extraction in Sickle Cell Patients Treated with Voxelotor
2520 - Improvement in Cerebral Vasoreactivity after 6 Months of Voxelotor Measured By Near-Infrared Spectroscopy (NIRS) in Sickle Cell Disease Patients

Alhamzi, A. A.

2531 - Multinational Assessment of Absolute Neutrophil Counts and White Blood Cell Counts Among Healthy Individuals with the Duffy Null Phenotype or Genotype

Alharbi, A.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alharbi, K.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alharbi, M.

5158 - Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Alhayli, S.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients
4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Alhejazi, A.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alhomoud, M.

2034 - Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Alhomoud, M.

912 - CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Alhossiny, M.

4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population

Alhumaid, M.

778 - Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD
4930 - Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

Alhuniti, A.

1217 - Accuracy of a Bleeding Assessment Tool in Predicting the Diagnosis of an Inherited Bleeding Disorder: Systematic Review and Meta-Analysis

Alhuraiji, A.

2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Alhusayan, M.

2730 - CBL Loss or Mutations Reduces MHCII Expression through Downregulating ERG in Myeloid Malignancies
4574 - CBL Loss or Mutations Upregulates AXL to Promote Cytokine-Independent Growth in Myeloid Malignancies: AXL Upregulation Promotes Cytokine-Independent Growth in CBL-Mutant CMML

Ali, A.

71 - Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)

Ali, A. K.

915 - One-Step Construction of Allogeneic CAR-NK Cells Preventing Rejection and Mediating Enhanced Anti-Tumor Responses

Ali, A.

2892 - Optimizing Venetoclax Duration in Combination with Hypomethylating Agents for Newly Diagnosed AML: Impact on Treatment Response and Survival Outcomes
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Ali, A.

467 - Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC^TM Degrader, in Patients with Non-Hodgkin’s Lymphoma
3366 - Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC^TM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Ali, F.

2472 - Effect of Monoferric Transferrins on Fetal Iron Homeostasis and Erythropoiesis

Ali, H.

3910 - High Prevalence of Concomitant Autoimmunity in Patients with Rosai-Dorfman Disease

Ali, H.

729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
1043 - Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Ali, H.

1640 - Waldenström Macroglobulinemia: A Retrospective Survival Analysis Study from SEER Database

Ali, H. A.

2781 - The Cyclin-G Associated Kinase (GAK) Is a Critical Targetable Dependency for Successful Mitosis By Diffuse Large B-Cell Lymphomas Linked to Retinoblastoma Loss of Function

Ali, H.

2023 - CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT
3402 - Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells

Ali, J.

2235 - Systematic Identification of Gene-Drug Interactions Using an Advanced CRISPR Screening Platform to Predict Therapy Response across Cancer Types

Ali, L.

2522 - Effect of Rituximab on Spleen and Blood B-Cell Subpopulations in Allo-Immunized Children with Sickle Cell Anemia

Ali, M.

3421 - In Vitro and In Vivo Activity of a Lipid Nanoparticle System for the In Vivo Generation of CAR T Cells

Ali, M.

2167 - Recipient-Derived Hematopoietic Cells Are the Source of Hematologic Malignancies after Graft Failure and Mixed Chimerism in Adults with Sickle Cell Disease

Ali, M.

2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Ali, M. A.

699 - Treatment Versus Prophylactic Apixaban or Rivaroxaban for Extended Venous Thromboembolic Disease Management

Ali, N.

3324 - Impact of Pre-Transplant Depth of Response on Outcomes in Patients with Multiple Myeloma: A Report on Behalf of Pakistan Blood and Marrow Transplant Group

Ali, N.

265 - CLAG-M or FLAG-Ida Followed Immediately By Allogeneic Hematopoietic Cell Transplantation for Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm
4919 - A Comparison of Different Comorbidity Indices in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): Comprehensibility Vs Simplicity Vs Objectivity

Ali, R.

3642 - Impact of Rapid Latex Immunoassay (LIA) Implementation on Management of Heparin Induced Thrombocytopenia (HIT): A Retrospective Single Institution Study

Ali, S.

3915 - HLH: Time to Transplant; A 10-Year UK Retrospective Cohort Study

Ali, S.

230 - Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma

Ali, S.

2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia

Ali, S.

3939 - Patient-Specific Platelet Phenotypes in Patients with Immune Thrombocytopenia

Ali, S. A.

677 - Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial
1024 - Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Ali, W.

4775 - MP0621 (cKit x CD16a x CD47), a Multi-Specific Switch-Darpin with Conditional Blockade of CD47 Targeting Hematopoietic Stem Cells: Preclinical Evaluation of a Next-Generation Conditioning Agent for Stem Cell Transplantation

Aliazis, K.

123 - Loss of LDH-a Accelerated CD8⁺ T Memory Cell Differentiation but Impairs Anti-Tumor Responses

Alibhai, S. M.

4583 - Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

Alici, E.

3318 - A Lightweight Risk Scoring System for Stratification of Newly Diagnosed Multiple Myeloma Patients
3320 - Outcomes of Relapsed and Refractory Multiple Myeloma with the Evolving Standard of Care
4686 - Predictive Biosignature and Risk Scoring for Bone Disease in Multiple Myeloma

Alig, S. K.

454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
565 - Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma
651 - Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
856 - Modulation of the Tumor Microenvironment By CCL19 in Primary CNS Lymphomas
1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
4374 - The Effect of Ibrutinib on the Myeloid Cell Compartment in Central Nervous System Lymphoma Slice Cultures

Alignani, D.

1879 - Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies
4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma

Alija, B.

2720 - Stag2 Loss Drives Abnormal Chromatin Remodeling with Fli1 Hyperactivity in Npm1c Leukemia

Alikarami, F.

316 - Multimodal Single-Cell Profiling of Minimal Residual Disease in B Acute Lymphoblastic Leukemia Reveals Genetic and Non-Genetic Factors of Early Drug Resistance
725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia

Alikhan, R.

2637 - Rapido: Results from a UK-Wide Audit of 2477 Patients Who Received a Reversal Agent for a Direct Oral Anticoagulant

Alikhanov, G.

2894 - Improved Real-World Outcomes of Patients with Acute Promyelocytic Leukemia Treated with First-Line Arsenic Trioxide in Specialized Centers in Portugal through a 24/7 Phone-Based Referral: A Study from the Portuguese Acute Leukemia Group

Alimam, S.

655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
1804 - Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
2537 - Immunoglobulin Replacement Therapy (IgRT) for the Treatment of Haematological Malignancy Associated Secondary Immunodeficiency (HM-SID) – a Large UK Tertiary Centre Experience
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
4557 - Mympnvoice – a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms

Alin, T.

5000 - Joint Sickle Cell-Gynecology Clinic Improves Access to Reproductive Health

Alin, T.

1662 - Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial
4426 - Impact of Treatment-Related Morbidity on Health-Related Quality of Life in Patients with Advanced-Stage Classical Hodgkin Lymphoma Receiving Multiagent Therapy: Findings from the HD21 Study

Alinari, L.

1402 - Novel Insights into SOX11 Modulation of BCR Signaling and Targeting of BTK Resistance
1403 - Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma
1611 - Transcriptome Analysis at Locus-Specific Resolution Identified Alteration in Human Endogenous Retroviruses, a Class of Transposable Elements in Mantle Cell Lymphoma
1719 - Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial
2078 - Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies
3737 - Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM)
3747 - Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma
4350 - Transcriptomic Analysis in Mantle Cell Lymphoma Patients Identified MALAT1 Long-Non-Coding RNA to Regulate Cell Cycle Progression By Modulating EZH2/p57/Sox11 Axis
4371 - Tumor Microenvironment-Induced Interleukin-6 Regulates Proliferation and Survival in Patients with Mantle Cell Lymphoma (MCL) By Activating FGFR1 Signaling
4460 - Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
4507 - Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Aliouat, A.

27 - Stable Contribution of Lineage-Restricted Stem Cells to Steady-State Aged Human Hematopoiesis
421 - Tolerance of Whole Genome Duplication in Megakaryocytes, and Consequences for Their Genome Integrity

Aliste Santos, C.

3593 - Automated Image Analysis Pipeline for Standardized Processing, Segmentation, and Feature Extraction in Diffuse Large B-Cell Lymphoma Histological Slides: Towards Enhanced Prediction of Immunotherapy Response and Risk Stratification

Alizadeh, A. A.

72 - Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
565 - Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma
648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders
651 - Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling
856 - Modulation of the Tumor Microenvironment By CCL19 in Primary CNS Lymphomas
1157 - Acquired Immunodeficiency Landscapes Via Integrated Noninvasive Viral & Immune Profiling in HIV-Associated Lymphoproliferative Disease
1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid
2223 - Direct Method for Estimating the Fraction of T and B/Plasma Cell-Derived DNA
2276 - The Clinical Impact and Cost-Effectiveness of PET-Based and Ctdna-Based Evaluation at End-of-Therapy after Frontline Treatment of DLBCL
2993 - Resolving the Microarchitecture of Classic and Transformed Follicular Lymphoma By Single Cell Alignment to Spatial Transcriptomes
3051 - High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD
3410 - Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study
4357 - Anatomic Genetic Heterogeneity Is Uncovered By Concurrent Cell-Free DNA and Tissue Profiling and Predicts Treatment Resistance in Diffuse Large B-Cell Lymphoma
4369 - Comprehensive Characterization of the Cell States and Ecosystems in Classic Hodgkin Lymphoma Using Single-Cell RNA-Seq, Digital Deconvolution, and Machine Learning
4374 - The Effect of Ibrutinib on the Myeloid Cell Compartment in Central Nervous System Lymphoma Slice Cultures
- Circulating Tumor DNA: All You Need Is Blood
- Moderator Introduction

Aljama, M.

703 - Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)
1927.1 - Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research

Aljawai, Y.

4937 - HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide

Aljawai, Y. M.

506 - Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial
1922 - Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis
1923 - Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis
3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
4890 - Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide

Aljijakli, A.

731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study

Aljitawi, O.

4065 - Immune Checkpoint Inhibitors Reverse the Mesenchymal Stromal Cell-Mediated Immunosuppression in Acute Myeloid Leukemia Microenvironment
4741 - Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

Aljudi, A. A.

2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Aljumaa, R.

3017 - Cardiac Safety Profiles of First-Generation Vs. Second-Generation BTK Inhibitors: A Meta-Analysis

Aljurf, M.

305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients
2184 - Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Alkaitis, M.

2955 - Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival

Alkan, B.

4808 - Identification of T Cell Senescence As a Cell Fate Limiting the Antitumor Activity of 41BB-Costimulated CART Cells

Alkhader, A.

1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis

Alkhaldi, H.

4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study
4930 - Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse

Alkharabsheh, O.

4742 - Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Alkharabsheh, O.

2288 - The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024)
2411g - Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Alkhateeb, H. B.

440 - Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome
1820 - Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)
1823 - Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
1827 - Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform
2297 - Prognostic Understanding for Older, Medically Infirm, and/or Frail Recipients of Allogeneic Hematopoietic Cell Transplantation in an Ongoing Seamless Phase 2/3 Randomized Interventional Trial (ACE-BMT)
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
2667 - A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
2869 - Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients
3183 - Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41^MT Germline Predisposition Syndrome
3204 - Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4593 - Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)
4918 - Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with High-Risk Myeloid Neoplasms Based on Ptcy Vs TAC/MTX Gvhd Prophylaxis
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Alkhraisat, S.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Allali, S.

180 - Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study
290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project
621 - Rap-536, a Murine Luspatercept Analog Ameliorates Anemia and Vaso-Occlusion in Experimental Model of Sickle Cell Disease
2486 - Inhibition of the Complement Alternative Pathway Attenuates Hemolysis and Preserves Renal Function in a Mouse Model of Sickle Cell Disease
3870 - Complement Activation and Its Implication in the Pathophysiology of Hemolytic Anemia and Aging in Mouse Models of Sickle Cell Disease and Beta-Thalassemia

Allam, R.

4111 - Ribonuclease Inhibitor (RNH1) Is a Novel Regulator in Myelopoiesis and Resolves Differentiation Blockade in Acute Myeloid Leukemia

Allam, S.

3279 - Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Allan, J. N.

746 - MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses
860 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
862 - Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study
866 - Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study
885 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study
1703 - Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study
1869 - Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
2349 - Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3118 - Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK^C481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia
4615 - Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up
4623 - Mutations in the Bruton Tyrosine Kinase (BTK) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Allangba, O. T.

4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Allavena, R.

1150 - Transcriptomic Analysis of the Functions of CSF1R-Dependent Macrophages in Postnatal Development in the Rat

Allegra, A.

992 - Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Allen, A.

1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Allen, C.

805 - ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Allen, C. E.

313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
3489 - Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab As a Bridge to Hematopoietic Stem Cell Transplantation: The Real-HLH Study

Allen, C.

2322 - Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas

Allen, E. K.

2243 - Microlearning in Sickle Cell Disease for Clinicians: A Practical Tool for Everyday Practice

Allen, H. E.

1454 - The Role of the Bone Marrow Immune Niche in Preventing Relapse in Adult B-ALL Following Reduced Intensity Conditioning Allogeneic HSCT

Allen, J. M.

652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
2354 - Financial Toxicity, Health-Related Quality of Life, and Medication Adherence Patient-Reported Outcomes (PROs) in Patients with Chronic Lymphocytic Leukemia (CLL) on First-Line Oral Oncolytics

Allen, K.

3866 - Oral Administration of Nitrous Oxide Reduces Acute Vaso-Occlusive Pain in Mice with Sickle Cell Disease

Allen, M.

4829 - CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies

Allen, P. B.

982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
1664 - Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy
1690 - Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study
1717 - Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis

Allen, S. L.

1849 - Delivery of Foreign Antigen Selectively to Membrane IgD on CLL and Normal B Cells Leads to Superior T-Cell Activation: A Possible Approach to Restore/Enhance T-Cell Immunity and T-Cell Help
1851 - Normal B Cells in MBL Are Biased Toward Antigen-Experienced B Cells, with Increased Percentages of DN1 Cells in IGHV-Mutated MBL and ABC/DN2 Cells in IGHV-Unmutated MBL Suggesting Distinct Follicular/Extrafollicular Maturation Pathways

Allen, S. W.

3909 - Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Allenspach, E.

3919 - Expanding the Role of SH2B3: T Cell Large Granular Lymphocytosis (LGL) and Common Variable Immune Deficiency in the Setting of Biallelic SH2B3 Mutations

Allepuz, A.

710 - A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

Allewelt, H.

3031 - Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study
3255 - Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study
4412 - Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)

Allgar, V.

235 - Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Allick, A.

3882 - Feasibility of Validating a Screening Tool for Neurocognitive Function in Adults with SCD

Allin, D.

4741 - Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

Allman, D.

1033 - P2RX5-Directed CAR-T Cells for Genotype-Guided Treatment of Lymphoid and Plasma Cell Malignancies in Patients of African Ancestry
3266 - Mast Cells Support Multiple Myeloma Survival and Engraftment through Secreted Factors

Allmer, C.

4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)

Allred, A.

215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Allred, C.

213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Allsup, D.

585 - IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study
4630 - Prevalence of BTK and PLCG2 Mutations in BTK Inhibitor Treated CLL Patients Who Experience Disease Progression: A Meta-Analysis

Allsup, D.

4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Almanza, E.

1511 - Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
2903 - Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
4293 - Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia
4584 - Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Almanza-Huante, E.

4262 - Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)

Almaraz, A.

Almási, L.

2805 - Diagnosing and Staging Central Nervous System Involvement in Pediatric ALL: A Global Survey on Its Heterogeneity

Almasri, E.

1551 - Detection of KMT2A Partial Tandem Duplication in Myeloid Samples By Pacbio® Long Read Sequencing

Almasri, M.

762 - Prevalence and Clinical Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Chronic Lymphocytic Leukemia and Richter Transformation
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
2980 - Integration of [¹⁸f]FDG-PET Radiomics with Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed DLBCL Patients

AlMasri, M. M.

1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis

Almeida, A. M.

665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium

Almeida, C.

2894 - Improved Real-World Outcomes of Patients with Acute Promyelocytic Leukemia Treated with First-Line Arsenic Trioxide in Specialized Centers in Portugal through a 24/7 Phone-Based Referral: A Study from the Portuguese Acute Leukemia Group

Almeida, D.

3961 - Proteolysis of Annexin A2 Leads to Inflammasome-Mediated Proinflammatory Response in Human Sepsis

Almeida, I.

1106 - IHP-102 Reduces Hypoxia-Induced Pain Behaviors in Townes SCD Mice

Almeida, J.

4218 - A Novel 12-Color 2-Tube Next Generation Flow Approach Enables Sensitive Detection of Measurable Residual Disease in Virtually All T-Cell Acute Lymphoblastic Leukemia Patients

Almeida, L. Y.

1539 - MLL5-Driven Leukemic Transformation Is Linked to Chromatin Remodeling and Can be Targeted with ATRA in Combination with PARP1 Inhibition

Almodovar Diaz, A. A.

3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia

Almohareb, F.

176 - Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients
4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population
4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Almuallem, L.

3028 - Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Almuina, N. M.

59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial

Alnajjar, A.

2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alnimer, Y.

4605 - Appropriate Timing of Allogeneic Bone Marrow Transplant in Patients with Myelodysplastic Syndrome

Alnughmush, A.

4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population
4863 - Strength to Endure: Superiority of MAC over RIC in Patients <65 Years Undergoing Stem Cell Transplantation Using ATG-Ptcy-CSA for Gvhd Prophylaxis

Alobaidi, H.

2285 - Insufficient Representation and Reporting of Race in the References Forming the Basis of the National Comprehensive Cancer Network Guidelines for Multiple Myeloma

Aloisi, M.

2018 - Local Myeloid Network Resilience Determines Organ-Specific Acute GvHD Outcomes

Alomar, M. E.

Alonso, A.

2232 - Targeted Non-Viral Gene Delivery through Transcutaneous Ultrasound Enables Robust, Redosable, Titratable, and Durable FVIII and FIX Gene Expression in the Liver in Murine Models

Alonso Alonso, J. M.

1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Alonso, A. A.

497 - Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis
2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)
4411 - Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Alonso, C. D.

2407 - Cytomegalovirus Infections Following CAR T-Cell Therapy: A Systematic Review and Meta-Analysis

Alonso, D.

3707 - Iron Deficiency in Pregnancy Is Ubiquitous

Alonso de Apellániz, P.

1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Alonso, E.

1838 - Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

Alonso Fernandez, R.

1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience
3414 - Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate
3442 - CRISPR/Cas9 Multi-Editing Enhances CAR NK Cells Therapeutic Potential Against Multiple Myeloma

Alonso Rodriguez, J.

2156 - Sativex Oromucosal Spray in Patients with Chronic Graft Versus Host Disease: Effect on Sclerodermal Features and Refractory Muscle Cramps

Alonso, S.

2113 - Predictive Value of Liver Sitffness Measurement for Early Diagnosis of Veno-Occlusive Disease and Final Stem-Cell Outcomes

Alonso Trillo, R.

1698 - Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo
4403 - Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study
4422 - Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?

Alonso Vence, N.

1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

Alonso-Dominguez, J. M.

212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Alonso-Dominguez, J. M.

215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
4549 - Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms

Alonso-Saladrigues, A.

112 - “Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
965 - Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT

Alonzo, T. A.

103 - Rapid Long-Read Epigenomic Diagnosis and Prognosis of Acute Myeloid Leukemia
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
2932 - Molecular Characteristics Influencing Relapse Risk in Low-Risk Pediatric Acute Myeloid Leukemia
2949 - Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children’s Oncology Group
4233 - Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial

Alotaibi, A.

778 - Multicenter, Real-World Experience Study of FLT3-Inhibitor Post-Transplant Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia with FLT3-ITD
1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients
4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population
4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Alotaibi, F.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients

Alotaibi, N.

641 - Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment

Alotaibi, S.

4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study
5129 - Impact of Extranodal Involvement on Outcomes with Chimeric Antigen Receptor T-Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Alothaimeen, H.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients
4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Alouch, S.

3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia

Alouni, S.

2500 - Voxelotor Impact after 6 Months on Blood Rheology in Patients with Sickle Cell Disease
2506 - Improvement in Kidney Function after 6 Months of Voxelotor in Sickle Cell Disease Patients
2508 - Parameters Associated with Improved Peripheral Oxygen Extraction in Sickle Cell Patients Treated with Voxelotor
2520 - Improvement in Cerebral Vasoreactivity after 6 Months of Voxelotor Measured By Near-Infrared Spectroscopy (NIRS) in Sickle Cell Disease Patients

Alousi, A. M.

506 - Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial
1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1511 - Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia
2810 - Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
3514 - Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis
4251 - Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation
4841 - Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies
4890 - Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide
4937 - HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide

Alperovich, A.

2351 - Non-White and Hispanic Patients Have Significantly Longer Time from Intent to CAR T Infusion (“Brain-to-Vein” Time) in Multiply Relapsed Diffuse Large B Cell Lymphoma

Alpert, A. B.

- Hematologic Aspects of Gender Affirming Care

Alptekin, S.

753 - Identification and Functional Interrogation of Dormant Cancer Stem Cells in JAK2V617F-Driven MPNs

Alqahatni, A.

2845 - Metabolomic Profiling of Asparaginase-Induced Hepatotoxicity in Pediatric Acute Lymphoblastic Leukemia

Alqahtani, S.

374 - Critical Care Support in Infants Post-Allogeneic HCT: Large Single-Center Cohort Experience
1158 - Cultured Thymus Tissue Implantation for Congenital Athymia Post FDA Approval: Auto-Immunity and Novel Genetic Mutations

Alquist, L.

3477 - Improvements in Axicabtagene Ciloleucel Manufacturing Result in High Delivery Success and More Predictable Turnaround Time for Patients with Relapsed/Refractory Large B-Cell Lymphoma

Alquraan, H.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alrabi, K.

3797 - Genetic Profiling and Risk Stratification of Acute Myeloid Leukemia (AML): Comparative Analysis of the Jordanian AML Cohort (JAMLC) to the German-Austrian AML Study Group (AMLSG)

Alrawabdeh, J.

2277 - Characteristics and Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A 14-Year Experience in a Limited Resource Setting
2405 - Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
3789 - Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma

Alsabbagh Alchirazi, M.

1777 - Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Alsadi, H. M.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alsaedi, H.

5079 - Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Alsaied, T.

799 - Longitudinal Assessment of Myocardial Fibrosis in Sickle Cell Disease

Alsaleh, A.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care

AlSaleh, A.

2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alsdorf, W.

895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
2005 - Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting
2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis
3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

Alserawan, L.

2084 - The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)
3452 - Euplagia-1: A Phase 1/2 Trial of GLPG5201, a Fresh Stem-like Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, in Patients with Relapsed/Refractory CLL and RT

Alshaibani, A.

4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Alshareef, A.

1784 - Outcomes Are Similar for Combination Interferon and Ruxolitinib Versus Ruxolitinib in Myelofibrosis: A Propensity-Score Matched Study

Alsharif, F.

4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population

Alsharif, F. Z.

4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Alsharif, O.

2254 - Implementing Evidence-Based Practices into Thrombophilia Order Sets: A Single Institution Quality Improvement Project

Alshehri, F.

1121 - Newborn Screening Program (NBS) for Early Detection of Sickle Cell Disease and G6PD: The Saudi Experience

Alshehri, M.

1121 - Newborn Screening Program (NBS) for Early Detection of Sickle Cell Disease and G6PD: The Saudi Experience

Alshreef, A.

2349 - Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Alshuraym, N.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alsina, M.

Alsouqi, A.

4629 - Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects

Alsugair, A.

4586 - PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival

Alsugair, A. K.

1827 - Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform

Alsuwaidan, A.

4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population

Alt, A.

3264 - Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling

Altaf, F.

4932 - Outcomes with Venetoclax and Hypomethylating Agents in Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis

Altamimi, S.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Altamura, S.

9 - Inflammation-Driven NFκB Signaling Represses Ferroportin Transcription in Macrophages Via HDAC 1 and 3

Alten, J.

318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL

Altera, A.

1893 - Age-Associated Macrophage Polarization to an M2 Phenotype Drives Myeloma Proliferation in the Aged Bone Marrow By Loss of Tumor-Associated Phagocytosis
4113 - Repolarisation of M2 Macrophages Via Cgas-Sting Activation Enhances Phagocytosis of Acute Myeloid Leukaemia

Althoff, M. J.

39 - MCL1 Promotes Fatty Acid β-Oxidation in Therapy-Resistant AML through Cytoplasmic Sequestration of the Transcriptional Repressor IRF2BP2

Altimari, S.

5043 - Study Assessing the All4Cure Health Technology Intervention on Patient Activation in Multiple Myeloma

Altman, J.

214 - Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
2801 - Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study
2880 - Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007
2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
3794 - Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis
2907.1 - A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Altman, J. K.

221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Altmann, B.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Altmann, H.

3392 - FLT3-ITD Driven CMTM6 Expression Contributes to Immune Escape of Acute Myeloid Leukemia

Altmeyer, S.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial
4903 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Altmüller, J.

1351 - Parallel Sequencing of Transposons and Transcriptomes in Single Cells for Genome-Wide Cancer Gene Discovery

Altom, J.

3281 - CREB1 and TXNIP Regulate Autophagy and Unfolded Protein Response in Multiple Myeloma

Altrock, E.

2670 - Primary Hematopoietic Cells of Vexas Patients Are Highly Sensitive to Treatment with TAK-243 and Pevonedistat

Altuna Mongelos, A.

1034 - CART Cell Therapy Targeting CD84 Alone or in Combination with CD19 for the Treatment of B-Cell Malignancies

Altunsoy, E.

1094 - A New Diagnostic Method for Premarital Screening of Thalassemia and Hemoglobinopathies: Microchip Electrophoresis (Gazelle) Method

Altuntas, F.

2080 - Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease
4411 - Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study

Alturas, J. C.

465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Alturkistani, A.

514 - Prime Editing Enables Precise and Efficient Single Amino Acid Substitutions to Shield CD34+ Hematopoietic Stem Cells from Anti-CD117 Antibody-Based Conditioning

Altwasser, R.

44 - Tracing Clonal Hematopoiesis and Tumor-Specific Mutations in Hematopoietic Progenitors of B Cell Non-Hodgkin Lymphoma (NHL) Patients

Aluri, S.

326 - KRAS G12D Specific Inhibitors Relieve Erythroid Differentiation Block and Modulate Inflammatory Pathways at the Single Cell Level in Myeloid Malignancies
589 - BCMA CART Therapy Failure in Myeloma Is Associated with Immunosuppressive S100A8/9 Overexpression and Can be Ameliorated with Novel Monoclonal Antibodies
878 - TGF-β1-SMAD2 Axis Regulates Hematopoiesis and β-Globin Gene Expression Via Super-Enhancer Associated Chromatin Reorganization
943 - Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion
2909 - Degrading SMARCA2/4 Relieves the Differentiation Block in AML Via Chromatin Alterations Affecting S100A8/9

Alva, H.

1064 - Defining the Impacts of Iron Overload in Children Receiving Hematopoietic Stem Cell Transplantation for Non-Malignant Hematologic Disorders: A Multicenter Analysis

Alvarado Ibarra, M.

1718 - Using Polatuzumab Plus Chemotherapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Study from the Grupo De Estudio De Linfoproliferativos De Latinoamerica (GELL)

Alvarado, L.

2737 - Proteomic Analysis of Thyroid Hormone-Induced Secretome in Cutaneous T Cell Lymphoma

Alvarado Valero, Y.

Alvarado-Navarro, D. M.

4030 - Reassessing Blood Product Irradiation in Haploidentical Transplantation: A Single-Center Perspective

Alvarellos Outeiro, M.

713 - Avespa Study: Effectiveness and Safety of Avatrombopag in Immune Thrombocytopenia (ITP). a Real-World Study of the Spanish ITP Group (GEPTI)

Alvarenga Thiebaud, J.

777 - Prediction of Post-Transplant Relapse of the Myelodysplastic Syndromes Via Evaluation of Stem Cells
4234 - Should “Medically Fit” Older Patients with Acute Myeloid Leukemia (AML) Continue to Receive Intensive Chemotherapy in the Venetoclax (VEN) Era?

Alvares Borges, G.

- Inflamm-Aging Impairs Anti-Tumor Immune Responses in Clonal Hematologic Disease

Alvarez Argote, J.

1554 - Immune-Scape in Myeloid Sarcoma and Acute Myeloid Leukemia

Alvarez Arias, D.

2991 - Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings

Alvarez, C. A.

3807 - Burden and Clinical Outcomes in Patients (pts) with Myelofibrosis (MF) and Anemia Treated with Ruxolitinib (RUX): Data from the Veterans Affairs Corporate Data Warehouse (VACDW)

Alvarez, F.

290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project
1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease
2228 - DeepSurf2-FF: Introducing Force Fields in Deep Learning for Improving in-Silico Prediction of Bcr-Antigen Interactions in B Cell Lymphomas
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Alvarez, F.

153 - Pharmacological Targeting of the Heme-Regulated Inhibitor Kinase Overcomes Ineffective Erythropoiesis in Patients with Myelodysplastic Syndromes with Ringed Sideroblasts and Sickle Cell Disease

Alvarez, G.

5098 - Application of Bone Mineral Density Study Guidelines across California Pediatric Oncology Survivorship Programs

Alvarez, J.

735 - Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Alvarez Mediavilla, E.

1051 - Ex Vivo Lentiviral Hematopoietic Stem Cell (HSC) Gene Therapy May Represent a Curative Therapy for the Life-Threatening Inborn Error of Immunity Severe Combined Immunodeficiency Due to Adenosine Deaminase (ADA) Deficiency (ADA-SCID)

Alvarez, M.

4937 - HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide

Álvarez, N.

3442 - CRISPR/Cas9 Multi-Editing Enhances CAR NK Cells Therapeutic Potential Against Multiple Myeloma

Alvarez, O. A.

2305 - Voxelotor Therapy Reduces Whole Blood Adhesion to VCAM-1 and P-Selectin, and Shows Modest Improvements in Self-Reported Pain in a Real-World Clinical Setting in a Multi-Center Retrospective Analysis
3875 - Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)

Alvarez Roman, M. T.

713 - Avespa Study: Effectiveness and Safety of Avatrombopag in Immune Thrombocytopenia (ITP). a Real-World Study of the Spanish ITP Group (GEPTI)

Alvarez, R.

3705 - Sentiment Analysis Applied to Digital Conversations Among Warm Autoimmune Hemolytic Anemia (wAIHA) Patients Receiving Rituximab and/or Blood Transfusion

Alvarez Soto, A.

2406 - Racial and Socioeconomic Disparities in Patients with Waldenström’s Macroglobulinemia. a SEER Database Analysis

Alvarez-Fernández, C.

920 - HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30⁺ T Cell Lymphoma: Clinical Results of a Phase I/II Trial

Alvarez-Larran, A.

241 - Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia
1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis

Alvarez-Román, M. T.

714 - Use of Avatrombopag in Patients with Immune Thrombocytopenia: Interim Analysis of the Phase 4 Adopt Study
717 - Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study
2569 - B-Cell Distribution in Immune Thrombocytopenia and Its Relation to Ageing
3968 - Fourth Interim Analysis of the Hem Powr Study: A Post Hoc Analysis of Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Adolescent and Older Patients with Hemophilia a
3977 - Concizumab As a Possible Treatment for Bleeding Disordersof Unknown Cause

Alvarez-Twose, I.

3164 - Ultra-Sensitive KIT testing Uncovers Previously Undetected KIT mutations in Patients with Indolent Systemic Mastocytosis: Results from the Pioneer Trial

Álvarez-Twose, I.

1801 - Overall Survival and Duration of Treatment in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib Versus Midostaurin or Best Available Therapy in a Real-World Setting

Alves, A.

3866 - Oral Administration of Nitrous Oxide Reduces Acute Vaso-Occlusive Pain in Mice with Sickle Cell Disease

Alves, L.

1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)
2522.1 - Learner- Low Dose Aspirin Preterm Trial (Angola). Low Dose Aspirin in Pregnant Women with Sickle Cell Disease When Started in the First Versus Second Trimester– a Clinical Control Study in Angola

Alves-Silva, A. B.

4518 - Synergistic Effect of Tamoxifen and Ruxolitinib Combination in Reducing Disease Burden in Myeloproliferative Neoplasms

Alvey, C.

4966 - Abbv-453: A Highly Potent and Selective Next Generation Small Molecule Inhibitor of BCL-2

Alviar-Ortiz, M. P.

4463 - Polatuzumab-Vedotin Plus Bendamustine and Rituximab for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis

Alwadi, M.

3810 - Retrospective Evaluation of BCR::ABL Kinase Domain Mutation Profiles and Treatment Outcomes in Patients with Chronic Myeloid Leukemia to Confirm Clinical Relevance of in Vitro Sensitivity-Based Treatment Switch: Real-World Experience

Alwan, I.

1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis

Alwan, M.

1649 - Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study

Alwang, A.

2241 - Validation of ICD-10 Codes for Identifying Acute Chest Syndrome in Patients with Sickle Cell Disease

Alyamani, A.

3797 - Genetic Profiling and Risk Stratification of Acute Myeloid Leukemia (AML): Comparative Analysis of the Jordanian AML Cohort (JAMLC) to the German-Austrian AML Study Group (AMLSG)

Alyamany, R.

4863 - Strength to Endure: Superiority of MAC over RIC in Patients <65 Years Undergoing Stem Cell Transplantation Using ATG-Ptcy-CSA for Gvhd Prophylaxis

Alyea, III, E.

2295 - Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Alzabibi, M. A.

1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis

Alzahrani, H.

1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients
3575 - Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec
4078 - Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab
4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Alzahrani, H. A.

4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population

Alzahrani, M.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alzahrani, T.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients

Alzaidi, A.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Alzaidy, N.

4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Alzayed, B.

4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population
4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Alzubi, M.

2277 - Characteristics and Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A 14-Year Experience in a Limited Resource Setting
2405 - Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Real-World Experience
3789 - Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma

Amador, C.

231 - Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement– an L.L.M.P.P. Study
456 - An Llmpp Study: Genomic Characterization of Novel PTCL- Biological Subtypes Reveal Distinctive Therapeutic Vulnerabilities
829 - Decoding the Pivotal Roles of BCL10 Activating Mutations in DLBCL Drug Resistance and Lymphomagenesis
1357 - Tet2 Loss and IDH2^R172K Mutation Develop T_FH-Cell-like Lymphoma with Restricted T_H1 Differentiation Program and Cognate Interaction with B Cells
2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
2976 - HIV-Associated Diffuse Large B-Cell Lymphoma Shows Different Genomic Patterns between EBV-Positive and EBV-Negative Tumors
2981 - Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response

Amador, V.

1371 - The SOX11 Interactome Reveals the SOX11:SMARCA4 Complex As a Driver of Oncogenic Transcriptional Programs in Mantle Cell Lymphoma

Amadori, S.

218 - 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
848 - Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3-ITD–Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial
2890 - Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)

Amaki, J.

3058 - Number of Sites of Involvement Predicts Central Nervous System Relapse in Patients with Localized Extranodal Natural Killer/T-Cell Lymphoma

Amallraja, A.

1589 - Genomic Characterization and Classification of BCL6 Rearranged Follicular Lymphomas

Amanam, I.

655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
1043 - Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Amanda, L.

355 - Direct Visualisation of BCMA Bispecific Antibody and the Myeloma Immune Microenvironment

Amano, K.

1211 - TSUBASA Study: A Prospective Study Evaluating the Association between Physical Activity and Bleeding Events, Quality of Daily Life, and Safety in People with Hemophilia A without FVIII Inhibitors

Amaral, A.

2992 - Unveiling the Tumor Microenvironment in Extranodal NK/T-Cell Lymphoma (ENKTCL) Patients with in Situ Spatial Transcriptomics

Amaral Antues, D.

4818 - Cord-Derived Invariant Natural Killer T Cells As Novel Cell Therapy to Improve the Outcome of Hematopoietic Stem Cell Transplantation

Amaral, S.

1064 - Defining the Impacts of Iron Overload in Children Receiving Hematopoietic Stem Cell Transplantation for Non-Malignant Hematologic Disorders: A Multicenter Analysis

Amarante, G. D.

3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)

Amarsy, R.

3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Amatangelo, M.

1973 - Iberdomide, Daratumumab, and Dexamethasone Shows Deep Antimyeloma Activity across Molecular Patient Subsets with Transplant-Ineligible Newly Diagnosed Multiple Myeloma from the CC-220-MM-001 Trial
3261 - Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide

Amato, C.

3800 - Myelodysplastic Neoplasms Patients’ and Caregivers’ Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Amato, V.

1541 - Genomic Landscape and Clonal Hematopoiesis Dynamics in Patients with Ovarian Cancer during PARP Inhibitors Treatment: Preliminary Results of a Prospective Longitudinal Study

Amatya, C.

4789 - Development of Novel Chimeric Antigen Receptors Targeting the Gamma-Delta (γδ) T-Cell Receptor

Amatya, S.

2047 - Enabling Potent T Cell Delivery and Mitigating Key Off-Target Concerns of In Vivo

CAR T Lentiviral Vectors with the Targeted Paramyxovirus Fusogen System

Amaya, M. L.

664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
969 - Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts
2722 - STAT3-VDAC1 Axis Modulates Mitochondrial Function and Plays a Critical Role in the Survival of Leukemic Stem Cells
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3803 - Access to Novel Therapies Impacts Overall Survival (OS) in Low Socioeconomic (SES) Acute Myeloid Leukemia (AML) Patients (Pts)
4259 - Results from a Clinical Study of the All-Oral Regimen of CC-486 (Oral Azacitidine) and Venetoclax for Newly Diagnosed and Relapsed and Refractory Acute Myeloid Leukemia
4266 - Efficacy and Molecular Predictors of Response and Survival for Venetoclax/Azacitidine Therapy in Relapsed or Refractory Acute Myeloid Leukemia

Ambalavanan, A.

1768 - Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML Patients

Ambati, J.

3394 - Therapeutic Targeting of the Inflammasome to Mitigate Murine Sclerodermatous Chronic Graft Versus Host Disease

Ambati, S.

3076 - Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Ambati, S.

862 - Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study
866 - Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study
1628 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study
1650 - Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab
3080 - Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab
3118 - Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
4411 - Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study
4486 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B‑Cell Lymphoma Treated with Odronextamab in the ELM-2 Study
4502 - Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study

Ambinder, A. J.

324 - Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium
450 - A Retrospective Analysis of Intensive Chemotherapy Vs. Venetoclax/Hypomethylating Agents for Patients Aged 60-75 with Favorable-Risk, NPM1-Mutated AML
2436 - The Use of Antifungal Prophylaxis Is Associated with Worse Outcomes in Patients with Newly Diagnosed AML Treated with Venetoclax/HMA: A Retrospective Analysis of Patients in the Flatiron Health Database
2855 - Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML – a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax
3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Ambinder, R. F.

870 - Daratumumab with Dose-Adjusted EPOCH Is Feasible in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105
3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Ambrose, E. E.

289 - Pharmacokinetic (PK)-Guided Dosing of Hydroxyurea for Tanzanian Children with Sickle Cell Anemia
520 - Building Capacity in Sub-Saharan Africa to Address Sickle Cell Disease: The Consortium on Newborn Screening in Africa (CONSA)
541 - Newborn Screening for Sickle Cell Disease in Sub-Saharan Africa: Initial Results of the ASH Consortium on Newborn Screening in Africa (CONSA) Program
2495 - Effects of Splenomegaly in Children with Sickle Cell Anemia Treated with Hydroxyurea: Secondary Analysis of the Sphere Trial

Ambrose, H.

3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Ambrose, J.

3743 - End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting
5101 - Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting

Ambrosoni, C.

3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study

Ame, S.

478 - 18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting
1826 - A Phase 2 Prospective Study Evaluating Low-Dose Deferasirox in Patients with Low-Risk Myelodysplastic Syndrome Resistant or Relapsing after Erythropoietin Stimulating Agents (LODEFI)

Ameerul Faiz, N. M.

872 - Mutation-Specific Differences in the Relationship between Obesity and Clonal Hematopoiesis, with a Focus on JAK2^V617F and MPN Prevention

Amel Riazat-Kesh, Y. J. R.

243 - TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms

Ameli, S.

3312 - Comprehensive (Epi)Genetic Tumor Characterization and Disease Follow-Up in Multiple Myeloma Using Blood-Derived Cell-Free DNA

Amelunxen, E.

318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL

Amend, C. E.

2574 - Interaction between Collagen IV and Heparin-Binding Sites in the Activity, Distribution and Clearance of Factor IX(a)

Amendola, A.

2464 - Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results
4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Amengual, J. E.

336 - Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas
573 - Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort
973 - Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma
3077 - Diagnostic Utility of the ¹⁸f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder
3112 - Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma
4427 - Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)
5042 - Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma
3123.2 - S2207: Randomized Phase II Study of the Addition of Targeted Agents to Tafasitamab-Lenalidomide in Transplant Ineligible Patients with Relapsed/Refractory LBCL

Amer, M.

2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Amer Salas, N.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Amerikanou, R.

1454 - The Role of the Bone Marrow Immune Niche in Preventing Relapse in Adult B-ALL Following Reduced Intensity Conditioning Allogeneic HSCT

Amerikanou, R.

1802 - Efficacy and Tolerability of Trametinib in Adults with Histiocytic Neoplasms

Amico, V.

2464 - Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Amid, A.

298 - Clinical Outcomes of Neonatal Central Line-Related Thrombosis: A Multicentric Retrospective Cohort Study

Amigo, R.

1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Amigorena, S.

3480 - FAS Ablation Confers Resistance to Allogeneic CAR-T Rejection By T Cells in Absence of NK Cell Sensitization

Amin, A.

1759 - Intense Monitoring of JAK2V617F and Wild-Type Hematopoiesis during IFNα Exposure to Dissect Its Mechanism of Action

Amin, H.

494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Amin, J.

3953.1 - A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

Amin, M. K.

Amin, P.

3734 - The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma (NHL) - a Large, Multicenter Study

Amin, V.

1428 - Epidemiological Trends of Acute Lymphoid Leukemia in Individuals Younger Than 20 Years across 204 Countries and Territories from 1990-2021: A Benchmarking Global Analysis
1494 - Exploring the Burden of Acute Myeloid Leukemia Attributable to Smoking in G20 Countries: A Three-Decade Analysis from the Gbd 2021

Amini, R. M.

747 - Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial
3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Amini, S. N.

2554 - The ‘Stop TPO-Receptor Agonist in ITP Patients’ (STIP) Study: Clinical and Immune Modulatory Effects of Romiplostim Tapering
3950 - Platelet Sequestration Patterns and Clearance Rates in Patients with ITP Compared to Healthy Individuals

Amini-Farsani, Z.

4128 - Role of Glucocorticoid Receptor in Normal and Malignant Germinal Center B Cells

Aminilari, M.

2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Aminov, S.

2774 - Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia
2909 - Degrading SMARCA2/4 Relieves the Differentiation Block in AML Via Chromatin Alterations Affecting S100A8/9

Amireault, P.

36 - Vexas Syndrome Is a New Cause of p53-Mediated Erythroblastopenia

Amisha, F.

2004 - Predictive Markers for Outcomes after Disease Progression Post BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
4692 - Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

Amiss, A.

166 - Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia

Amissah-Arthur, K. N.

3 - Double-Blind, Placebo-Controlled Randomized Controlled Trial of Hydroxyurea for HbSC: Results of the Prospective Identification of Variables As Outcomes for Treatment (PIVOT) Trial

Amit, I.

4788 - Single Cell Analysis of Pre-Treatment Peripheral Immune Composition Can Predict CAR-T Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Amit, O.

2086 - Standardization Protocol to Mitigate Progression of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Elderly Patients Treated with CD28 Co-Stimulatory Anti-CD19 CAR-T Cells – a Pilot Study
4504 - CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Amit, S.

76 - Identifying Novel Drug Vulnerabilities in Specified Molecular Subsets of Chronic Lymphocytic Leukemia

Amitani, H.

1453 - Combined Targeting Patient-Specific Anti-Apoptotic Molecules and CXCR4-Expressing CAR-T Cells Eliminated High-Inflammation State Leukemia with Poor-Prognostic Mutations

Amjad, M. A.

4587 - Characteristics of Myelodysplastic Syndromes with Idiopathic Pulmonary Fibrosis

Amjad, Z.

5170f - Global and Regional Burden of Multiple Myeloma from 1980 to 2021: An Analysis of Gbd Study 2021

Amling, M.

4940 - Reconstructing Skeletal Homeostasis through Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis

Ammad Ud Din, M.

1848 - Identifying the Role of Endoplasmic Reticulum Stress in CLL T-Cell Dysfunction
2118 - Outcomes after Bone Marrow Versus Peripheral Blood Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis

Ammad-ud-din, M.

4607 - Enhancing CAR-T Therapy in CLL By Modulating the Immunosuppressive Tumor Microenvironment: A Novel Approach with Significant Therapeutic Potential

Ammatuna, E.

1350 - The Oncogenic ΔNp73α Isoform Contributes to Aggressiveness in APL By Leading to ATRA Resistance through NANOG/BMP4 Axis Upregulation
1393 - DGAT1 Inhibition Enhances Metformin-Induced Ferroptosis in AML By Targeting Lipid Metabolism
4518 - Synergistic Effect of Tamoxifen and Ruxolitinib Combination in Reducing Disease Burden in Myeloproliferative Neoplasms

Ammerlaan, A.

310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Ammirati, L.

835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Amoako, E.

3 - Double-Blind, Placebo-Controlled Randomized Controlled Trial of Hydroxyurea for HbSC: Results of the Prospective Identification of Variables As Outcomes for Treatment (PIVOT) Trial

Amoloja, T.

2375 - Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States

Amonoo, H. L.

2163 - Medication Adherence in Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation
3811 - Factors Associated with Quality of Life Impairments in Patients with Myeloproliferative Neoplasms: Looking Beyond Symptom Burden
5056 - Factors Associated with Early Quality of Life Response to Palliative Care during Hematopoietic Cell Transplantation

Amoozgar, B.

2408 - Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

Amor, G.

1727 - Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework

Amôr, N. G.

1266 - Knockout of the Beta-2 Microglobulin Gene in Adipose Tissue-Derived Cells Using CRISPR/CAS9 System for the Generation of Universal HLA Class I Platelets
3589 - PIM447, a Pan-PIM Kinase Inhibitor, in Combination with Venetoclax Exerts a Potent Anti-Tumor Activity in the Bone Marrow Niche
4968 - Novel MET Inhibitors Provide a Therapeutic Opportunity for AML By Overcoming the Protective Action of the Bone Marrow Niche

Amor-Chelihi, L.

1117 - Autoimmune and Inflammatory Diseases in Children with Sickle Cell Disease: A French Multicenter Observational Study on Diagnostic and Therapeutic Issues

Amorim, R.

1408 - JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models

Amorim, S.

4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Amorouayeche, Z.

3890 - Protection Against Coronary Atherosclerosis in High Cardiovascular Risk Sickle Cell Disease Patients: A Beneficial Role of Intravascular Hemolysis?

Amory, J. K.

905 - Donor XCR1⁺ and CD11b⁺ Dendritic Cells Determine the Severity of Th1 and Th17-Dependent Acute Gvhd within the Gastrointestinal Tract

Amos, C. I.

161 - Optimized Multi-Class VTE-BERT Large Language Model for Prediction of Cancer Associated Thrombosis Phenotype
688 - Biomarker Dynamics in Pediatric Transplantation-Associated Thrombotic Microangiopathy (TA-TMA): A Prospective Cohort and Nested Case-Control Study
812 - External Validation of EHR-CAT Risk Assessment Model for Cancer Associated Thrombosis in 150 Healthcare Organizations
3641 - Implementation of Automated Thrombosis and Bleeding Risk Assessment in Cancer Patients Undergoing Systemic Therapy

Amos, L. E.

556 - Combatt HMB-Recon: Combination Therapy in Adolescents to Treat Heavy Menstrual Bleeding-Review of Charts to Observe Treatment Patterns

Amos, Q.

3980 - Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset

Amoura, Z.

4553 - Characteristics and Therapeutic Response of Erdheim-Chester Disease Associated with Myeloid Neoplasm, an Observational Multicenter Study

Ampatzidou, M.

1444 - Results of the ALL-IC REL 2016 Registry Trial: 1^st Relapses of Childhood ALL Treated in High-Middle Income Countries

Amrein, P. C.

1833 - Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Amri, E.

4080 - High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Amrolia, P. J.

373 - Significant Incidence of Mixed Donor Chimerism Despite TBI Conditioning in Paediatric B-ALL Patients Bridged to Transplant with Blinatumomab – a Report from the UK and Ireland Paediatric Bone Marrow Transplant/Cellular Therapies Group
925 - The Influence of HLA Matching of the Winning and Losing Units in Relapse of Patients Receiving Double Cord Blood Transplantation for Acute Leukemia or Myelodysplastic Syndrome
968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial
2024 - Potent and Effective Targeting of AML with ‘Off-the-Shelf’ Engineered CD45-Targeting CAR T-Cells
4206 - Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective
4317 - Single Cell Multimodal Framework Identifies CD84 As a Leukaemic Stem Cell Target in Paediatric AML

Amses, K. R.

4 - Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate
2051 - Deciphering the Impact of Immunological Aging in CLL CAR T Cell Therapy

Amutio, E.

3049 - The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin’s Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Amzallag, A.

579 - Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)
2967 - Role of Clonal Hematopoiesis (CH) in Lymphoma: Prevalence and Clinical Impact in Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL)

An, G.

832 - TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism
1590 - Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis
1648 - Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia
1678 - Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes
1861 - Prognostic Significance of Monoclonal Gammopathy in Chronic Lymphocytic Leukemia Under Different Therapeutic Backgrounds
1932 - Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma
1990 - First-in-Human, Phase Ia_, Dose Escalation, Monotherapy Study of QLS32015, a Novel GPRC5D×CD3 T-Cell Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
3262 - Critical Roles of LILRB4 in Promoting PIM Kinase Mediated Cell Proliferation and Tumorigenesis in Multiple Myeloma
3356 - MBS314, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x B-Cell Maturation Antigen (BCMA) x CD3 Trispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM): Preliminary Results from a Phase Ⅰ, First-in-Human, Open-Label, Dose Escalation Study
3377 - Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study
3385 - BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)
3386 - CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities
3389 - A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression
4709 - T(11;14) with Multiple Myeloma: Standard Risk Survival but Slow and Poor Response

An, H.

1088 - Young Women with Iron Deficiency Anemia Demonstrate Cerebral Metabolic Stress to Maintain Cerebral Oxygen Metabolism

An, J. J.

2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

An, K.

681 - Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

An, L.

3433 - Engineering a Controllable and Reversible Switch for CAR-T Cell Immunotherapy Via a Genetic Code Expansion System

An, Q.

4632 - Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

An, R.

4291 - Prognostic Implications of KMT2A Rearrangements and Partial Tandem Duplications in AML: Outcomes and the Role of Allogeneic Hematopoietic Cell Transplantation

An, W.

4188 - Relapse Risk and Outcome of Discontinuing Asparaginase in Children with Acute Lymphoblastic Leukemia

An, X.

2790 - EVOLVE205, a Highly Potent 2:1 CD20-Targeted CD2 Co-Stimulatory T Cell Engager Engineered for the Treatment of B Cell Malignancies and B Cell Autoimmune Diseases

An, X.

539 - A Novel Role of LKB1 in Erythroblast Enucleation
619 - IFN-I Promotes T Cell-Independent Immunity and RBC Autoantibodies Via Modulation of B-1 Cell Subsets in Murine SCD
1108 - Quinine-Hemin Compound As an Anti-Inflammatory Therapy in Sickle Cell Disease
2449 - Mettl3-Mediated m⁶a Modification Is Essential for the Maintenance of Genomic Stability of Erythroid Cells
2468 - TFR2 Coordinates Erythroid Iron Availability and Erythropoietin Receptor Sensitivity By Monoferric Transferrin Forms

An, Y. K.

166 - Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia

An, Y.

4810 - Oncolytic Herpes Simplex Virus-Loaded CD19 CAR-T Cells Improves the Therapeutic Effect of Diffuse Large B-Cell Lymphoma

An, Z. Y.

300 - Effects of Low-Molecular-Weight Heparin on Pregnancy Outcomes in Protein S Deficiency: A Prospective, Randomized Controlled Phase II Clinical
425 - β2-Adrenergic Receptor Agonist Terbutaline Regulates Macrophage Polarization Via HMGB1 in Immune Thrombocytopenia
2041 - Tandem CAR-T-Cell Therapy Targeting CD5 and CD7: Facilitating Condition-Free Engraftment of Epitope-Edited Allogeneic HSCs
2566 - Genetic Associations and Platelet Count Trajectories in Gestational Thrombocytopenia and Immune Thrombocytopenia during Pregnancy

Anagnou, N. P.

1603 - The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations

Anam, K.

852 - Machine Learning Identifies Gene Mutations and Variant Allele Fractions That Refine the 2022 European Leukemianet Risk Stratification for Acute Myeloid Leukemia

Anamarija, P. M.

2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Anami, K. I.

1426 - Prognostic Factors for T-Cell Acute Lymphoblastic Leukemia in Children and Young Adults: ALL-T11 Study Conducted By Japan Children’s Cancer Group and Japan Adult Leukemia Study Group

Anampa-Guzmán, A. C.

398 - Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Anand, D.

4519 - The Histone Methyltransferase DOT1L Cooperates with LSD1 to Control Cell Division in Blast-Phase MPN

Anand, S. K.

137 - Targeting Neutrophil CD14 Inhibits Deep Vein Thrombus Formation and Enhances Thrombus Resolution Following Inferior Vena Cava Stenosis in Mice

Anandappa, A. J.

2713 - Codon-Specific Differences in RAS Mutations in AML and Differential Response to Therapeutic Agents

Anani, H.

4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Ananth, S.

679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL

Anasetti, C.

2071 - Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
2130 - Letermovir Prophylaxis Reduces the Risk of Cytomegalovirus Infection in HLA-Matched and Mismatched Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide
4871 - Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis

Anasetti, C.

1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms
4826 - Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic Transplantation

Anastasia, A.

4473 - Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience

Anastasia, A.

1872 - Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi

Anastasiadi, A.

1317 - Characterization of Erythrocytes in PNH: Can We Predict Response to Complement Inhibition Based on Different Erythrocyte Markers?

Anastasiadou, A.

3002 - Distinct Signaling Profiles in Primary Splenic Small B-Cell Lymphomas

Anastasopoulou, A.

3257 - Immunogenicity and Safety of the Recombinant Adjuvanted Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia and Multiple Myeloma

Anazodo, A.

618 - A Systematic Review of Communication Tools to Improve Reproductive and Sexual Health Outcomes in Female Cancer Patients Identified Significant Gendered Data Gaps in Care
2428 - Acute Leukaemia in Pregnancy: A Systematic Review of Maternal and Fetal Outcomes

Anbuselvan, A.

2782 - ATR Inhibition and Replication Stress Converge on a BCL6-Mediated Reversal of the Dark Zone Signature in DLBCL

Anckaert, J.

3297 - Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial

Ancliff, P.

968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Ancliff, P.

2816 - Blinatumomab with De-Escalated Chemotherapy for Infant KMT2A-Rearranged B-Cell Acute Lymphoblastic Leukemia

Ancos-Pintado, R.

2230 - Leveraging AI for Predicting Genetic Alterations in Multiple Myeloma through Morphological Analysis of Bone Marrow Aspirates
3414 - Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Ancukiewicz, M.

68 - Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Andemariam, B.

179 - Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks
522 - Enhanced Artificial Intelligence (AI)-Driven Prediction of Vaso-Occlusive Crises in Sickle Cell Disease: Precision through Advanced Machine-Learning Frameworks and Digital Remote Monitoring
617 - Community Health Worker Engagement with Adolescents and Young Adults with Sickle Cell Disease: Findings from the Comets Study
1066 - Community Health Worker and Mobile Health Programs to Help Young Adults with Sickle Cell Disease Transition to Using Adult Healthcare Services -- the Comets Study; Results from Patient-Reported Outcomes at 6 Months
1135 - Characterizing People with Sickle Cell Disease Who Share Attitudes Regarding Clinical Trial Participation: Findings from the Global LISTEN Survey
1137 - How People with Sickle Cell Disease Rate Motivators is Associated with the Likelihood of Wanting to Participate in a Clinical Trial: Findings from the Global LISTEN Survey
1139 - Motivators and Barriers for People with Sickle Cell Disease Participating in Clinical Trials: United States Findings from the Listen Survey
2339 - Feasibility of Advanced Remote Health Monitoring in Waldenstrom Macroglobulinemia: Integrating Wearable Technology and Digital Quality of Life Tracking
5071 - Comparison of Sickle Cell Disease Patient Experiences in Developed and Developing Countries: Insights from UK and India Patient Cohorts
5072 - A Virtual Hospital Approach in Sickle Cell Disease | Remote Biometric, Quality of Life, and Hospitalisations Monitoring

Andermann, T.

- Impact of Antibiotic Exposure on Outcomes Following TCT

Andersch, F.

2235 - Systematic Identification of Gene-Drug Interactions Using an Advanced CRISPR Screening Platform to Predict Therapy Response across Cancer Types

Andersen, C. R.

3733 - Perceptions of Clinical Trials and Factors Influencing Trial Participation Among Hispanic Patients with Non-Hodgkin Lymphoma

Andersen, E. F.

2704 - Prospective Genomic Study for Optimizing Clonal Hematopoiesis Surveillance in Bone Marrow Failure Syndromes and Related Cytopenia

Andersen, L. S.

1594 - NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

Andersen, M. D.

2997 - Impact of the Immune Landscape in Follicular Lymphoma: Insights into Histological Transformation in the Rituximab Era

Andersen, M. K.

3201 - Oral Vitamin C Supplementation Modulates Inflammatory Cytokines in Clonal Cytopenia of Undetermined Significance and Low-Risk Myeloid Malignancies: Results from EVI-2 Trial

Andersen, Jr., M.

1247 - Anticoagulation and Major Bleeding or Recurrent Thrombosis in Patients with Isolated Cancer-Associated Splanchnic Vein Thrombosis: A Multi-Center Cohort Study

Andersen, M.

1806 - Identification of Calr Mutations in Individuals of the Background Population Reveals Undiagnosed Myeloproliferative Neoplasms and Surprisingly Stable Low Levels of Calr Mutant Allele Burden in Individuals Not Developing Myeloproliferative Neoplasm during 10-14 Year Follow-up

Anderson, C. E.

5174 - Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Anderson, D. R.

1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy

Anderson, E.

3305 - Proteomic Determinants of Renal Organ Response in AL Amyloidosis

Anderson, E.

3674 - Emergency Medicaid Policies Enabling Equitable Access to Healthcare Coverage for Undocumented Individuals with Hematologic Malignancies across the United States

Anderson, G. S.

1891 - Development and Optimisation of a CLEC12A-Targeting Inhibitory CAR to Improve the Safety Profile of SEMA4A CAR-T Cells in Multiple Myeloma

Anderson, H. M.

4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Anderson, J.

2253 - Addressing the Use of Direct Anticoagulants in Antiphospholipid Syndrome – Quality Improvement Initiative

Anderson, J.

4793 - Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Anderson, J.

2562 - Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-Fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-Mediated Diseases

Anderson, J.

4234 - Should “Medically Fit” Older Patients with Acute Myeloid Leukemia (AML) Continue to Receive Intensive Chemotherapy in the Venetoclax (VEN) Era?

Anderson, K.

1089 - Results from the Aurora Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin in Erythropoietic Protoporphyria

Anderson, K. C.

488 - Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma
492 - Single-Cell Whole-Genome Sequencing of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma Patients Receiving BCMA- or GPRC5D-Targeted Immunotherapies
590 - Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma
1018 - Differentiating between MM like Smoldering Myeloma (SMM) and Non-Progressor SMM
1027 - Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma
1896 - Proteasome Shuttle Factor and DNA Repair Protein Rad23A Is a Potential Therapeutic Target in Multiple Myeloma
1905 - 26S Proteasome Non-Atpase Subunit 3 (PSMD3/Rpn3) Is a Potential Therapeutic Target in Multiple Myeloma
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
1947 - Full Spectrum Multi-Parameter Single-Tube Flow Cytometry Analysis for Cross-Sectional Immune-Profiling of Natural Killer Cells in Multiple Myeloma Clinical Samples
1972 - Initial Results from the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2393 - Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3278 - Lipid Nanoparticle-Mediated Combinational mRNA Vaccine for Multiple Myeloma: The Next Stage of Cancer Immunotherapy
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
3360 - Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
3792e - Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network
4130 - Isoform-Level Long Noncoding RNA Dependencies in Multiple Myeloma
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Anderson, Jr., L. D.

496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
675 - Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups
861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
900 - Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
922 - Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
933 - Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
2069 - BMS-986393, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3379 - Phase 2 Study Using Minimal Residual Disease-Driven Adaptive Strategy in Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy – First Report from the Maestro Trial
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
3792h - Upfront Use of Anti-CD38 Monoclonal Antibodies Is Associated with Improvement in Renal Failure in Multiple Myeloma: A Flatiron Real World Analysis from 2010 to 2023
4712 - Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience
5170e - Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents
2000.1 - MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Anderson, M. A.

1012 - Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101
1700 - Real-World Outcomes of Patients with High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements Treated in the Contemporary Era
4384 - Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment
4511 - Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience

Anderson, M.

3690 - Use of Chronic Blood Transfusion Therapies and Pharmaceutical Disease Modifying Treatments in Sickle Cell Disease: A Retrospective Cohort Analysis (2014-2021)

Anderson, N. D.

2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia

Anderson, P. F.

181 - TMEM16E and TMEM16F Regulate the Generation and Procoagulant Activity of Extracellular Vesicles during Endothelial Cell Inflammation

Anderson, S.

390 - AI Predicts Early Relapse Post-Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma Patients in a Multi-Center Real-World Study

Anderson-Crannage, M.

2515 - Defibrotide Reduces Hypercoagulable State in Patients with Sickle Cell Disease-Related Acute Chest Syndrome (IND 127812)

Andersson, B. S.

378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
506 - Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Andersson, C.

2212 - Mapping the Spatial Proteome of Individual Leukemia Cells Undergoing Fludarabine Treatment

Andersson, P. O.

654 - Temporal Trends in Relative Survival of Diffuse Large B-Cell Lymphoma in Sweden and Denmark in the Era of Targeted and Cellular Therapies: A Population-Based Binational Study

Andersson, R.

4070 - Dissecting the Interactions between Leukemic Cells and the Aging Bone Marrow Niche

Andina, N.

3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Andión Catalan, M.

462 - Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Ando, J.

2029 - iPSC-Derived Chimeric Antigen Receptor T Cells That Originally Lack CD5 Expression Exhibits Robust Cytotoxicity Against T-Cell Malignancies
4811 - Preclinical Study of HLA Class I-Edited Allogeneic iPSC-Derived Virus-Specific T Cells Targeting Epstein-Barr Virus-Associated Lymphomas

Ando, M.

2588 - Emicizumab and Immune Tolerance Induction in People with Hemophilia A and Factor VIII Inhibitors: 96-Week Interim Analysis of the AKATSUKI Study

Ando, M.

2029 - iPSC-Derived Chimeric Antigen Receptor T Cells That Originally Lack CD5 Expression Exhibits Robust Cytotoxicity Against T-Cell Malignancies
4811 - Preclinical Study of HLA Class I-Edited Allogeneic iPSC-Derived Virus-Specific T Cells Targeting Epstein-Barr Virus-Associated Lymphomas

Andolfo, I.

410 - pkm2 Binds to the Regulatory Regions of Gata-1 and stat5 in β-Thalassemic Mouse Erythroblasts
1069 - Evaluating the Clinical Impact of Hemoglobinopathy and Hereditary Red Blood Cell Disorder Co-Inheritance in a Cohort of 315 Patients
3837 - PIEZO1 Gain-of-Function Variants Lead to Alterations in Late-Stage Erythropoiesis By Enhancing Enucleation Rate
3867 - Single-Cell Transcriptomic Analysis of Bone Marrow from Humanized Sickle Cell Mice Reveals a Subpopulation of Highly-Expressing S100A8/A9 Mesenchymal Stem Cells

Andorno, A.

2980 - Integration of [¹⁸f]FDG-PET Radiomics with Liquid Biopsy Improves Outcome Prediction in Newly Diagnosed DLBCL Patients

Andorsky, D.

475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
479 - Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Andrade, J.

2429 - Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT

Andrade-Campos, M.

1833 - Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Andraghetti, L.

2207 - Selective Inhibition of the m⁶a RNA Reader, YTHDC1, As a Novel Therapeutic Strategy for MYC-Driven Acute Myeloid Leukemia

André, A.

3124 - CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry

Andre, I.

3457 - SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post HLA Mismatched Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Reset-02 First-in-Human Phase I/II

Andre, K.

802 - Fertility Preservation Outcomes for People with Ovaries and Sickle Cell Anemia: A Multi-Center Study

Andre, M.

565 - Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma
853 - Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling

André, M.

575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
745 - Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

André, O.

4298 - Targeting Cholesterol Homeostasis Enhances Phagocytosis of Acute Myeloid Leukemia Cells

Andreadis, C.

524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
3042.3 - Combination of Glofitamab with Pirtobrutinib in BTK Inhibitor (BTKi)-Naive or Btki-Intolerant Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

Andreadis, C.

887 - Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
3125 - Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4633 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004
4422.2 - Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma

Andreas, H. T.

827 - Targeting Mitochondrial Metabolism to Promote Viral Mimicry and Type I Interferon Response in Acute Myeloid Leukemia

Andreas, M.

648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders

Andreassen, P. R.

4035 - Loss of Cpt1a Results in Elevated Mitochondrial Reactive Oxygen Species from Glucose-Fueled Mitochondrial Oxidative Phosphorylation and Defective Hematopoietic Stem Cells

Andreasson, B.

4543 - Myelofibrosis Therapies and Risk of Major Bleeding, Thrombotic Events and Mortality, a Matched Nationwide Population-Based Study

Andreeff, M.

53 - Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML
61 - Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones
216 - Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML
330 - TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML
726 - Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors
735 - Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
841 - Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations
882 - Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms
1301 - Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML
1389 - Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus RNA Signaling in AML Cells and Induces T Cell Activation
1400 - Targeting Lipid Droplet Biogenesis to Enhance Ferroptosis in Acute Myeloid Leukemia
2755 - Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells
2759 - ERK1/2 Inhibition Mediates Bax Dependent Proteolysis of OPA1 and Induces Mitochondrial Cristae Remodeling to Overcome Resistance to Venetoclax
2765 - Molecular Interactions between Mitochondrial Ferroptosis and Apoptosis Pathways in Acute Myeloid Leukemia
2766 - Transcriptomic Signature of Resistance to Decitabine/Venetoclax in AML Patients
2883 - Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
2903 - Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
4155 - Reactivation of p53 in TP53-Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations
4263 - Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Andreozzi, F.

4929 - Return to Work after Allogeneic HSCT: Further Insights in the Patients-Related Predictive Factors (The SOPRALLO Project)

Andres, J.

5195 - Predictors of Individual Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study

Andres, M.

3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Andresen, F.

441 - Outcomes of Hematopoietic Stem Cell Transplantation for High-Risk Marrow Features without Malignancy in Shwachman-Diamond Syndrome

Andresson, T.

2490 - 8-Oxoguanine DNA Glycosylase 1 Recruits Transcription Factor STAT1 to Promote the Inflammatory Responses in Sickle Cell Disease

Andrew, G.

59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial
2950 - Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Andrews, C.

1506 - Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Andrews, R. K.

3939 - Patient-Specific Platelet Phenotypes in Patients with Immune Thrombocytopenia

Andricopulo, A. D.

3868 - Novel Selective HDAC1/2 Inhibitor 2-Aminobenzamide Derivative Potently Induces Fetal Hemoglobin

Andrieu, C.

2881 - MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Andrieu, G. P.

2793 - APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities

Andrieux, G.

442 - Hematological Phenotypes in GATA2 Deficiency Syndrome Arise from Secondary Injuries and Maladaptation to Proliferation

Andrieux, G.

1298 - SPARC Stabilizes Integrin α4-VCAM-1 Interactions and Is Regulated By Intracellular Rac in NPM1-Mutated AML
4119 - STAT5-Activating Oncogenes Drive Oncostatin M Production Causing T Cell Exhaustion and Suppressive Myeloid Cell Recruitment
4365 - Identification of Ikaros As Novel Interaction Partner of Cyclin D1/CDK4 in MCL

Andronache, A.

334 - B Cell Receptor Inactivation Boosts NK Cell Killing of MYC-Driven Lymphomas

Aneke, J. C.

2509 - Evaluating the Effect of Hydroxyurea on Fertility in Individuals Identifying As Women

Anesi, A.

3992 - Very Long-Chain Saturated Fatty Acids Are Inversely Correlated with Thrombin Generation and Linked to a Reduced Risk of Coronary Artery Disease and Myocardial Infarction: Preliminary Findings from an Angiographically-Controlled Study

Ang, C.

4610 - Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK^C481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Ang, Q. X.

3724 - Impact of Cardiovascular Diseases on in-Hospital Outcomes of CAR T-Cell Therapy in the United States
3741 - Sex Difference in Outcomes of CAR T-Cell Therapy
5118 - Age and CAR T-Cell Therapy: Assessing Outcomes across Different Age Groups

Ang, Z.

1033 - P2RX5-Directed CAR-T Cells for Genotype-Guided Treatment of Lymphoid and Plasma Cell Malignancies in Patients of African Ancestry
4170 - PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Angeletti, I.

4621 - Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study

Angelillo, P.

3131 - Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study

Angelillo-Scherrer, A.

1120 - Transcriptomic Profiling Supports the Phenotypic Classification of Stable-State Sickle Cell Disease Patients
4111 - Ribonuclease Inhibitor (RNH1) Is a Novel Regulator in Myelopoiesis and Resolves Differentiation Blockade in Acute Myeloid Leukemia

Angelini, D. E.

2259 - Utilization and Clinical Outcomes of an Electronic Best Practice Alert to Prevent Venous Thromboembolism in High-Risk Cancer Patients
3633 - Patient-Centered Management of Heavy Menstrual Bleeding on Anticoagulants: An International Survey
5086 - Clinical Outcomes of Cancer-Associated Venous Thromboembolism in Patients with Gastrointestinal or Genitourinary Cancers Treated with Direct Oral Anticoagulant Vs. Low Molecular Weight Heparin

Angelopoulou, M.

1317 - Characterization of Erythrocytes in PNH: Can We Predict Response to Complement Inhibition Based on Different Erythrocyte Markers?

Angelopoulou, M.

4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Angelos, M. G.

504 - Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Angelov, D.

4121 - A Novel Form of AEBP2-Containing PRC2.2 Is a Genetic Dependency in Germinal Centre B-Cell Lymphoma and Its Targeting Can Overcome Acquired Resistance to EZH2 Inhibition

Angelucci, E.

176 - Allogeneic Transplantation for Sickle Cell Disease Offers High Rates of Cure with Low Incidence of Severe Chronic GVHD in Both Children and Adults: Real World Data from 2010-2021. An Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
2136 - Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
2180 - Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2184 - Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party
2186 - Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Retrospective Multicenter Analysis on 285 Procedures Performed between 2000 and 2020
2190 - Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3559 - Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
3856 - Risk Assessment of Complications Prevalence in Italian Chelated Transfusion Dependent Thalassemia Patients

Angenendt, L.

4242 - “As Treated” Validation of the European LeukemiaNet (ELN) Classification for Adult Acute Myeloid Leukemia (AML) Patients (pts) Treated in a Large AML-Referral Center from 2010-2022

Angénieux, C.

19 - Liver and Spleen Work Together to Clear Allogeneic Platelets from the Bloodstream during Transfusion Refractoriness
2642 - Anti-HLA-I IgG Subclass Influences Antibody-Mediated Platelet Activation in the Context of Platelet Transfusion Refractoriness

Angerman, C.

2320 - Real-World Use of Efanesoctocog Alfa in Adult Patients with Hemophilia a Including Those with a History of Factor VIII Inhibitor

Angermann, H.

3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Angheben, C.

3992 - Very Long-Chain Saturated Fatty Acids Are Inversely Correlated with Thrombin Generation and Linked to a Reduced Risk of Coronary Artery Disease and Myocardial Infarction: Preliminary Findings from an Angiographically-Controlled Study

Anghelescu, D.

3688 - Health-Related Communication in Adolescents and Young Adults with Sickle Cell Disease

Angiolillo, A.

1 - Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
315 - Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
2855 - Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML – a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax
3226 - Improved Hematologic Recovery with Ivosidenib in Patients with mIDH1 Relapsed or Refractory MDS: Results from a Phase 1 Substudy
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131

Angona, A.

241 - Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia
1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia
4549 - Impact of Atrial Fibrillation on Patients with Myeloproliferative Neoplasms

Angoso, M.

4075 - Upfront HSCT with an Alemtuzumab Based Conditioning Regimen in Children with Acquired Aplastic Anemia: A Retrospective Study from the SFGM-TC
4859 - Up-Front Matched Unrelated Donor Transplantation in Pediatric Patients with Idiopathic Aplastic Anemia: A Phase II Feasibility Study, on Behalf of Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and French Reference National Center of Severe Aplastic Anemia

Angotzi, F.

1523 - Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study

Anguille, S.

93 - Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Anguita, J.

2044 - Molecular Tumor Burden and Clonal Evolution As Factors Associated with Early Progression in Large B-Cell Lymphomas Treated with CAR-T Therapy
4889 - Outcomes of Allogeneic Transplantation with Clofarabine and Post-Transplant Cyclophosphamide-Based Conditioning in Patients with Very High-Risk Acute Myeloid Leukemia

Angulo Llorente, A.

2230 - Leveraging AI for Predicting Genetic Alterations in Multiple Myeloma through Morphological Analysis of Bone Marrow Aspirates

Angulo Salazar, M.

642 - Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1-Mutated Myeloid Malignancies

Angus, S. P.

1390 - Belvarafenib Inhibits the Growth of RAS-Mutant Acute Myeloid Leukemia Cell Lines in Vitro and Drives Adaptive Resistance In Vivo

Anie, K. A.

522 - Enhanced Artificial Intelligence (AI)-Driven Prediction of Vaso-Occlusive Crises in Sickle Cell Disease: Precision through Advanced Machine-Learning Frameworks and Digital Remote Monitoring
5071 - Comparison of Sickle Cell Disease Patient Experiences in Developed and Developing Countries: Insights from UK and India Patient Cohorts
5072 - A Virtual Hospital Approach in Sickle Cell Disease | Remote Biometric, Quality of Life, and Hospitalisations Monitoring
- The Intersection of Sickle Cell Disease, Stigma, and Pain in Africa

Anil, V.

2443 - Unveiling Regional Disparities in Cancer Care - Analysis of the Geographical Journey and Relocation Patterns of Hematology/Oncology Fellowship Graduates

Anilkumar Sithara, A.

1887 - Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment

Anim-Burton, S.

4892.1 - Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST): A Multi-Center Randomized Double-Blinded Placebo-Controlled Phase IIa Trial

Anizi, E.

518 - Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care
2173 - Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Anjum, M. U.

1794 - Utilizing Large Language Models to Automate Prognostication in Patients with Myelofibrosis: A Retrospective Cohort Study

Ankita, S.

4817 - Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine

Ann, B.

2892 - Optimizing Venetoclax Duration in Combination with Hypomethylating Agents for Newly Diagnosed AML: Impact on Treatment Response and Survival Outcomes
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Anna, M.

1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Annesley, C.

4827 - Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Annett, G.

2085 - A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Annette, C.

1033 - P2RX5-Directed CAR-T Cells for Genotype-Guided Treatment of Lymphoid and Plasma Cell Malignancies in Patients of African Ancestry

Annibali, O.

1639 - Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi
3020 - Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study
4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Annis, D. S.

2574 - Interaction between Collagen IV and Heparin-Binding Sites in the Activity, Distribution and Clearance of Factor IX(a)

Annoni, A.

4050 - Poisoning of Healthy Hematopoiesis Is an Unanticipated Mechanism Driving Clonal Dominance in Vexas Syndrome

Annunziata, K.

3762 - The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe

Annunziata, M.

113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia
995 - FATE and Role of Peripheral Blood CD26+ Leukemia STEM CELLS at Diagnosis in Chronic Myeloid Leukemia Patients: FINAL Results of Prospective Flowers Study
1778 - Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy
3162 - Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

Annunziata, S.

854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma

Annunzio, K.

398 - Addition of Monoclonal Protein to MALT-IPI Improved Identification of MALT Patients at High Risk of Progression with Current First-Line Therapies
473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
2344 - Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study
3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Annyapu, E.

254 - Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Anota, A.

4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Ansah, P.

2441 - Prospective, Multicenter Study to Assess the Effect of the Speaking Book on Patients’ Understanding of Clinical Research Knowledge: The SOUND Study

Ansaldo, K.

655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
3179 - Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Ansar, S.

5197 - FLT3 Inhibitors As Maintenance Therapy Post Allogenic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients with FLT3 Mutations; A Systematic Review and Meta-Analysis

Ansari, B.

5045 - Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma
5162 - Social Determinants of Health (SDOH) and Access to CART for Multiple Myeloma
5163 - Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma

Ansari, M.

968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial
2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
3540 - Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party

Ansari, S.

72 - Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Ansari, S.

4541 - A Novel BCR::ABL1 Rearrangement Harboring the Gatekeeper Mutation Drives Hyper-Kinase Activity Conferring Resistance to Ponatinib and Asciminib Combination Therapy

Ansari-Pour, N.

1909 - A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

Ansell, S. M.

458 - PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601
570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
580 - A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience
866 - Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study
1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
1618 - Cytokine-Inducible SH2-Containing Protein (CISH) Is an Intracellular Immune Checkpoint That Controls T Regulatory Cells in Splenic Marginal Zone Lymphoma
1624 - Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
1629 - Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
1672 - Real World Experience with Sequential Brentuximab Vedotin Plus AVD Chemotherapy As Frontline Therapy for Older Patients with Classical Hodgkin Lymphoma: A Multicenter Retrospective Study
1710 - Characteristics and Outcomes of Incidentally Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
2372 - Correlation between Pre-Apheresis Biomarkers and Development of Severe Cytopenias and Therapy-Related Myeloid Neoplasms in Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy
2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
2977 - Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUV_max in Follicular Lymphoma
3045 - Brentuximab Vedotin (BV) and Nivolumab (nivo) for Untreated Patients with Hodgkin Lymphoma (HL): Long-Term Results
4381 - BCL2 Expression Correlates with New Molecular Classification of Anaplastic Large Cell Lymphoma
4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study
4427 - Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma Enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)

Ansoleaga, B.

738 - Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE^®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Anson, L.

2582 - Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a

Anstee, N. S.

51 - Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission
217 - A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial
223 - Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
2941 - Lipidomic Analysis of Flt3-ITD AML Cells Treated with Intensive Chemotherapy and Independent of Concomitant Sorafenib Display a Profile of Increased Susceptibility to Ferroptosis
4136 - CD74 Antibody Conjugated to an MCL1 Inhibitor (S227928) Combines Synergistically with Venetoclax to Enhance Killing of Acute Myeloid Leukemia

Ansuinelli, M.

149 - Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform
838 - Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph⁺ Acute Lymphoblastic Leukemia Patients
1041 - Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation

Ante, Z.

2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
3749 - Subsequent Primary Malignancies in Patients with Indolent B Cell Non-Hodgkin Lymphoma Receiving Frontline Bendamustine Rituximab Therapy
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Antel, K.

4340 - Access to Diagnosis through Liquid Biopsy (ADLiB): A Cell-Free DNA Assay to Diagnose Lymphoma and Differentiate from Other Causes of Enlarged Lymph Nodes

Anthias, C.

925 - The Influence of HLA Matching of the Winning and Losing Units in Relapse of Patients Receiving Double Cord Blood Transplantation for Acute Leukemia or Myelodysplastic Syndrome

Anthony, L.

3882 - Feasibility of Validating a Screening Tool for Neurocognitive Function in Adults with SCD

Anthony, S. P.

3587 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia
4622 - LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton’s Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort

Antico, G.

1628 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Odronextamab in the ELM-2 Study
4486 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B‑Cell Lymphoma Treated with Odronextamab in the ELM-2 Study

Antignani, G.

3596 - Predicting Antigen-Specific T Cell Immunity Against Wilms Tumor 1 in Hematologic Cancer

Antin, J.

1045 - Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT

Antin, J. H.

379 - Heterogeneity of PD-1⁺regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease
1041 - Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation
3500 - BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study
3538 - Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse
4833 - Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant
4866 - Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4885 - Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Antipov, L.

3585 - AUTX703, a Novel and Potent KAT2A and KAT2B Protein Degrader, Induces Differentiation and Offers Survival Advantage in a Primary Human AML Xenograft Model

Antmen, A. B.

409 - ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
2136 - Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party
3575 - Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec

Antmen, B.

2184 - Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party

Antolino, G.

5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Antonacci, M.

113 - Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Antonelli, B.

1696 - Post-Transplant Lymphoproliferative Disorders (PTLD) in a Referral Center

Antonelou, M.

1083 - High Incidence of Thalassemia Traits Among Myelodysplastic Syndrome Patients May Mask Macrocytic Anemia but Not the Enhanced Proteasome Proteolytic Activity

Antongiorgi, J.

2250 - Bridging the Gap for Sickle Cell Disease Patient Data in Sub-Saharan Africa By Expanding Access to Specialty Biomarkers and Clinical Trials

Antonilli, S.

654 - Temporal Trends in Relative Survival of Diffuse Large B-Cell Lymphoma in Sweden and Denmark in the Era of Targeted and Cellular Therapies: A Population-Based Binational Study

Antonio, B.

2168 - HLA-DQ8 Haplotype Increases the Risk of Relapse after Allogeneic Stem Cell Transplantation Possibly Affecting Graft-Versus-Leukemia: A Single-Center Study on 400 Patients

Antonio, D.

981 - CTCL Clustering in Iowa, Illinois, and Kentucky and Its Association with Environmental Factors

Antonioli, E.

2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials
5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Antoniou, E.

228 - Significance of RT-qPCR-Based Measurable Residual Disease for Optimizing the Treatment of Pediatric Acute Myeloid Leukemia
3548 - Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group
4322 - Comprehensive Analysis of Target and Immune Checkpoint Markers in Pediatric AML

Antoniou, N.

1927 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
1979 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group

Antony, C.

416 - CEBPA Regulates Molecular Kinetics of RNA Polymerase I in Myeloid Progenitors
1275 - Ribosomal RNA Transcription Is Differentially Regulated Across the Hematopoietic Tree
4099 - Leukemia-Mutated Proteins PHF6 and PHIP Form a Repressive Chromatin Complex That Suppresses AML Stemness

Antony-Debré, I.

3585 - AUTX703, a Novel and Potent KAT2A and KAT2B Protein Degrader, Induces Differentiation and Offers Survival Advantage in a Primary Human AML Xenograft Model

Antoon, J.

3682 - Ketamine Use in Hospitalized Children and Young Adults with Sickle Cell Disease

Antopia, M. C.

756 - HMGA1 Chromatin Regulators Disrupt 3D Genome Architecture and Chromatin Looping to Repress MHC II Genes and Drive Immune Evasion during MPN Progression

Antoranz, A.

1617 - Golcadomide Extends Survival of Lymphoma GEMM Mice in Combination with a CD20xCD3 T-Cell Bispecific through Increased T-Cell Activation and Infiltration

Antoszewski, M.

953 - Targeted Protein Degradation Reveals a Repressive Role of Mecom at the CEBPA Locus to Prevent Differentiation in High-Risk Acute Myeloid Leukemia

Antti, M.

2049 - Optimizing the IFNγ Axis Improves CAR T-Cell Potency in AML but Not B-ALL

Antun, A. G.

2620 - Fetal and Maternal Morbidity in Pregnant Patients with Thrombotic Thrombocytopenic Purpura: A Nationwide Analysis

Antunes, D. A.

1059 - Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia

Antunes Dos Reis, R.

34 - T Cell Receptor Clonal Dynamics and Hematopoietic Recovery after Immunotherapy in Severe Aplastic Anemia
104 - Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome

Antunes Ferreira, E.

2536 - Deep Cellular and Molecular Characterization Reveal a Distinct Phenotype and Metabolic Signature of Human Senescent CD8⁺ T Cells: Implication for Cancer Cellular Therapy
3444 - Dual Inhibition of Histone and DNA Methylation in AML Enhances the Effectiveness of TCR-Based Cellular Therapy through Upregulation of Surface MHC Class I/p53 Antigen Complex

Antunes Heck, L.

3958 - Whole Genome Sequencing to Elucidate Genetic Modifiers of FVIII Clearance Heterogeneity in Patients with Hemophilia a

Antunovic, P.

639 - Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

Anuncio, S.

824 - Immunotherapy of Acute Myeloid Leukemia Enabled By Targeting of Pan-Cancer Molecular Patterns with a Novel Trispecific T Cell Engager

Anupindi, K.

2200 - Selection for an HIV-Resistant Immune System By Base-Edited CD45 CAR-T Cell Therapy

Anuraj, A.

671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
3776 - Racial Differences in Proportion of Myeloma Cases Attributable to Modifiable Risk Factors in the United States, 2016-21

Anwar, H.

2327 - Baseline Characteristics of Individuals with Paroxysmal Nocturnal Hemoglobinuria in an App-Based Home-Reported Outcomes Study to Evaluate Disease Burden

Anwar, I.

Anwar, N.

3324 - Impact of Pre-Transplant Depth of Response on Outcomes in Patients with Multiple Myeloma: A Report on Behalf of Pakistan Blood and Marrow Transplant Group

Anwer, F.

897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1252 - Superior Safety and Efficacy of Doacs over Warfarin in Obese Patients: A Propensity-Matched Cohort Study
1911 - Assessing the Efficacy and Safety of Reduced Dexamethasone Duration in Newly Diagnosed AL Amyloidosis Versus Standard Therapy
1918 - Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients
1924 - Clinical Outcomes and Disease Progression after Daratumumab-Based Treatment in Primary Amyloidosis
1959 - Infectious Risk in Multiple Myeloma Patients Undergoing Treatment with Teclistamab
1969 - Epidemiological Trends in Incidence, Death and Associated Risk Factors of Multiple Myeloma 1990-2021 and Projection to 2040
2008 - Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory Multiple Myeloma – a Meta-Analysis
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4706 - Impact of Kidney Transplantation on Hospitalization Outcomes in Patients with Multiple Myeloma
4708 - An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
5032 - Disparities in Time to First Prescription Fill for Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma
5040 - Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns
5045 - Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma
5163 - Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma
5170h - Improving Specialty Access for Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Plasma Cell Disorders (PCDs): 10 Years of Experience and a Successful Model of Care

Aoki, J.

4548 - Optimal Procedures of Allogeneic Transplantation for BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia

Aoki, T.

646 - Tumor Microenvironment Differences between Diagnostic and Relapsed Classic Hodgkin Lymphoma Revealed By Single Cell Transcriptome Sequencing
855 - CSF2RB Mutations Result in Cytokine-Dependent Gain-of-Function Phenotypes in Classic Hodgkin Lymphoma
2966 - Multiomic Profiling Reveals Pleiotropic Effects of Somatic IRF4-C99R Mutations in Primary Mediastinal Large B-Cell Lymphomas
4385 - Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD
- Sequencing Technologies in Hodgkin Lymphoma

Aotsuka, N.

4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy

Aparicio, J.

3327 - Characterization of the Tumor Microenvironment of Diagnostic Bone Marrow Core Biopsies from African American Multiple Myeloma Patients Using Imaging Mass Cytometry

Apazidis, A.

1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Apea, V.

2531 - Multinational Assessment of Absolute Neutrophil Counts and White Blood Cell Counts Among Healthy Individuals with the Duffy Null Phenotype or Genotype

Apelu, S.

4806 - A Regulated Cytokine Engineering Strategy to Augment in Vitro and In Vivo persistence of Allogeneic iPSC Derived CD8 T-Cells

Aperna, F.

3171 - Autoimmune or Inflammatory Diseases in 1,968 Consecutive Patients with Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcome and Co-Morbidities
4552 - Cancers in Polycythemia Vera and Essential Thrombocythemia: A before and after Diagnosis Survey and Analysis of Risk Factors

Apithy, M. J.

2642 - Anti-HLA-I IgG Subclass Influences Antibody-Mediated Platelet Activation in the Context of Platelet Transfusion Refractoriness

Aplan, P. D.

1404 - Cytarabine Resistance Leads to a Specific Mutator Phenotype in Leukemic Cells
4108 - HoxBlinc LncRNA Reprograms CTCF Independent TADs to Drive Leukemic Transcription and HSC Dysregulation in NUP98 Fusion Transformed Leukemia
4126 - The Hypomethylating Agent 5-Aza-4’-Thio-2’-Deoxycytidine Targets Early B Progenitor Cells and Leads to B Cell Precursor Acute Lymphoblastic Leukemia in Rag1 Knockout Mice

Aplenc, R.

103 - Rapid Long-Read Epigenomic Diagnosis and Prognosis of Acute Myeloid Leukemia
116 - Near Universal National Uptake of Dexrazoxane in the Real-World Setting Associated with Reduced Cardiac ICU Care Requirements in Pediatric Acute Myeloid Leukemia
369 - Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro, In Vivo, and Ex Vivo Anti-Leukemia Activity
531 - Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)
967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
2932 - Molecular Characteristics Influencing Relapse Risk in Low-Risk Pediatric Acute Myeloid Leukemia
2946 - Serum-Based Proteomic Analysis of Cytokine Release Syndrome in Pediatric AML Patients Receiving CART123

Apodaca Chavez, E. I.

3941 - "Platelet Variability Index As a Diagnostic Tool in Primary Immune Thrombocytopenia: Findings from a Cohort Study"

Apollonsky, N.

617 - Community Health Worker Engagement with Adolescents and Young Adults with Sickle Cell Disease: Findings from the Comets Study
1066 - Community Health Worker and Mobile Health Programs to Help Young Adults with Sickle Cell Disease Transition to Using Adult Healthcare Services -- the Comets Study; Results from Patient-Reported Outcomes at 6 Months

Apolot, D.

3629 - Caregivers and Healthcare Workers Experiences and Preferences with Use of Penicillin Prophylaxis in Young Children with Sickle Cell Anemia in Uganda

Apostolopoulou, C.

1083 - High Incidence of Thalassemia Traits Among Myelodysplastic Syndrome Patients May Mask Macrocytic Anemia but Not the Enhanced Proteasome Proteolytic Activity

Appanasamy, V.

1617 - Golcadomide Extends Survival of Lymphoma GEMM Mice in Combination with a CD20xCD3 T-Cell Bispecific through Increased T-Cell Activation and Infiltration

Appelbaum, D.

3336 - Identifying 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA and Treatment Response in Multiple Myeloma with a Multi-Step Machine Learning Approach

Appelbaum, F. R.

6 - Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study
218 - 10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years
1544 - Karyotype AI for Precision Oncology
4309 - Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG

Appelbaum, J. S.

6 - Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study
265 - CLAG-M or FLAG-Ida Followed Immediately By Allogeneic Hematopoietic Cell Transplantation for Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm
629 - Loss of 5q Drives Evolution to Aneuploidy in an iPSC Model of Complex Karyotype AML
1530 - 4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)
4288 - Phase I Trial Combining Venetoclax with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) for Patients with Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms
4780.1 - Trials in Progress: Decoy-Resistant Interleukin-18 (DR-18) for Relapse or Pre-Emptive Treatment of Measurable Residual Disease after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome (DR. DREAM), a Phase I Trial

Apperley, J.

1104 - Small Activating RNA-Mediated Induction of HBG Via Liposome Delivery for In Vivo Treatment of Sickle Cell Disease and Beta-Thalassemia
2435 - The Impact of Ponatinib on Pregnancy Outcomes
3148 - 5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results
3163 - BCR::ABL1 transcript Type Does Not Impact Allogeneic Stem Cell Transplant Outcome in Chronic Myeloid Leukaemia

Appiah-Kubi, A.

175 - Individualized, PK-Guided Dosing of Hydroxyurea for Young Children with Sickle Cell Anemia: Final Results from the Hydroxyurea Optimization through Precision Study (HOPS)
617 - Community Health Worker Engagement with Adolescents and Young Adults with Sickle Cell Disease: Findings from the Comets Study
1066 - Community Health Worker and Mobile Health Programs to Help Young Adults with Sickle Cell Disease Transition to Using Adult Healthcare Services -- the Comets Study; Results from Patient-Reported Outcomes at 6 Months

Appius, A.

1313 - Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab
2687 - Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition

Applegate, K.

1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Aprile, L.

2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Apsel Winger, B.

2846 - GWAS Identifies Pharmacogenetic Markers Associated with Premedication-Related Pegaspargase Hypersensitivity and Toxicities in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma

Apte, S.

3635 - Patient Decision Aid for Extended Duration Thromboprophylaxis for Major Abdominopelvic Cancer Surgery: A Usability Study

Apte, S.

715 - Annualized Bleeding Rates in Patients with Hemophilia a or B and Inhibitors with and without Target Joints at Baseline: Results from the Concizumab Phase 3 Explorer7 Study

Aptekar, J.

2077 - Secondary Hematologic Malignancies in Patients Following Chimeric Antigen Receptor T-Cell Therapy: Aggregated Clinical Trial Data from 1542 Patients

Aptekmann, A.

1888 - Repurposing DNA Methyltranferase Inhibitors As Epigenetic Priming Agents for T Cell Directed Therapies in Multiple Myeloma

Apudhyay, A.

5062 - Comparing Emergency Department and Infusion Clinic Outcomes Among Individuals with Sickle Cell Disease Seeking Care for Vaso-Occlusive Crises

Aqil, B.

2801 - Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study

Aquilina, C.

4473 - Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience

Aquino, A.

3926 - Large Scale Manufacturing of GMP Grade Cord Blood Derived Megakaryocytes for Chemotherapy Induced Thrombocytopenia

Aquino, S.

4699 - Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Aquino-Fernandez, E.

5205 - Moral Distress and Burnout Among Hematologists in Mexico: Results of a National Survey

Ar, M. C.

710 - A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3

Ara, T.

260 - Gvhd-Induced Inflammatory Memory in Intestinal Stem Cells Enhances IFN-y-Induced Antigen Presentation and Apoptosis of Intestinal Epithelial Cells
902 - Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation
903 - Early Initiation of Calcineurin Inhibitor Induces CD8⁺ Transitory Exhausted-like and CD4⁺ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide

Arad, A.

1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation
3189 - DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms

Arad-Cohen, N.

322 - Comparison of the WHO and ICC Classifications of Cytogenetic Abnormalities in Childhood Acute Myeloid Leukemia
323 - Measurable Residual Disease Monitoring during Treatment for Pediatric Acute Myeloid Leukemia in First Relapse Predicts Outcome
2954 - Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with RUNX1::RUNX1T1

Arai, A.

3059 - Treatment and Outcome of ATL Diagnosed in 2021 to 2023 By the Kagoshima ATL Registry

Arai, A.

2204 - Functional Analysis of EBV-Derived microRNAs in Systemic Chronic Active EBV Disease Using Novel Antisense Oligonucleotides
2969 - The Potential of Plasma CXCL10 As a Biomarker That Reflects Pathogenesis and Prognosis in Systemic Chronic Active EBV Disease
4851 - Novel Method to Evaluate the Quantitative Immune Functionality of CAR T-Cells to Analyze the Localization Change of CAR Molecules

Arai, S.

69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
386 - Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
679 - Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
2006 - Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
2116 - A Standard Operating Protocol for Pre-Transplant Low Dose Splenic Radiotherapy for Patients with Myelofibrosis
3536 - Spatial Characterization of Molecular Pathways Suggests the Dysregulation of LGR5 Expressing Fibroblasts in Patients with sclerodermatous Chronic Graft-Vs-Host Disease
4681 - Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis
4902 - Cytokines associated with organ manifestations in chronic graft-versus-host disease
2134.1 - Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

Arai, Y.

2621 - Immediate Therapeutic Intervention for Acute Mortality in Immune-Mediated Thrombotic Thrombocytopenic Purpura with Positive Chest Findings at Initial Presentation
3569 - To What Extent Have Post-Transplant Outcomes Improved Following the Introduction of Tyrosine Kinase Inhibitors in Elderly Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia? a Retrospective Nationwide Survey in Japan

Araji, G.

2641 - Cancer-Associated Venous Thromboembolism Among Solid and Hematological Malignancies: A Comprehensive National Study
3936 - Maternal Bleeding Complications in Pregnant Women with Immune Thrombocytopenic Purpura: A Retrospective National Study

Araki, D.

1273 - CD38 Inhibition Enhances Human Hematopoietic Stem Cell Maintenance in Ex Vivo Cultures

Araki, K.

26 - Chromatin Modifier Hmga1 Maintains Hematopoietic Stem Cell Integrity in Stress Conditions

Aral, B.

3842 - Hereditary Erythrocytosis: Results from Europe's Largest Idiopathic Erythrocytosis Database

Aramaki, T.

4146 - BP1223, a Novel T Cell Engager Targeting CD39 for Potent Antitumor Activity in Acute Myeloid Leukemia

Arana Yi, C. Y.

1798 - Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials
1823 - Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
2667 - A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations
2800 - Ph-like ALL Is Associated with Unfavorable Outcomes in Hispanics and Native Americans: A Multicenter Analysis
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
2869 - Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4556 - Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis
5195 - Predictors of Individual Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Arandela, J.

873 - Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells

Arango Ossa, J. E.

248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
1589 - Genomic Characterization and Classification of BCL6 Rearranged Follicular Lymphomas

Aranha, M. P.

155 - Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma
488 - Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
1928 - Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Aranha, M. A.

2348 - Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL
3774 - Smoldering Multiple Myeloma in Latin America- Risk Stratification

Arani, N.

4293 - Patterns of Relapse Following Venetoclax-Based Therapies of Differing Intensity in Acute Myeloid Leukemia

Arany, Z.

2881 - MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study

Arar, A.

349 - Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial

Arat, M.

2193 - Optimizing Haploidentical Transplant for Adults with Acute Lymphoblastic Leukemia: The Role of Donor and Graft Selection. a Study from the ALWP of the EBMT
3570 - Ptcy Overcomes HLA Mismatch in Unrelated Donor Transplant for Acute Lymphoblastic Leukemia: A Study from the ALWP of the EBMT

Araten, D.

3706 - The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry: Highlights of the Data from the First Three Years

Araujo, C.

774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma

Araujo, G. H.

1168 - G6b-B Directs Megakaryocyte Transcriptional Program Controlling Differentiation and Bone Marrow Homeostasis

Araujo-Ayala, F.

333 - CD70 Deregulation in Follicular Lymphoma at Diagnosis Is Associated with Relapse and Opens New Avenues for Dual CD19-CD70 CAR-T Therapy
1613 - Patient-Derived Follicular Lymphoma Tumoroids: A Tool to Recapitulate Biological Features of Low and High-Grade Lymphoma

Arauz, G.

4805 - P-CD19CD20-ALLO1: Potent Fully Allogeneic CAR-T Therapy Targeting CD19 and CD20 with Superior Efficacy over Single-Target Products

Arauz, G.

2232 - Targeted Non-Viral Gene Delivery through Transcutaneous Ultrasound Enables Robust, Redosable, Titratable, and Durable FVIII and FIX Gene Expression in the Liver in Murine Models

Arays, R.

2615 - Improving Thrombotic Thrombocytopenic Purpura Outcomes with a TMA Team and TTP Pathway

Arbel, R.

5120 - Atrial Fibrillation Management and Outcomes in Bruton’s Tyrosine Kinase Inhibitor Treated Chronic Lymphocytic Leukemia Patients

Arbelaez Monroy, M. I.

2084 - The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Arber, C.

2032 - Novel Natural Ligand Chimeric Antigen Receptors (CARs) Targeting CD70 with a Redesigned CD27 Binding Interface Provide Enhanced Potency Against Acute Myeloid Leukemia

Arber, D. A.

244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
1425 - Clinical and Molecular Characterization of TP53-Mutant Acute Lymphoblastic Leukemia
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Arbet-Engels, C.

3924.1 - Trials in Progress: A Phase 3 Study to Investigate Efficacy, Safety, and Tolerability of Mavorixafor in Participants with Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders

Arbeteta Juanis, J.

1131 - Non-Invasive Prenatal Diagnosis of Sickle Cell Disease in Spain

Arbini, A.

3608 - AI-Powered Evaluation of Bone Marrow Biopsies Can Distinguish Myeloid Neoplasms from Clinical Mimics

Arboe, B.

3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Arbona-Haddad, E.

3500 - BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study

Arcaini, L.

339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi
2269 - A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUV_max in Follicular Lymphoma
3328 - An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response
4362 - Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)
4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study
4786 - High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion
1927.1 - Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research
3042.1 - Mosunetuzumab and Zanubrutinib in Relapsed/Refractory Follicular Lymphoma Patients (MOZART): A Phase II, Chemo-Free Trial from Fondazione Italiana Linfomi (FIL)

Arcaini, L.

1580 - Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients
1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
1639 - Survival after First Relapse in Marginal Zone Lymphomas: Prospective Data from the International Observational NF10 Study By the Fondazione Italiana Linfomi
1854 - Treatment with Venetoclax Positively Modulates Immunological Parameters and T-Cell Features in Patients with Chronic Lymphocytic Leukemia
2168 - HLA-DQ8 Haplotype Increases the Risk of Relapse after Allogeneic Stem Cell Transplantation Possibly Affecting Graft-Versus-Leukemia: A Single-Center Study on 400 Patients
3020 - Hepatitis C Virus and Hepatitis B Virus in Indolent Lymphomas: Prospective Data from the International Observational NF10 Study
3520 - Endothelial Dysfunction and Risk of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation: END-GAME Prospective Study Final Results
4400 - Persistence of Monotypic Plasma Cells after Chemoimmunotherapy in Patients with Waldenström Macroglobulinemia: A Matter of Time?
4797 - Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Arcari, A.

339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
1580 - Longitudinal Monitoring of Circulating Tumor DNA to Predict Survival in Newly Diagnosed Peripheral T-Cell Lymphoma Patients

Arce, N.

2785 - LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

Arce, O.

1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
4328 - Single-Cell Multiomics Data-Driven Measurable Residual Disease (MRD) Assessment Using Multidimensional Flow Cytometry (MFC) in Acute Myeloid Leukemia (AML)
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Arcese, W. G.

2186 - Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Retrospective Multicenter Analysis on 285 Procedures Performed between 2000 and 2020

Archer, D. R.

2487 - Placental Abnormalities in the Humanized Mouse Model of Sickle Cell Disease
3863 - Pharmacological Inhibition of TMPRSS6 Decreases Hemoglobin Concentration and Red Blood Cell (RBC) Hemolysis in a Mouse Model of Sickle Cell Disease

Archer, K. G.

581 - Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial
3106 - Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Archer, N.

602 - Opportunities for Standardizing Conversations about Curative Therapy for Sickle Cell Disease
1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)
3682 - Ketamine Use in Hospitalized Children and Young Adults with Sickle Cell Disease

Arcila, M. E.

248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
4346 - Molecular Features Are Associated with Disease Stage in Diffuse Large B-Cell Lymphoma and Reveal Heterogeneity in Patient Outcomes

Arcioni, F.

3859 - Pregnancy and Childbirth in Women with Thalassemia: Past and Present

Arcos, D.

3801 - Molecular Features of Acute Myeloid Leukemia in Hispanics: An Analysis from the Marrow Consortium

Arcuri, L. J.

2698 - Higher Graft Failure after Haploidentical in Comparison to Matched Related and Unrelated Stem Cell Transplantation for Severe Aplastic Anemia: A Single-Center Retrospective Study

Arcuri, L.

1327 - Application of Machine Learning in the Diagnostic Work-up of Telomere Biology Disorders
2533 - Unsupervised Analysis Applied to a Cohort of Likely Acquired Neutropenia: Is It a Unique Entity ?

Arcuri, P.

2440 - Clinician’s Knowledge and Awareness of Patient-Reported Outcomes in Immune Thrombocytopenia: Results of a National Survey (ITP NET, GIMEMA Working Group Anemia and Thrombocytopenia)

Ardeshna, K.

4387 - Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Ardizzoia, F.

2916 - T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

Arellano, M. L.

211 - Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
1841 - Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (mIDH1) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria
4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Arellano, M.

622 - Social Stress Impacts Multicellular Molecular Mechanisms in the Brain Affecting Nociception and Neuroimmune Activity in Sickle Cell Disease
3869 - Mechanisms Underlying Acute Pain in Sickle Cell Disease
3871 - Mechanism-Based Treatable Targets for Organ Damage and Pain in Sickle Cell Disease

Arellano-Rodrigo, E.

241 - Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia

Arellano-Viera, E.

3397 - TNFR2, GITR and DR3 Agonists Exert Distinct Response Durations in Treg-Mediated Acute Graft-Versus-Host Disease Protection

Aremu, Y.

686 - Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Arena, L.

3620 - Feasibility, Safety and Effectiveness of Intranasal Fentanyl in the Treatment of Acute Pain Episodes Among Adults with Sickle Cell Disease: A Retrospective Single Center Study
5069 - How Does Cognition Impact Healthcare Transition Skills, Engagement and Utilization in Young Adults Living with Sickle Cell Disease?

Arena, V.

1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
4329 - Leukemic Phenotype Determines Prognostic Relevance of Limit of Quantification for Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

Arenas Merizalde, C.

369 - Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro, In Vivo, and Ex Vivo Anti-Leukemia Activity
1361 - Targeting HMGA1 Epigenetic Regulators and Downstream ETV5 Pathways with Histone Deacetylase Inhibitors in Combination Therapy for Relapsed, Pediatric B-ALL

Arepally, G.

174 - Molecular Mechanism Underlying Excessive Phosphatidylserine Exposure in Sickle Red Blood Cells and Potential Therapeutics
2459 - Targeting Gardos Channel to Regulate Lipid Scrambling in Red Blood Cells
2605 - Complement Activation As a Biomarker for Platelet Activating Antibodies in Heparin-Induced Thrombocytopenia (HIT)
2606 - The PF4-Centric Immunothrombotic Disorders, HIT, Vitt and APS, Lead to Complement Activation Responsive to Complement-Blocking Therapeutics
2609 - Inflammasome Cytokine Secretion in Heparin-Induced Thrombocytopenia Is Supported By Platelet-Derived Mediators and Complement

Arepally, G. M.

2611 - Anti-Phospholipid Syndrome (APS) Antibody (Ab)-Induced Thrombosis Can be Blocked By Platelet Factor 4 (PF4)-Directed Abs: A Novel Therapeutic Approach for APS?

Arethuse, A. E.

521 - Baseline Neurological Morbidity Assessment in Adult Patients with Sickle Cell Disease : The Montreal Brain-SCD Cohort

Arevalo Leon, C. E.

4947 - Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Arfa, A.

4551 - Comparison of the Clinicopathological Findings of Patients with SF3B1/JAK2, SF3B1/Calr, or SF3B1/MPL co-Mutations

Arfeuille, C.

1433 - Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia

Arffman, M.

1601 - Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas

Argabright, A.

1446 - Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia

Argnani, L.

3740 - Immune Checkpoint Inhibitors in Primary Mediastinal B-Cell Lymphoma: A Monocentric Real-Life Experience and Future Potential

Arguello De Tomas, M.

3232 - Patients with Chronic Lymphocytic and Non-Hematologic Autoimmune Disorders Show Distinctive Clinical and Immune Alterations in Th17 and Treg Cells

Argueta, D. A.

622 - Social Stress Impacts Multicellular Molecular Mechanisms in the Brain Affecting Nociception and Neuroimmune Activity in Sickle Cell Disease
3869 - Mechanisms Underlying Acute Pain in Sickle Cell Disease
3871 - Mechanism-Based Treatable Targets for Organ Damage and Pain in Sickle Cell Disease

Arguiñano, J. M.

3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Arguiñano Perez, J. M.

1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Argunhan, F.

1284 - DNMT3A-Mutant Clonal Haematopoiesis Is Associated with Worse Recovery after ST-Elevation Myocardial Infarction Via Increased Inflammation

Argyle, C.

4026.1 - Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Cardiac Surgery Patients: Protocol Update for an Ongoing Phase 3, Double-Blind, Placebo-Controlled, Multicenter Study

Argyropaidas, P.

2358 - Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study

Argyropoulos, K. V.

463 - Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
817 - Single-Cell Spatial Transcriptomics Identifies Lymphoid Aggregates with Location-Specific Alterations of Adaptive Immune Cells in Human MDS Bone Marrow
2010 - Regulatory T Cell Derived Trefoil Factor 1 Drives Thymic Regeneration in Allogeneic Hematopoietic Cell Transplantation

Arias, J.

4339 - Genome-Wide Meta-Analysis Identifies Multiple Germline Genetic Variants Associated with Increased Risk of Follicular Lymphoma
4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)

Aribi, A.

729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
966 - CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study
1008 - IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results
1840 - PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study
2278 - Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
4264 - Phase 1 Trial of Navitoclax/Venetoclax/Decitabine Combination in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR^® Registry
1504.2 - Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy

Ariceta, B.

1889 - Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses

Aries, J.

2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Arif, T.

937 - Sting and Vdac Inhibitors Ameliorate Ineffective Erythropoiesis in a Mouse Model of Anemia Induced By Mutation in EKLF/KLF1

Ariffin, H.

4192 - Improved Outcomes for Pediatric B-ALL but Inferior Survival for T-ALL Using the Same Treatment Protocol: Results of Consecutive Malaysia-Singapore 2003 and 2010 Childhood ALL Trials

Arihara, Y.

149 - Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform

Arima, H.

334 - B Cell Receptor Inactivation Boosts NK Cell Killing of MYC-Driven Lymphomas
453 - B Cell Receptor Silencing Reveals Origin and Impacts Treatment of High-Grade B Cell Lymphomas with MYC and BCL2 Rearrangements
3030 - Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan

Arima, N.

3059 - Treatment and Outcome of ATL Diagnosed in 2021 to 2023 By the Kagoshima ATL Registry

Arimura, A.

1850 - Impact of Docirbrutinib (AS-1763) Treatment in CLL: Preclinical Data and Early Clinical Biomarkers
1866 - Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies

Ariotti, A.

573 - Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Aristei, C.

147 - Treg Selection from G-CSF Stimulated Donors Improves Outcomes of Immune-Suppression Free HLA-Haploidentical Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy
269 - Safety of 20Gy Total Marrow Irradiation Based Conditioning Regimen for Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy

Arita, M.

1453 - Combined Targeting Patient-Specific Anti-Apoptotic Molecules and CXCR4-Expressing CAR-T Cells Eliminated High-Inflammation State Leukemia with Poor-Prognostic Mutations

Arjani, S.

4443 - Impact of Patient and Donor Factors on Successful Hematopoietic Stem Cell Transplantation for Acute T-Cell Leukemia/Lymphoma Patients in an Underserved Minority Population

Arkenau, H. T.

1500 - EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Final Results of Dose Escalation and Optimization Cohorts from a Phase I/IIa Study in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS)

Arking, D. E.

4054 - Mitochondrial Heteroplasmy Is a Novel Predictor of Chronic Lymphocytic Leukemia Risk

Arlauckas, S.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Arlet, J. B.

3904 - Circulating Erythroblasts Are Associated with Specific Characteristics in Adult Patients with Sickle Cell Disease: The Drepablast Study

Arman Bilir, Ö.

2679 - Mitochondrial Quality Control in Acute Lymphoblastic Leukemia Bone Marrow Stem Cells

Armand, M.

3241 - Prognosis of the IGLV3-21^R110 Mutation in a Real-Life Chronic Lymphocytic Leukemia Cohort

Armand, M.

857 - A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation

Armand, P.

459 - A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
1669 - Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
2031 - Early MRD Detection after CAR-T Associated with Poor Outcome in Patients with Large B-Cell Lymphoma
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study
4406 - Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma
4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
4409 - Long-Term Follow-up of Bendamustine/Rituximab – Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)
4611 - Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients
4617 - Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL
4628 - A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
4947 - Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Armand-Ugon, M.

1034 - CART Cell Therapy Targeting CD84 Alone or in Combination with CD19 for the Treatment of B-Cell Malignancies

Armant, M.

4957 - Impact of BEAM-101 Treatment on Red Blood Cell Hemoglobin Expression, Rheology and Sickling Properties: Initial Data from the BEACON Phase 1/2 Study of Autologous CD34⁺ Base Edited Hematopoietic Stem Cells in Sickle Cell Disease

Armari Alla, C.

2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)

Armaroli, A.

3856 - Risk Assessment of Complications Prevalence in Italian Chelated Transfusion Dependent Thalassemia Patients

Armatys, A.

319 - Clinical Features and Outcomes in 228 Patients Diagnosed with Blastic Plasmocytoid Dendritic Cell Neoplasm: A Pethema/PALG Study
320 - Treatment Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Data from the Pethema and PALG Epidemiologic Registry

Armengol, G.

2803 - Single Center Experience Combining Multiple Tools for Genetic Diagnosis of B-Cell Acute Lymphoblastic Leukemia

Armenian, S.

14 - Clonal Hematopoiesis and Venous Thromboembolism Risk in Lymphoma Patients Surviving Autologous Transplantation
403 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Myeloid Malignancies: A BMTSS Report
947 - Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation
2338 - Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Lymphoid Malignancies: A BMTSS Report
2411d - Long-Term Health Outcomes in Older (≥60 Years) Blood or Marrow Transplantation (BMT) Recipients: A Report from the Blood or Marrow Transplant Survivor Study (BMTSS)
3715 - Individual- and Area-Level Socioeconomic Disadvantage and Risk of Death Due to Chronic Health Conditions Among Autologous Blood or Marrow Transplant (autoBMT) Recipients for Lymphoma: A BMT Survivor Study (BMTSS) Report
4924 - Social Vulnerability Is an Important Predictor of Cardiovascular Disease Risk after Allogeneic Hematopoietic Cell Transplantation
5036 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Lymphoid Malignancies – a BMT Survivor Study (BMTSS)
5053 - Predictors of Risky Health Behaviors Among Blood or Marrow Transplant (BMT) Survivors of Myeloid Malignancies – a BMT Survivor Study (BMTSS)
5146 - Self-Rated Health Is an Independent Predictor of Late Mortality after Blood or Marrow Transplantation (BMT) Among Survivors of Plasma Cell Disorders: A BMTSS Report

Armistead, P.

919 - CD30.CAR-T Cells Co-Expressing the CCR4 Chemokine Receptor in Relapsed/Refractory Hodgkin Lymphoma
1481 - Azacitidine and Venetoclax with or without Donor Lymphocyte Infusion in Relapsed AML Post Allo-HSCT: A Single-Institution Retrospective Study

Armitage, J. O.

2368 - Impact of Icans on Long-Term Neurocognitive Function in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy

Armoon, M.

2381 - Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA
3760 - Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study
5151 - Real World Evidence on Patient Reported Outcomes Among Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Regimens in Frontline (1L)

Armstrong, K. A.

786 - Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer

Armstrong, L.

1617 - Golcadomide Extends Survival of Lymphoma GEMM Mice in Combination with a CD20xCD3 T-Cell Bispecific through Increased T-Cell Activation and Infiltration

Armstrong, S. A.

188 - In Vivo barcoded CRISPR-Cas9 Screen Identifies Ncoa4-mediated Ferritinophagy As a Dependence in Tet2-Deficient Haemopoiesis
724 - Discerning the Landscape of Menin Inhibitor Resistance
825 - The Histone Acetyltransferase MOZ (KAT6A) Is a Molecular Dependency and Therapeutic Target in NUP98-Rearranged Acute Myeloid Leukemia
952 - Identification of a Novel Chromatin Structure Associated with the Transcriptional Response to Menin Inhibitors in AML
4060 - Loss of Negative Metabolic Feedback Drives TET2 Mutant Inflammation
4162 - Transient Menin Inhibition Is Sufficient to Induce Irreversible Polycomb-Mediated Silencing and Potent Anti-Proliferative Effects in MLL-Rearranged AML

Armytage, T.

568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial
1445 - Health-Related Quality of Life in Adolescents and Young Adults Treated with Blinatumomab Consolidation for CD19+ Ph-Negative Acute Lymphoblastic Leukemia in the Australasian Lymphoma and Leukaemia Group (ALLG) ALL09 "Sublime” Study
2359 - Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study
5126 - Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study

Arnaldos, C.

2084 - The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)

Arnaldos López, Á.

1698 - Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo

Arnan, M.

225 - Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations
738 - Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE^®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study
1838 - Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group
2874 - A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
4591 - Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Arnan, M.

597 - Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis
1825 - Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)
2708 - Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes

Arnason, J. E.

72 - Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study
866 - Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study
887 - Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
1874 - A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
2407 - Cytomegalovirus Infections Following CAR T-Cell Therapy: A Systematic Review and Meta-Analysis
3118 - Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies
3125 - Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3724 - Impact of Cardiovascular Diseases on in-Hospital Outcomes of CAR T-Cell Therapy in the United States
4408 - Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)
4617 - Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL
4628 - A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)

Arnaud, A.

4001 - Caplacizumab in Immune-Mediated Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Literature Review and Meta-Analyses of Clinical Trials and Observational Studies

Arnaud, A.

2582 - Cost Comparison of Efanesoctocog Alfa with Existing Factor VIII Replacement Therapies for Major Surgeries in People with Severe Hemophilia a

Arnaud, C.

1117 - Autoimmune and Inflammatory Diseases in Children with Sickle Cell Disease: A French Multicenter Observational Study on Diagnostic and Therapeutic Issues

Arnaud-Borboa, I.

1420 - Liver Steatosis and Metabolic Toxicities in Acute Lymphoblastic Leukemia Adults Undergoing Asparaginase-Based Therapy: Findings from a Non-Invasive Assessment Study

Arnaud-Borboa, I.

1424 - P53 Protein Expression By Immunohistochemistry and Its Impact on Survival in Adults with Acute Lymphoblastic Leukemia
3946 - Iron Deficiency in Immune Thrombocytopenia: Are We Doing Enough?
4189 - Vincristine Dose Adjustments in Acute Lymphoblastic Leukemia: Impact on Treatment Outcomes and Neuropathy

Arnautou, P.

2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study

Arndt, B.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Arndt, P. F.

1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome

Arner, A.

275 - ALL-R: An Anchoring Score to Predict Relapse in Acute Lymphoblastic Leukemia (ALL) Using a Zebrafish Patient-Derived Xenograft Model

Arnhardt, I.

847 - Prognostic Impact of Subclinical FLT3-ITD Microclones in Patients with Acute Myeloid Leukemia
2951 - Prognostic Role of NGS-Based MRD Assessment in FLT3-TKD Mutated Patients with Acute Myeloid Leukemia

Arnold, C.

148 - A Synthetic Receptor Enables Breakthrough Scale Manufacturing of iPSC-Derived CD19-CAR Cell Therapies for Hematologic and Autoimmune Diseases

Arnold, C.

845 - Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements – Experience from UK NCRI AML17 and AML19
2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Arnold, C.

286 - COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy

Arnold, D.

547 - Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicentre Cohort Study
1182 - Mean Platelet Volume in Patients with Liver Cirrhosis and Chronic Liver Disease: A Case-Control Study
1243 - Clinical and Serological Characteristics of Vaccine-Associated Immune Thrombocytopenia Following COVID-19 Vaccination
2565 - Simplifying Eligibility Criteria for Clinical Trials in Immune Thrombocytopenia Using the Platelet Count Variability Index
3945 - Platelet Laboratory Markers of Failure of First-Line Treatments in Immune Thrombocytopenia (ITP)
5083 - Quality of Life, Physical and Mental Health of Patients with Vaccine Induced Immune Thrombotic Thrombocytopenia after Extended Followup
- Plenary Introducer

Arnold Egloff, S.

3734 - The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma (NHL) - a Large, Multicenter Study

Arnold, J.

1051 - Ex Vivo Lentiviral Hematopoietic Stem Cell (HSC) Gene Therapy May Represent a Curative Therapy for the Life-Threatening Inborn Error of Immunity Severe Combined Immunodeficiency Due to Adenosine Deaminase (ADA) Deficiency (ADA-SCID)

Arnold, O.

253 - Evolution of Clonal Hematopoiesis after Discontinuation of Therapy for Multiple

Arnold, S. D.

709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
2691 - Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration

Arnold, V.

2864 - A Prospective, Multicenter Study Assessing Functional and Psychosocial Parameters in AML Patients ≥ 60 Years Receiving Induction Chemotherapy

Arnone, M.

49 - MRC2+ AML Stem Cells Reveal the Role of Proline Metabolism in Venetoclax Resistance

Arnould, A.

1433 - Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia

Arnould, B.

3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Arnoux, I.

226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network

Arnulf, B.

1980 - Effect of Daratumumab on Renal Outcome in Newly Diagnosed Multiple Myeloma with Light Chain CAST Nephropathy
4343 - Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)
4760 - Immunological Predictive Markers of Response to Idecabtagene Vicleucel Therapy in Multiple Myeloma : A Real-World Experience from St Louis Hospital (France)
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Aroldi, A.

3117 - Lorlatinib Monotherapy in Relapsed/Refractory ALK + Lymphomas Previously Treated with Other Tyrosine Kinase Inhibitors: 5-Year Update of a Phase 2 Open Label Monocentric Study
4797 - Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Arons, E.

863 - A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia
1586 - Non-V600E BRAF Gene Alterations in Hairy Cell Leukemia

Aroori, S.

235 - Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich
1641 - A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank

Arora, A.

1366 - Loss of IRF2BP2 Drives an Actionable IL-1β/IL-1R Signaling Loop in DLBCL

Arora, E.

1759 - Intense Monitoring of JAK2V617F and Wild-Type Hematopoiesis during IFNα Exposure to Dissect Its Mechanism of Action
3134 - Uncovering Non-Canonical Signalling Mediated By JAK2V617F in Myeloproliferative Neoplasms

Arora, M.

2207 - Selective Inhibition of the m⁶a RNA Reader, YTHDC1, As a Novel Therapeutic Strategy for MYC-Driven Acute Myeloid Leukemia

Arora, P.

3056 - Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Arora, S.

735 - Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
841 - Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations

Arora, S.

2207 - Selective Inhibition of the m⁶a RNA Reader, YTHDC1, As a Novel Therapeutic Strategy for MYC-Driven Acute Myeloid Leukemia

Arora, U.

4039 - Transcription Factor Networks Disproportionately Enrich for Heritability of Blood Cell Phenotypes

Aroshidze, B.

5170g - Multiple Myeloma (MM) Clinical Characteristics, Prognostic Factors and Survival in Adolescents and Young Adults (AYA)

Arpas, T.

2806 - Central Nervous System Involvement Does Not Worsen Survival in Hematologic or Molecular Relapse of Adult Acute Lymphoblastic Leukemia Patients – Retrospective Analysis By the Czech Leukemia Study Group for Life (CELL)

Arquero, T.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Arrais-Rodrigues, C.

4413 - Importance of Access Inequality and Biological Prognostic Factors in Mantle Cell Lymphoma Outcomes in Brazil: A Real-World Evidence Study from a Third World Country

Arrais-Rodrigues, C.

1524 - Safety and Efficacy of Venetoclax, Cytarabine and Metformin for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia
2348 - Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL

Arreola, M.

1276 - Reticular Dysgenesis-Associated Adenylate Kinase 2 Deficiency Has Opposing Metabolic Consequences on Granulopoiesis and Lymphopoiesis

Arriaga-Gomez, E. A.

344 - MDS-Associated SF3B1 Mutations Promote Aberrant Hematopoietic Cell Fate Choice By Disrupting Mediator Kinase Module Component CDK8

Arriazu, E.

670 - An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited

Arribas, I.

225 - Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Arribas, M.

3269 - A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

Arrieta-Bolanos, E.

692 - Immunopeptidome Divergence between Mismatched HLA Haplotypes and Survival after Haploidentical HCT: A Retrospective Study from the CIBMTR
901 - Memory CD4⁺ T Cells Recognize Divergent HLA-DP Immunopeptidomes and Contribute to Leukemia Control after Allogeneic HCT

Arrington, M.

3885 - OEF Measured with Diffuse Optical Spectroscopies As a Biomarker of Silent Stroke in Pediatric Sickle Cell Anemia

Arrouasse, R.

2500 - Voxelotor Impact after 6 Months on Blood Rheology in Patients with Sickle Cell Disease
2506 - Improvement in Kidney Function after 6 Months of Voxelotor in Sickle Cell Disease Patients
2508 - Parameters Associated with Improved Peripheral Oxygen Extraction in Sickle Cell Patients Treated with Voxelotor

Arroum, T.

1376 - Loss of Cystathionine-β-Synthase Activity Results in Increased Oxidative Phosphorylation and Cytarabine Resistance in Myeloid Leukemia Associated with Down Syndrome

Arroyo Barea, A.

1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience
3414 - Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Arroyo Galende, B.

1138 - Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease

Arroyo, M. A.

4215 - Divergent CD4+ T-Cell Fates Govern Relapse and Remission in B-Cell Acute Lymphoblastic Leukemia

Arruarana, V. S.

5170g - Multiple Myeloma (MM) Clinical Characteristics, Prognostic Factors and Survival in Adolescents and Young Adults (AYA)

Arruda, A.

953 - Targeted Protein Degradation Reveals a Repressive Role of Mecom at the CEBPA Locus to Prevent Differentiation in High-Risk Acute Myeloid Leukemia
2723 - AML Cells Have Increased Mitochondrial RNA Degradation and Inhibiting This Degradation Promotes Cell Differentiation, Decreases Viability, and Increases Sensitivity to Immune-Mediated Killing
2724 - The Exportin, CSE1L, Regulates Ribosome Biogenesis and Is a Selective Dependency in Childhood and Young Adult Acute Myeloid Leukemia
2778 - The Mitochondrial Unfolded Protein Response (UPR^mt) Is Upregulated in Acute Myeloid Leukemia (AML) and Inhibiting the UPR^mt Protease, LONP1, Leads to Mitochondrial Protein Aggregation and Cell Death Selectively in AML
2912 - Blood-Based Proteomic Profiling Identifies Osmr As a Novel Biomarker
2937 - Examining the Clinical Relevance of the AML Plasma Metabolome
4995 - Single-Cell Proteogenomic Analysis of Clonal Evolution in Patient-Derived Xenograft Models of AML Treated with IDH Inhibitors

Arsang-Jang, S.

4719 - Genome-Wide Association Study Identifies Novel Loci Associated with Survival in Multiple Myeloma

Arsene, C.

3652 - Comparison of Healthcare Utilization in Patients Undergoing CAR T-Cell Therapy for Multiple Myeloma and Lymphoma

Arslan, A.

4495 - Combining Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in Relapsed or Refractory Central Nervous System Lymphoma – a Retrospective Clinical Study

Arslan, S.

1043 - Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Artadji, D.

632 - PKCδ-Mediated Phosphorylation of CD25 Initiates Feedback Control of Oncogenic Tyrosine Kinases in Acute Lymphoblastic Leukemia

Artaza, G.

4012 - Reduce Dose of Apixaban Vs. Standard of Care for Secondary Prevention in Cirrhotic Patients with Chronic Portal Vein Thrombosis

Artemenko, M.

4851 - Novel Method to Evaluate the Quantitative Immune Functionality of CAR T-Cells to Analyze the Localization Change of CAR Molecules

Arter, W. E.

2207 - Selective Inhibition of the m⁶a RNA Reader, YTHDC1, As a Novel Therapeutic Strategy for MYC-Driven Acute Myeloid Leukemia

Arters, F.

1027 - Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma
3360 - Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Arthur, B.

325 - Genetic and Functional Characterization of NUP98-Rearranged Leukemia
825 - The Histone Acetyltransferase MOZ (KAT6A) Is a Molecular Dependency and Therapeutic Target in NUP98-Rearranged Acute Myeloid Leukemia

Arthur, C. K.

3148 - 5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Arthur, D.

3564 - Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Arthur, L.

916 - W-NK1 Choreographs Innate and Adaptive Immune Responses to Provide a Robust and Durable Anti-AML Response
4257 - WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Arthur, N. B.

1336 - Identification of MYC-Driven Vulnerabilities in Acute Myeloid Leukemia
4144 - Targeting the IRE1α-XBP1s Pathway to Enhance Venetoclax Effectiveness in AML

Artiles, D.

983 - Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL
1687 - Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study
1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)

Arts, J.

2054 - Discovery of JNJ-89853413, a First-in-Class CD33xVδ2 T-Cell Engager for the Treatment of Acute Myeloid Leukemia

Artz, A.

685 - The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704
729 - TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
966 - CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study
1043 - Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
4924 - Social Vulnerability Is an Important Predictor of Cardiovascular Disease Risk after Allogeneic Hematopoietic Cell Transplantation
4935 - Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
- Moderator Introduction and Session 4 Initial Audience Voting

Arulselvan, A.

547 - Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicentre Cohort Study

Arumugam, N.

1092 - Phase 1 Healthy Volunteer Study of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6

Arumugam, S.

2054 - Discovery of JNJ-89853413, a First-in-Class CD33xVδ2 T-Cell Engager for the Treatment of Acute Myeloid Leukemia

Arunachalam, A.

647 - Rationalization of Anti-PD-1 Therapy Using Receptor Occupancy Data to Guide Drug Dosing – a Single Arm Phase II Trial Using Immunomodulation in Relapsed/Refractory Hodgkin Lymphoma
2090 - Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)

Arunachalam, A. K.

94 - Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma

Arunachalam, J.

3351 - Survival Following Quadruplet and Triple Therapy in Transplant in-Eligible Multiple Myeloma - a Meta-Analysis of Recent Clinical Trials

Arvantis, M.

189 - The High Mobility Group A1 (HMGA1) Chromatin Regulator Induces Inflammatory Signals and Promotes Atherogenesis in Tet2 Mutant Clonal Hematopoiesis

Arvindam, U. S.

514 - Prime Editing Enables Precise and Efficient Single Amino Acid Substitutions to Shield CD34+ Hematopoietic Stem Cells from Anti-CD117 Antibody-Based Conditioning

Arwert, E.

3284 - IMiDs and Celmods Enhance Antigen Presentation Via MHC Class 1 – a Potential Novel Immunostimulatory Effect

Arya, Y.

2386 - Impact of Protein Energy Malnutrition on Hospitalized Patients with Multiple Myeloma: A United States Population-Based Cohort Study
3894 - Impact of Malnutrition on Patients with Sickle Cell Anemia Hospitalized with Vaso-Occlusive Crisis: A US Collaborative Network Cohort Study
3951 - Protein Energy Malnutrition and in-Hospital Outcomes Among Hospitalized Patients with Immune Thrombocytopenia: A United States Collaborative Network Cohort Study
5106 - Impact of Protein Energy Malnutrition on Hospitalized Patients with Hodgkin’s Lymphoma: A United States Population-Based Cohort Study

Aryal, A.

76 - Identifying Novel Drug Vulnerabilities in Specified Molecular Subsets of Chronic Lymphocytic Leukemia

Aryal, N. K.

4969 - Discovery of UBE2B and RNF144b As Potential Candidates for Selective Degradation of NPM1c in AML

Arza-Apalategi, S.

2933 - Genetic Classification of Acute Myeloid Leukemia By Differential Long Noncoding RNA Expression

Arztenroth, J.

3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

Asada, N.

1297 - Alpha 2-Adrenergic Agonist As a Novel Microenvironment-Directed Agent for Acute Myeloid Leukemia Via Notch Signaling Inhibition
1312 - Efficacy and Safety of Cyclosporine Monotherapy for Patients with Non-Severe Aplastic Anemia Not Requiring Transfusions: Results from a Prospective Multicenter Phase II Study
1368 - Single-Cell DNA Sequencing Reveals Cell-Level Genetic Evolutionary Processes and Clonal Structure in B-Cell Lymphomas

Asada, S.

949 - CRISPR/Cas9 Library Screens Identified Atp2a2 As an In Vivo Specific Tumor Suppressor in Myeloid Neoplasms
2747 - Cyclin D1 Overexpression in Mantle Cell Lymphoma Causes Cellular Dependence on Microhomology-Mediated End-Joining

Asami, T.

1850 - Impact of Docirbrutinib (AS-1763) Treatment in CLL: Preclinical Data and Early Clinical Biomarkers

Asangani, I.

2730 - CBL Loss or Mutations Reduces MHCII Expression through Downregulating ERG in Myeloid Malignancies
4574 - CBL Loss or Mutations Upregulates AXL to Promote Cytokine-Independent Growth in Myeloid Malignancies: AXL Upregulation Promotes Cytokine-Independent Growth in CBL-Mutant CMML

Asano, A.

3075 - The Impact of MYD88 and/or CD79B Gene Mutations on Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma
3342 - Stratifying 'frail' Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes
4638 - _{Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma}

Asano, H.

2060 - Bispecific T Cell Engager with Trbc-Targeting Antibody Against Effector T Cells for the Treatment of T Cell Malignancy

Asano, N.

1682 - Comparison of Clinical Characteristics and Prognosis between Aggressive NK-Cell Leukemia and Advanced-Stage Extranodal NK/T-Cell Lymphoma
3030 - Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan
3058 - Number of Sites of Involvement Predicts Central Nervous System Relapse in Patients with Localized Extranodal Natural Killer/T-Cell Lymphoma

Asano, T.

379 - Heterogeneity of PD-1⁺regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease

Asano-Mori, Y.

2189 - Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL
3485 - What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes
3508 - Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation
4926 - Single Cord Blood Transplantation with Fludarabine, Busulfan and Melphalan Is Crucial Therapeutic Strategy for AML Not in Remission: A Single-Center Retrospective Study of 286 Patients Including Prognostic Factor Analysis

Asao, Y.

3342 - Stratifying 'frail' Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes

Asare, A.

726 - Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors

Asare, E. V.

606 - An e-Health Pain Assessment Tool Incorporating Animations and Images Is Feasible and Useful for Patients in a Ghanaian Sickle Cell Disease Cohort

Asare, J.

634 - TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL

Asayama, K.

741 - Spatially Resolved Single-Cell Transcriptomics of T Cells in Follicular Lymphoma Reveals Distinct Immune Ecosystems

Asby, R.

190 - Delayed Trp53 Activation Protects Dnmt3a-Mutant Haematopoietic Stem Cells from Inflammatory Attrition

Asch, A. S.

221 - Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML
2080 - Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease

Asch, J.

1749 - The “Walk through the Clinic Door” Effect: Differences in Survival and Toxicity Based on Site of CAR T Administration in a Default Outpatient CAR T Program

Ascha, M. S.

3756 - Symptoms Detection Among Patients with Lymphoid Malignancies (LM) Using Electronic Patient-Reported Outcomes (ePROs) in Community Hematology-Oncology Clinics
5046 - Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy

Aschauer, G.

3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Aschenbrenner, E.

2374 - Split-Dose R-CHOP for Older Patients with Treatment Naïve DLBCL

Asensi, P.

2111 - Current Challenges in the Assessment of Related Donors for Hematopoietic Stem Cell Transplantation

Asgarisabet, P.

2375 - Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States

Ashango, A.

62 - Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML

Ashaye, A.

1662 - Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial
2346 - Estimation of Health State Utility Values for Patients Undergoing First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the HD21 Trial
2825 - Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
4426 - Impact of Treatment-Related Morbidity on Health-Related Quality of Life in Patients with Advanced-Stage Classical Hodgkin Lymphoma Receiving Multiagent Therapy: Findings from the HD21 Study

Ashburner, C.

1216 - Athn 10 – Novel Variants in Persons with Rare Coagulation Disorders across Hemophilia Treatment Centers in the United States

Ashby, C.

1885 - Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression
1937 - Identification of Risk Factors for Myeloma Progression in African American Patients
4729 - Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages

Ashby, J.

5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Asherie, N.

894 - Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis
1030 - Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma

Ashfaq, H.

3947 - Trends and Disparities in Idiopathic Thrombocytopenic Purpura-Related Mortality in the United States: A Retrospective Study over Two Decades

Ashford-Hicks, A.

3964 - A Novel Synthetic Short-Chain Polyphosphate (polyP) Complexed with Silica Nanoparticle (SNP) Improves Hemostatic Outcomes in Severe Swine and Rat Injury Models

Ashizawa, M.

4870 - Appropriate Threshold of Quantitative Cytomegalovirus DNA Polymerase Chain Reaction for Preemptive Treatment in Stem Cell Transplant Recipients
4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy

Ashley-Koch, A. E.

1110 - Novel Loci Associated with Acute Chest Syndrome in Sickle Cell Disease Patients
2512 - A Phase 2 Prospective Randomized Trial of Topical Sodium Nitrite in Patients with Sickle Cell Disease and Leg Ulcers

Ashman, O.

3322 - Symptomatic Progression Free Survival (SPFS): A New Endpoint for Multiple Myeloma (MM) Combining Patient-Reported Outcomes (PROs) and Progression-Free Survival (PFS)

Ashok, D.

1298 - SPARC Stabilizes Integrin α4-VCAM-1 Interactions and Is Regulated By Intracellular Rac in NPM1-Mutated AML

Ashour, D.

296 - Mechanical Thromboprophylaxis and Hospital-Acquired Venous Thromboembolism: A Report from the Children’s Healthcare Advances in Thrombosis Consortium

Ashouri, A.

2971 - Decoding the Epigenetic and Transcriptional Signatures of Pathogenic B-Cells in Patients at High Risk of Transformation to Lymphoma

Ashouri, K.

2892 - Optimizing Venetoclax Duration in Combination with Hypomethylating Agents for Newly Diagnosed AML: Impact on Treatment Response and Survival Outcomes
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Ashraf, A.

4605.1 - Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)

Ashraf, H.

3947 - Trends and Disparities in Idiopathic Thrombocytopenic Purpura-Related Mortality in the United States: A Retrospective Study over Two Decades

Ashrani, A. A.

613 - Assessment of Classical Hematologists and Hematology-Focused Fellowship Programs at NCI-Designated Cancer Centers: Implications for Addressing Workforce Shortages and Enhancing Mentorship Opportunities

Ashruf, O.

1924 - Clinical Outcomes and Disease Progression after Daratumumab-Based Treatment in Primary Amyloidosis

Ashtiani, Y.

2892 - Optimizing Venetoclax Duration in Combination with Hypomethylating Agents for Newly Diagnosed AML: Impact on Treatment Response and Survival Outcomes

Ashton, J. M.

1302 - Temporal Single Cell Analysis of Myeloid Leukemia Microenvironment

Ashton, V.

697 - Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients with Pulmonary Embolism and Right Ventricular Dysfunction

Ashworth, K.

875 - Monocyte-Driven Aberrant Inflammation in Myeloproliferative Neoplasms Is Regulated By Galectin-1
1169 - Altered Calcium Signaling Via STIM1 Drives Aberrant Megakaryopoiesis and Myelofibrosis

Asif, M. A.

1959 - Infectious Risk in Multiple Myeloma Patients Undergoing Treatment with Teclistamab

Asija, S.

4809 - Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies

Asimomitis, G.

1830 - Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count

Asirvatham, S.

1788 - QRISK3: A New Marker for Thrombotic Events in Essential Thrombocythemia and Polycythemia Vera at Diagnosis and during Follow up
4547 - Rapid and Sustained Recovery of Cellular Immunity in Patients with Myelofibrosis on Momelotinib Therapy

Askanase, A.

4846.1 - A Phase 1 Study of NKX019, an Allogeneic Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy in Patients with Systemic Lupus Erythematosus

Askari, E.

1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease

Askeland, F. B. B.

4730 - Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Aslam, M. F.

5186 - Impact of Sociodemographic Factors on Mortality in Acute Myeloid Leukemia in the United States: A Time-Trend Analysis

Aslanova, M.

2257 - A Pilot Quality Improvement Initiative for Implementation of Venous Thromboembolism Prophylaxis for Patients with Gastrointestinal Malignancy

Asnafi, V.

731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
2793 - APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)

Asomaning, N.

177 - A Machine Learning-Based Workflow for Predicting Transplant Outcome in Patients with Sickle Cell Disease
800 - The Amyloidogenic Transthyretin V122I Variant Increase Severity of Cardiac Phenotype and Mortality in Sickle Cell Disease
2485 - Acquired Mutations in the Mitochondrial Genome As Prognostic Markers in Sickle Cell Disease
2491 - Mitapivat-Induced Improvements in RBC Deformability and Membrane Integrity in Patients with Sickle Cell Disease Are Sustained during Extended Therapy

Asoori, S.

704 - Outcomes of Frailty Subgroups Treated with Teclistamab in the Real-World: An International Myeloma Foundation Study Database Analysis
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
5166 - Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Aspas Requena, G.

846 - Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
1475 - Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
1518 - Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group
4275 - Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study
4335 - Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Aspas Requena, G.

3564 - Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Asper, M.

2646 - UV-C Irradiation: Virus Inactivation in Fibrinogen Concentrate Manufacturing Process

Aspuria, P. J.

3453 - A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

Assabill, F.

5176 - National Trends and Disparities in Sepsis-Related Mortality in Adults with Hematological Cancers, 1999-2020

Assal, A.

4886 - Successful Allogeneic Alternative Donor Hematopoietic Stem Cell Transplantation in High-Risk Patients with Severe Sickle Cell Disease

Assanelli, S.

3956 - Role of Factor VIII As a Regulator of Angiogenesis and Promoter of Endothelial Barrier Stability
3991 - Role of Factor VIII in Angiogenesis, Vessel Stability and the Regulation of Extracellular Matrix Proteins

Assante Miranda, L.

1609 - Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Assanto, G. M.

339 - Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from "FOLL12" Phase III Trial of the Fondazione Italiana Linfomi

Assayag, M.

894 - Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis
1030 - Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma

Assefa, A.

1408 - JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models

Assefa-Kebede, H.

1284 - DNMT3A-Mutant Clonal Haematopoiesis Is Associated with Worse Recovery after ST-Elevation Myocardial Infarction Via Increased Inflammation

Assenmacher, C. A.

1054 - Long-Term Factor VIII Expression Post AAV in Adult Hemophilia a Mice Demonstrates No Evidence of Adverse Liver Health or Tumorigenesis
2195 - An Erythroid-Specific Lentiviral Vector Improves Anemia and Iron Metabolism in a New Model of Xlsa

Assimakopoulos, I.

1317 - Characterization of Erythrocytes in PNH: Can We Predict Response to Complement Inhibition Based on Different Erythrocyte Markers?

Assini, A.

463 - Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
3068 - Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma

Assonov, D.

2384 - Evaluating Multiple Myeloma Treatment and Clinical-Decision Making with Real-World Data
5043 - Study Assessing the All4Cure Health Technology Intervention on Patient Activation in Multiple Myeloma

Assouline, S. E.

286 - COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy
533 - Sex-Related Differences in CML Outcomes in a Real-World Prospective Registry (GQR LMC-NMP)
989 - A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
1506 - Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis
1645 - Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II
1646 - Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma
2291 - Using the Serious Illness Conversation Guide (SICG) in Patients with Hematological Malignancies As a Tool to Address Their Perspectives on Palliative Care
3670 - The Serious Illness Conversation Guide Is Meaningful to Patients with Hematologic Malignancies and Impacts Death in Acute Care
4407 - Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study
4419 - A Comparison of the Timing of Treatment Initiation for Older Versus Younger Patients with Follicular Lymphoma
4501 - Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Aster, J. C.

43 - The Follicular Lymphoma and Chronic Lymphocytic Leukemia Proliferative Microenvironment at Single-Cell Resolution
590 - Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Aster, R. H.

1229 - A Subset of Antibodies to the Spike Protein's Receptor-Binding Domain in Severe COVID-19 Activate Platelets

Asteris, P.

1163 - Long-Term Safety and Efficacy of Autologous Hematopoietic Cell Transplantation for Patients with Progressive Systemic Sclerosis

Asti, G.

105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
3194 - Single-Cell Multi-Omics Reveals Anticipated Erythroid Differentiation and Transcriptional Regulation in Differentiation Trajectories of SF3B1 - JAK2/MPL Mutated Cells in MDS/MPN-RS-T
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Astibia Mahillo, B.

3349 - Clinical, Biological and Prognostic Characterization of Multiple Myeloma According to the Presence of Circulating Plasma Cells
3491 - Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation

Astigarraga, I.

3909 - Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Aston, H.

3884 - Hindsight 20/20: The Role of Hemoglobin F in Sickle Cell Retinopathy

Ataga, K. I.

3872 - The Association between Urinary Biomarkers 3-Indoxyl Sulfate, Monocyte Chemoattractant Protein-1, Neutrophil Gelatinase-Associated Lipocalin and Klotho with Chronic Kidney Disease in Patients with Sickle Cell Disease
3886 - The Natural History of Glomerular Hyperfiltration in Sickle Cell Disease

Ataher, Q.

1863 - Real-World Insights into the Demographics, Infection Burden, and Use of Immunoglobulin Replacement in Patients with Chronic Lymphocytic Leukemia and Secondary Immune Deficiency

Atakilit, A.

818 - Targeting EBF1-ITGB8 Axis in MPN Bone Marrow Niche

Atallah, A.

3495 - CMV Reactivation Kinetics in Patients Undergoing Haploidentical Stem Cell Transplantation Using Low-Dose Post-Transplant Cyclophosphamide: A Single Center Experience

Atallah, E. L.

447 - Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
479 - Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)
779 - Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial
993 - Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia
1487 - Leukemia Physician’s Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia
1554 - Immune-Scape in Myeloid Sarcoma and Acute Myeloid Leukemia
2426 - Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium
2801 - Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
3812 - Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) – a Chart Review Study in the United States
4184 - The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
4211 - Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial
4258 - Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy
5052 - U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)
5173 - CNS Status at Diagnosis Can Identify Acute Myeloid Leukemia Patients with Poor Induction Outcomes
5174 - Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
2907.1 - A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Atallah-Yunes, S. A.

238 - Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
1710 - Characteristics and Outcomes of Incidentally Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)
3305 - Proteomic Determinants of Renal Organ Response in AL Amyloidosis
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Atamna, B.

1762 - Interferon Inhibits Netosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Subpopulation-Specific Manner
4476 - Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma

Atanackovic, D.

936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Atanasio, A.

1785 - Revised International Working Group Risk Model for Survival in Polycythemia Vera
1795 - Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera

Atarere, J.

3299 - Early Versus Delayed Intervention in Smoldering Multiple Myeloma: A Meta-Analysis of Clinical Trials

Atchison, M.

2657 - YY1-Mediated PcG Regulation Dictates Hematopoietic Stem Cell Fate

Atenafu, E.

1483 - Intensive Chemotherapy Vs. Azacitidine + Venetoclax for AML with Secondary Mutations
4690 - Handgrip Strength – Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma
5193 - What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?

Atenafu, E. G.

1506 - Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis
3376 - Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Atenafu, E. G.

1956 - Outcomes of Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Therapies after Exposure to T-Cell Redirected or BCMA-Targeted Novel Immunotherapies

Atencio, L.

947 - Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation
4924 - Social Vulnerability Is an Important Predictor of Cardiovascular Disease Risk after Allogeneic Hematopoietic Cell Transplantation

Athanasiadou, A.

3484 - Long-Term Safety and Efficacy of Treosulfan-Based Conditioning Regimens of Allogeneic Hematopoietic Cell Transplantation

Athanasopoulos, E. N.

3257 - Immunogenicity and Safety of the Recombinant Adjuvanted Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia and Multiple Myeloma

Atibalentja, D. F.

1612 - MYC Inactivation Restores Immune Surveillance in a Transgenic Mouse Model of T-Cell Acute Lymphoblastic Lymphoma

Atiq, F.

3958 - Whole Genome Sequencing to Elucidate Genetic Modifiers of FVIII Clearance Heterogeneity in Patients with Hemophilia a

Atiya, M.

2349 - Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
3115 - Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)

Atiyah, N.

2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Atkins, H.

4955 - Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial

Atkins, J.

1384 - ADH5/ALDH2 Dehydrogenases and DNA Polymerase Theta Protect Hematopoietic Cells from Formaldehyde Challenge: Therapeutic Implications

Atkins, O.

2745 - Characterizing and Targeting Follicular Lymphoma's Common Progenitor Cells

Atkinson, C.

285 - Lovesick: Examining Couples Health during Myeloma Transplant

Atkinson, I.

2703 - Incidence of Myeloid Malignancy in Shwachman-Diamond Syndrome: An International Cohort Study

Atkinson, S.

4152 - Specific Bone Marrow Niche Components Determine Degree of Protection from Gilteritinib Induced Differentiation Response in FLT3-ITD AML

Atkinson, S. N.

3893 - Individuals with Sickle Cell Disease Have Decreased Intestinal Microbial Diversity Compared to Healthy Related and Unrelated Black Individuals without Sickle Cell Disease

Atlasi, Y.

3144 - Interferon Alpha Activates the Unfolded Protein Response Resulting in Synergy with Bortezomib in JAK2 V617F Myeloproliferative Neoplasms

Atluri, H.

1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
2883 - Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials
3246 - Predictors for Time-to-First-Treatment in Patients with Del(17p) and/or TP53-Mutated Chronic Lymphocytic Leukemia

Atluri, S.

1705 - Factors Affecting the in-Hospital Mortality in Patients with Diffuse Large B-Cell Lymphoma: A National Inpatient Sample Study (2018-2020)
2306 - Prevalence of Pulmonary Hypertension in Patients Hospitalized with Sickle Cell Crisis

Atmakuri, A.

1429 - Clinical Implications of Treatment-Related Clonal Hematopoiesis in Adolescent and Young Adult Survivors of Acute Lymphoblastic Leukemia

Atmane, M. I.

2030 - Effector Differentiation and Exhaustion Attenuate on-Target, Off-Tumor Toxicity of CD24 CAR T Cells

Atmuri, U.

3123.1 - Trial in Progress: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-Cop to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma - Crescendo

Atodaria, K.

3351 - Survival Following Quadruplet and Triple Therapy in Transplant in-Eligible Multiple Myeloma - a Meta-Analysis of Recent Clinical Trials

Atrash, S.

897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1964 - Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions
2009 - A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment
2287 - Supportive Care Utilization in Patients with Multiple Myeloma—a Single Center Retrospective Study
2288 - The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024)
2381 - Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA
2382 - Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
2404 - Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities—a Multicenter Study
2411b - Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial
2411g - Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma
2669 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy
3317 - Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3355 - Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)
3769 - Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4702 - Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes
4720 - Prophylactic Dexamethasone and Remote Monitoring for Patients with Relapsed Refractory Multiple Myeloma (RRMM) Receiving Bispecific Antibodies (BsAb): Experience at a Single Institution
4751 - Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy
5040 - Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns
5162 - Social Determinants of Health (SDOH) and Access to CART for Multiple Myeloma
5163 - Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma

Atrash, S.

1965 - Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study
5170d - Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients
5170e - Treatment Outcomes of Monoclonal Gammopathy of Renal Significance with Novel Agents

Atreya, C.

5185 - Living with CML: A Qualitative Analysis

Atshan, R.

2412 - Impact of Extramedullary Disease on the Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Acute Myeloid Leukemia - a CIBMTR Analysis

Atsuta, Y.

384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
1311 - Frequent Loss of HLA-B*40:02 from Leukocytes in Male Patients with Hepatitis-Associated Aplastic Anemia
1332 - A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia
1469 - Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia with t(16;21)(p11;q22)
2121 - Kinetics of Recipients with Thrombocytopenia and Its Impact on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study
2166 - Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma with Stable or Progressive Disease
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
2819 - JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults
3203 - Molecular Taxonomy Classification for Transplant Decision Making of Myelodysplastic Syndromes
3569 - To What Extent Have Post-Transplant Outcomes Improved Following the Introduction of Tyrosine Kinase Inhibitors in Elderly Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia? a Retrospective Nationwide Survey in Japan
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021
4548 - Optimal Procedures of Allogeneic Transplantation for BCR::ABL1-Negative Atypical Chronic Myeloid Leukemia

Atsuta, Y.

4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Atta, E. H.

2698 - Higher Graft Failure after Haploidentical in Comparison to Matched Related and Unrelated Stem Cell Transplantation for Severe Aplastic Anemia: A Single-Center Retrospective Study

Attah, A.

1126 - Maternal and Fetal Outcomes in Sickle Cell Disease: Single Center Review

Attar, R. M.

487 - Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study
594 - Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide
949 - CRISPR/Cas9 Library Screens Identified Atp2a2 As an In Vivo Specific Tumor Suppressor in Myeloid Neoplasms

Attarbaschi, A.

112 - “Real World” Outcome of Hematopoietic Stem Cell Transplantation after CAR19 T Cell Therapy in Children and Adults with B-ALL: A Gocart Coalition Study on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
309 - A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009
730 - Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy
965 - Second Infusion of CAR T-Cells in Patients with Relapsed /Refractory B-Cell Acute Lymphoblastic Leukemia: Results from a Gocart Coalition Analysis on Behalf of the PDWP, ALWP, and Ctiwp of the EBMT
2333 - Real-World Outcomes of CD19-Targeted CAR T-Cell Therapy in Adult and Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Insights from the GoCART Coalition on Behalf of the PDWP, ALWP, and CTIWP of the EBMT

Attardi, E.

1332 - A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia

Attardi, E.

2704 - Prospective Genomic Study for Optimizing Clonal Hematopoiesis Surveillance in Bone Marrow Failure Syndromes and Related Cytopenia
2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Attelah, J.

1359 - Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma

Attolico, I.

1772 - Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50 – 60 Years: A “Campus CML” Study
2427 - Long-Term Safety and Effectiveness of Ponatinib Treatment in Patients with TKI Intolerance: Subgroup Analysis of the Observational Study of Ponatinib Treatment in Patients with CML in Italy (OITI)

Attucci, I.

5153 - Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Attwood, K.

4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Atwal, S. K.

4501 - Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Atzeni, I.

3859 - Pregnancy and Childbirth in Women with Thalassemia: Past and Present

Au, A.

2785 - LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

Au, C.

3794 - Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Au, C. H.

2726 - Activation of Cgas-Sting Pathway By Hypomethylating Agent in TP53 Mutated MDS/AML

Au, K.

4361 - Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Au, L.

1796 - Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Advanced Myelofibrosis

Au, P.

2198 - In Vivo Hematopoietic Stem Cell Engineering Restores the Function of NADPH Enzyme Complex in X-Linked Chronic Granulomatous Disease Model Mice

Au, Q.

4361 - Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma

Aubergeon, L.

1616 - EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
4395 - EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Auberger, P.

1378 - Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study

Aubert, G.

439 - Danazol Treatment for Telomere Biology Disorders: Long-Term Results of a Phase I/II Study

Aubert, G.

4094 - T Lymphopenia and Aged Immune System Characterize Immunodeficiency in Adult Patients with Telomere Biology Disorders
2808.1 - A Children’s Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress

Aubrey, M. T.

4913 - The Degree of HLA-DPB1 Mismatch Predicted By Evolutionary Divergence Scoring Informs the Risk of Chronic Graft-Versus-Host Disease after Haploidentical Transplantation with Post-Transplant Cyclophosphamide
4948 - High HLA Evolutionary Divergence in Donor HLA-B Locus Impacts Transplant Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Aubry, A.

3282 - Voltage-Dependent Anion Channel 2 Controls Mitochondrial Priming through BAK Stabilization in Multiple Myeloma

Auclair, D.

251 - DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease
1359 - Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma

Audard, V.

2506 - Improvement in Kidney Function after 6 Months of Voxelotor in Sickle Cell Disease Patients

Audebert, S.

4097 - Deciphering EZH2 Non-Canonical Activities in AML Resistance

Audia, S.

5 - Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)
2552 - Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study
3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Audisio, E.

835 - Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
1523 - Disease Course and Treatment Patterns of Acute Myeloid Leukemia with FLT3 Mutations and Myeloid Sarcoma Reveal High Efficacy of Gilteritinib: A Multicentric Retrospective Study
1574 - Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML
2836 - Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial
2891 - Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Auditeau, C.

3839 - Protein S Enhances the Phagocytosis of Phosphatidylserine-Positive Erythrocyte: Implications for the Erythrocytes Turnover

Audureau, E.

2500 - Voxelotor Impact after 6 Months on Blood Rheology in Patients with Sickle Cell Disease
2506 - Improvement in Kidney Function after 6 Months of Voxelotor in Sickle Cell Disease Patients
2508 - Parameters Associated with Improved Peripheral Oxygen Extraction in Sickle Cell Patients Treated with Voxelotor
2520 - Improvement in Cerebral Vasoreactivity after 6 Months of Voxelotor Measured By Near-Infrared Spectroscopy (NIRS) in Sickle Cell Disease Patients
3891 - Unique Nature of Sickle Cell Diastolic Cardiomyopathy: A Tailored Echocardiographic Definition to Refine Prognostic Stratification in Young Adults

Auer, R.

3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Auer, R.

3635 - Patient Decision Aid for Extended Duration Thromboprophylaxis for Major Abdominopelvic Cancer Surgery: A Usability Study

Auerbach, M.

3707 - Iron Deficiency in Pregnancy Is Ubiquitous

Auge, A.

4775 - MP0621 (cKit x CD16a x CD47), a Multi-Specific Switch-Darpin with Conditional Blockade of CD47 Targeting Hematopoietic Stem Cells: Preclinical Evaluation of a Next-Generation Conditioning Agent for Stem Cell Transplantation

August, A.

3411 - IL-2-Inducible T Cell Kinase Deficiency Enables Development of Sustainable Chimeric Antigen Receptor T Cell Therapy

August, K. J.

2846 - GWAS Identifies Pharmacogenetic Markers Associated with Premedication-Related Pegaspargase Hypersensitivity and Toxicities in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma

Augustine, K.

169 - Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD™ for the Treatment of Sickle Cell Disease

Augustson, B.

1026 - First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
1951 - Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry
2000.2 - A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Auletta, J. J.

2360 - Identifying Disparities in Autologous Hematopoietic Cell Transplantation (autoHCT) Utilization for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in California
2950 - Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia
3672 - Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial
3680 - Comparing Access to Allogeneic Hematopoietic Cell Transplant across the United States: Physician Density, Minority Health Social Vulnerability Index, Transplant Unmet Need and Utilization
3514.1 - OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Aumann, S.

1668 - Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma – International, Multi-Center Real-World Experience

Aumann, S.

3189 - DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms
4269 - For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious
5124 - Epcoritamab for Relapsed/Refractory B Cell Lymphoma – the Israeli Real-World Experience of a Compassionate Use Program

Aung, W. Y.

1492 - Influence of COVID-19 on Acute Myeloid Leukemia Treatment Efficacy: Insights from a Propensity Score-Matched Cohort Study
2539 - Synergistic Risks: The Impact of HIV on Kaposi Sarcoma and Lymphoma Incidence in Castleman’s Disease

Aurand, L.

306 - Efficacy and Safety of Pozelimab Plus Cemdisiran Vs Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Are Naïve to Complement Inhibition

Aurer, I.

2337 - Bone Mineral Density in Hodgkin Lymphoma Patients Treated with Escalated Beacopp: Focus on Steroid Administration and Age-Related Effects

Auriel, E.

1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation

Aurora, T.

392 - Determinants of Linkage to Care in a New Newborn Screening Care Program for Sickle Cell Disease in Ghana, West Africa

Aurran-Schleinitz, T.

584 - Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group
3256 - Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Aussel, C.

2201 - Gene Therapy for Artemis-SCID and Artemis-Leaky-SCID Patients: Preliminary Results of the French Artegene Phase I/II Clinical Trial

Austin, B.

1155 - Myofibroblast to T-Zone Reticular Cell Ratio Identifies Unicentric Castleman Disease Lymph Nodes
3923 - Lymph Node Transcriptomics in Idiopathic Multicentric Castleman Disease (iMCD) Identifies Pathogenic Mechanisms and Biomarkers Including Increased Clusterin Expression

Austin, S.

3953.1 - A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

Austin, W.

516 - CD117 Antibody Conditioning and Multiplex Base Editing Enable Rapid and Robust Fetal Hemoglobin Reactivation in a Rhesus Autologous Transplantation Model

Auth, J.

684 - Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Autore, F.

73 - Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway
3013 - Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study
4621 - Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study

AuYeung, A.

4806 - A Regulated Cytokine Engineering Strategy to Augment in Vitro and In Vivo persistence of Allogeneic iPSC Derived CD8 T-Cells

Avagyan, S.

4043 - Chemical Modulation of ELF1 Binding to RUNX1 Target Genes Leads to Increased Hematopoietic Stem Cell Self-Renewal
- Inflammation As a Regulator of Hematopoietic Homeostasis in Clonal Selection
- Effects of Somatic BCOR Mutations on Hematopoiesis

Avalos, B.

5194 - Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results

Avelar, D. M.

2294 - Multicentric Standardization of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia Using Multiparametric Flow Cytometry – a Brazilian Society of Bone Marrow Transplantation (SBTMO) Project

Avenarius, M. R.

2922 - A Rapid Diagnostic Assay to Detect a DNA Methylation Signature of Menin Inhibitor Response in Acute Myeloid Leukemia

Avendaño Pita, A.

1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2156 - Sativex Oromucosal Spray in Patients with Chronic Graft Versus Host Disease: Effect on Sclerodermal Features and Refractory Muscle Cramps
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia
4884 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

Averbuch, D.

3497 - Central Nervous System Disorders (CNSD) Following Hematopoietic Stem Cell Transplantation (HSCT): A Prospective Study from the Infectious Diseases Working Party (IDWP) and the Transplant Complications Working Party (TCWP), European Society of Blood and Marrow Transplantation (EBMT)

Aversa, L.

2826 - A Pediatric Laboratory Experience: Measurement of L-Asparaginase Activity in Patients with Acute Lymphoblastic Leukemia. a Multicentric Study

Avery, B.

1296 - Title: Clonal Hematopoiesis and Germline Predisposition in High-Risk Leukemia Pedigrees

Avet Loiseau, H.

250 - Increased Expression of the Sialyltransferase Gene ST3GAL1 Predicts Lack of Sustained MRD Negativity and Increased Risk of Progression in Newly Diagnosed, Transplant Eligible Multiple Myeloma Patients in the Maintenance/Observation Phase of Cassiopeia Study
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Avet-Loiseau, H.

764 - PKMYT1 Kinase Is an Actionable Synthetically Lethal Target for Del17p Myeloma
1018 - Differentiating between MM like Smoldering Myeloma (SMM) and Non-Progressor SMM
4651 - BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma
4722 - Using Single Cell Multi-Omic Clonal Tracking in SMM to Identify Clones That Progress to MM and Harbor Treatment Resistance Features
4765 - Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Avgeris, M.

3285 - Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome

Avigan, D.

3258 - Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
4256 - Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
4817 - Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine
4825 - Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis

Avigan, J. I.

4636 - Bone Marrow Fibroblasts at the Single-Cell Resolution Level in Multiple Myeloma

Avigan, Z. M.

1970 - Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway
3329 - Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation

Avigdor, A.

608 - Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma
912 - CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
988 - Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study
1734 - Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL
1746 - Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study
2369 - When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses
3110 - Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial
3752 - Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma
4393 - Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma
4504 - CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia
5124 - Epcoritamab for Relapsed/Refractory B Cell Lymphoma – the Israeli Real-World Experience of a Compassionate Use Program

Avila Rodriguez, A. M.

1993 - Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma
3298 - Real-World Outcomes of Monoclonal Gammopathy of Renal Significance (MGRS) in the Era of Novel Therapies

Aviles, L.

2914 - Mutational Landscape and Depth of Response in Patients with Acute Myeloid Leukemia (AML) Treated with Magrolimab in Combination with Venetoclax and Azacitidine Compared to Placebo

Aviles, M.

5207 - Analysis of the Hematology Health Equity Literature: Trends By Topic and Disparity, across Journals, and over Time

Avishai, E.

430 - A Novel Murine Model Rebalancing Coagulation Enables Gene Therapy Studies for Severe Protein C Deficiency, a Lethal Pro-Thrombotic Disorder

Avivi, I.

3049 - The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin’s Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Avivi, I. M.

1582 - Detection of B Cell Lymphomas By a Simple Epigenetic Blood Test
4788 - Single Cell Analysis of Pre-Treatment Peripheral Immune Composition Can Predict CAR-T Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Avivi Mazza, I.

866 - Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study
894 - Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis
1030 - Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma
1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
1734 - Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL
1985 - A Phase 1b Study of Step-up Dosing with ABBV-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma
2086 - Standardization Protocol to Mitigate Progression of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Elderly Patients Treated with CD28 Co-Stimulatory Anti-CD19 CAR-T Cells – a Pilot Study
3110 - Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial
3777 - Treatment Journey of Octogenarian Patients Outside Clinical Trials

Avni, B.

894 - Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis
1030 - Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma
4504 - CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Avni, N.

4772 - Mitochondrial Augmentation of Hematopoietic Stem and Progenitor Cells As a New Therapeutic Approach for Myelodysplasia

Avramova, B.

1444 - Results of the ALL-IC REL 2016 Registry Trial: 1^st Relapses of Childhood ALL Treated in High-Middle Income Countries

Avrumutsoae, J.

2764 - The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid

Aw, A.

1009 - Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Awad, S. A.

2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Awad, V.

1811 - Elucidating the Interplay between ddx41 and cux1 mutations in Hematopoiesis in Danio Rerio

Awada, H.

2943 - Geno-Transcriptomic Topography of Clonal Drivers in Trisomy 8 Myeloid Malignancies

Awada, H.

31 - Genetic Determinants of Hypercoagulability in Complement and Hemostatic Systems Shape the Thrombotic Risk of Paroxysmal Nocturnal Hemoglobinuria
850 - Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1332 - A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia
2224 - Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes
2695 - Predicting Extravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria
2920 - Distinct Phenotypes of Myeloid Neoplasia Associated with Truncating C-CBL Mutations
2943 - Geno-Transcriptomic Topography of Clonal Drivers in Trisomy 8 Myeloid Malignancies
4076 - Aplastic Anemia in the Elderly: Treatment Patterns and Outcomes from an International Observational Study
4085 - Counterpoising Immune Pressure and Privilege: Paroxysmal Nocturnal Hemoglobinuria Evolutionary Dynamics
4980 - Novel Machine Learning Approaches Tailored to Protein Configuration Predict Drug Vulnerabilities in Myeloid Neoplasia

Awadalla, P.

4053 - Mosaic Chromosomal Alterations Driving Clonal Hematopoiesis Show Shared and Divergent Patterns of Accumulation Among Humans of Diverse Ancestries

Awalu, J.

2250 - Bridging the Gap for Sickle Cell Disease Patient Data in Sub-Saharan Africa By Expanding Access to Specialty Biomarkers and Clinical Trials

Awan, F. T.

68 - Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
883 - Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1
2178 - Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)
4623 - Mutations in the Bruton Tyrosine Kinase (BTK) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)
5096 - Enrollment in Clinical Trials Demonstrates Benefit for Low Income DLBCL Patients; A Retrospective National Cancer Database (NCDB) Analysis
4422.1 - A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in Patients with B-Cell Malignancies

Awan, S. A.

4670 - Outcomes of Autologous Hematopoietic Stem Cell Transplantation in Patients with Light-Chain Amyloidosis: A Systematic Review and Meta-Analysis

Awan-Toor, S.

1755 - SH2B3 Loss of Function Variants Are Potential Drivers of Severe Thrombocytosis

Awasthi, R.

3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Awaya, N.

4166 - Infiltration of Innate Immune Cells into Tumors By Polatuzumab Vedotin Treatment Contributes to Its Antitumor Effect in Xenograft and Syngeneic Mouse Models
4171 - Revealing the Synergistic Potential of Mosunetuzumab Plus Polatuzumab Vedotin through CD20 Upregulation

Awe, E.

3335 - Prevalence and Clinical Implications of Germline Variants in Multiple Myeloma Patients

Awed, O.

2250 - Bridging the Gap for Sickle Cell Disease Patient Data in Sub-Saharan Africa By Expanding Access to Specialty Biomarkers and Clinical Trials

Aweh, G.

3783 - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval

Awofisayo, O.

2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK

Awogbade, M.

2237 - Utilising Patient-Reported Experience Measures to Drive Healthcare Improvements: The Application of Validated PREM Survey Tools in a Haemoglobinopathy Network in South London

Awoyemi, T.

1134 - Differences in the in-Hospital Outcomes of Sickle Cell Crisis Among Patients with and without Liver Cirrhosis: A Nationwide in-Patient Analysis

Awuku, N.

3 - Double-Blind, Placebo-Controlled Randomized Controlled Trial of Hydroxyurea for HbSC: Results of the Prospective Identification of Variables As Outcomes for Treatment (PIVOT) Trial

Awuonda, B. O.

520 - Building Capacity in Sub-Saharan Africa to Address Sickle Cell Disease: The Consortium on Newborn Screening in Africa (CONSA)
541 - Newborn Screening for Sickle Cell Disease in Sub-Saharan Africa: Initial Results of the ASH Consortium on Newborn Screening in Africa (CONSA) Program

Awwalu, S.

1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)

Axenopoulos, A.

2228 - DeepSurf2-FF: Introducing Force Fields in Deep Learning for Improving in-Silico Prediction of Bcr-Antigen Interactions in B Cell Lymphomas

Ay, C.

1212 - Mim8 Prophylaxis Beyond Bleeding: Investigating Multifaceted, Patient-Reported Outcomes for Hemophilia A in the FRONTIER2 Study
1218 - Discriminating Factors of Bleeding Disorder of Unknown Cause in a Cohort of Patients with Mild to Moderate Bleeding Disorders
3981 - A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding
3984 - Rondaptivon Pegol (BT200) to Correct Thrombocytopenia in a Peri-Interventional Setting in Type 2B Von Willebrand Disease (VWD)
- Treatment of VTE in the Thrombocytopenic Cancer Patient

Aya, S.

741 - Spatially Resolved Single-Cell Transcriptomics of T Cells in Follicular Lymphoma Reveals Distinct Immune Ecosystems

Ayala, A.

1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Ayala, E.

507 - Impact of Total Body Irradiation-Based Conditioning Regimens on Outcomes in Patients with Aggressive Mature T-Cell Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplant
513 - Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
2088 - Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies
5129 - Impact of Extranodal Involvement on Outcomes with Chimeric Antigen Receptor T-Cell Therapy in B-Cell Non-Hodgkin Lymphoma

Ayala, R.

597 - Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis
1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial

Ayala, R.

658 - Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
3442 - CRISPR/Cas9 Multi-Editing Enhances CAR NK Cells Therapeutic Potential Against Multiple Myeloma
4526 - Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Ayanambakkam Attanathi, A. A.

4245 - Epidemiology, Outcomes, and Healthcare Utilization in Acute Myeloid Leukemia: A Study Using the National Inpatient Sample - 2021
4844 - Demographic Characteristics, Incidence and Outcomes of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients Undergoing CAR T-Cell Therapy: An Analysis of the National Inpatient Sample (NIS) - 2021
5023 - Unveiling the Impact of Anemia of Chronic Disease: A Comprehensive Analysis of Mortality, Length of Stay, and Hospitalization Costs Using the NIS 2021 Database

Ayansola, O.

1768 - Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML Patients

Ayaz, Q.

2222 - Measuring the Mosaicism of Genome Integrity and Toxicity Events Associated with Gene and Cell Therapies at a Single-Cell Level

Aydemir, I.

821 - Bone Marrow Microenvironment Dictates the Progression of Clonal Hematopoiesis through Stromal-Macrophage Cell-Cell Interactions
2451 - ICAM4 Mediates Human Erythroid Centered Island Formation
4093 - Germline DDX41 Mutations Disrupt Hematopoiesis and Microenvironment in Patient-Derived Bone Marrow Organoids

Aydilek, E.

114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

Aydin, D.

3367 - Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Aydın, S.

1094 - A New Diagnostic Method for Premarital Screening of Thalassemia and Hemoglobinopathies: Microchip Electrophoresis (Gazelle) Method

Aydinok, Y.

1191 - Analysis of Durability of Response to Avatrombopag (AVA) from a Phase 3b Multicenter, Randomized, Double-Blind, Placebo (PBO)-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of AVA for the Treatment of Pediatric Patients with Immune Thrombocytopenia

Aydinyan, N.

1293 - iPSC Reprogramming Identifies the Role of Cryptic Drivers in Preleukemic Clonal Evolution

Ayed, A.

5043 - Study Assessing the All4Cure Health Technology Intervention on Patient Activation in Multiple Myeloma

Ayemoba, C.

2 - Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging
4968 - Novel MET Inhibitors Provide a Therapeutic Opportunity for AML By Overcoming the Protective Action of the Bone Marrow Niche

Ayers, A.

571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
3235 - PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy

Ayers, A.

4377 - Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy
4396 - Treatment Patterns and Real World Outcomes with Clinical Trials for Patients with Follicular Lymphoma across Lines of Therapy
5121 - Identifying the Barriers of Clinical Trial Access after CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Ayers, A. A.

524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
1679 - Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases
1680 - Survival Outcomes and Genetic Assessment in Patients with Dual Diagnoses of B-Cell and T-Cell Lymphomas
2982 - Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma
3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
3733 - Perceptions of Clinical Trials and Factors Influencing Trial Participation Among Hispanic Patients with Non-Hodgkin Lymphoma
3746 - Factors Influencing Clinical Trial Participation Among Patients with Non-Hodgkin Lymphoma Receiving Care in a Safety Net Hospital
4348 - Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients
4454 - Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma
4506 - Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma
4508 - Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma

Ayers, E.

111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
573 - Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Ayguasanosa, J.

2570.1 - Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)

Aygun, B.

545 - Hydroxyurea Treatment Reduces Infection Rates in African Children with Sickle Cell Anemia
617 - Community Health Worker Engagement with Adolescents and Young Adults with Sickle Cell Disease: Findings from the Comets Study
1066 - Community Health Worker and Mobile Health Programs to Help Young Adults with Sickle Cell Disease Transition to Using Adult Healthcare Services -- the Comets Study; Results from Patient-Reported Outcomes at 6 Months

Aymard, M.

239 - Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

Ayoobkhan, F. S.

2008 - Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory Multiple Myeloma – a Meta-Analysis
5045 - Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma
5163 - Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma

Ayora, P.

2084 - The CAR-Hematotox Identifies Patients at High Risk of Infectious/Inflammatory Complications in a Cohort of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Treated with ARI-0001 (Varnimcabtagene Autoleucel)
3757 - Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT

Ayoub, E.

53 - Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML
61 - Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones
330 - TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML
1301 - Spatial Analysis of Human p53 Mutated AML Bone Marrow Reveals Novel MRD Clusters and Spatial Microenvironmental Features of p53 Mutated AML
1513 - Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up
2755 - Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells

Ayoub, R.

5174 - Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Aypar, U.

1556 - Adult AML Patients with NUP98 Fusions Are Frequently Therapy-Related, and Are Associated with Monocytic Differentiation, Recurring Mutations in NRAS, DNMT3A and WT1 and Poor Outcome
1589 - Genomic Characterization and Classification of BCL6 Rearranged Follicular Lymphomas

Ayres, J. D.

2982 - Use of Molecular Immune Signatures for Frontline Treatment Selection in Patients with Advanced Stage Follicular Lymphoma
4348 - Genomic and Spatial Proteomic Characterization of the Microenvironment of Diffuse Large B-Cell Lymphoma in African American Patients

Ayub, U.

1794 - Utilizing Large Language Models to Automate Prognostication in Patients with Myelofibrosis: A Retrospective Cohort Study

Ayuk, F. A.

114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
380 - Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd
384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
2073 - CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis
3456 - Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
3547 - Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation
3571 - Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission
4917 - Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation
5037 - Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

Ayupe, A.

4333 - Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML

Ayyadevara, V. S. S. A.

1455 - KMT2A-Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation
4216 - Targeting the SWI/SNF Chromatin Remodeling Complex Subunit SMARCA4 in ALL

Ayyappan, S.

4486 - Dynamics of Complete Responses in Patients with Relapsed or Refractory Diffuse Large B‑Cell Lymphoma Treated with Odronextamab in the ELM-2 Study

Ayyappan, S.

3080 - Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab

Ayzman, A.

1690 - Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study

Azaceta, G.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Azad, P.

1080 - A Single Mutation in the SENP1 Region Regulates the Excessive Erythropoiesis in the Andes

Azad, T.

381 - Multi-Omics Immune Profiling of Graft-Versus-Host Disease (GvHD) in Humans

Azam, M.

4541 - A Novel BCR::ABL1 Rearrangement Harboring the Gatekeeper Mutation Drives Hyper-Kinase Activity Conferring Resistance to Ponatinib and Asciminib Combination Therapy

Azar, S.

4999 - Exploring the Patient Perspective of Gene Therapy for Sickle Cell Disease

Azarias, G.

2388 - Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network

Azazi, D. M.

190 - Delayed Trp53 Activation Protects Dnmt3a-Mutant Haematopoietic Stem Cells from Inflammatory Attrition

Azevedo, J.

417 - Autosomal Recessive COPZ1 Mutations Cause Isolated Severe Neutropenia or Complex Syndrome with Severe Neutropenia

Azevedo, R. S.

583 - Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy
4611 - Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients

Aziz, A. R.

236 - Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Aziz, N. A.

1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)

Aziz-Bose, R.

402 - Pediatric RISE: Development of a Poverty-Targeted Cash Support Intervention for Pediatric Cancer
3649 - Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001
3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies
5130 - Food Insecurity and Cardiovascular Risk Among Survivors of Pediatric Hematologic Malignancies

Azizi, E.

381 - Multi-Omics Immune Profiling of Graft-Versus-Host Disease (GvHD) in Humans
928 - Deconvolving Immunologic Networks of the AML Marrow Microenvironment with Spatial Multi-Omic Profiling

Azmi, A.

2768 - Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia
3123.4 - An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation

Azolino, M.

5192 - Real-World Experience of Patients and Caregivers with Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis

Azoulay, E.

139 - Obinutuzumab in Rituximab Refractory or Intolerant Immune-Mediated Thrombotic Thrombocytopenic Purpura
1433 - Characteristics and Outcome Determinants in Children, Adolescents and Young Adults Who Failed Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia

Azouzi, S.

2489 - Defining Mechanistic Responses to Different Vaso-Occlusive Triggers in Sickle Cell Disease: A Step Towards Personalized VOC Reversal Strategies
2522 - Effect of Rituximab on Spleen and Blood B-Cell Subpopulations in Allo-Immunized Children with Sickle Cell Anemia

Azucenas, C. R.

1071 - Inducible, Erythroid-Specific Knockout of Codanin-1 in Adult Mice Replicates Congenital Dyserythropoietic Anemia Type-Ia

Azul, M.

2240 - Preparing for the Future: Themes in Transition Readiness for Individuals with Sickle Cell Disease Using the ASH Transition Readiness Assessment Tool
2309 - Pain-Specific Patient-Reported Outcomes Are Worse in Adults Compared to Children with Sickle Cell Disease

Azulay, N.

4813 - A Spatial Atlas of Human Gastro-Intestinal Acute Gvhd Reveals Epithelial and Immune Dynamics Underlying Disease Pathophysiology

Azumi, H.

2621 - Immediate Therapeutic Intervention for Acute Mortality in Immune-Mediated Thrombotic Thrombocytopenic Purpura with Positive Chest Findings at Initial Presentation

Azusawa, Y.

4811 - Preclinical Study of HLA Class I-Edited Allogeneic iPSC-Derived Virus-Specific T Cells Targeting Epstein-Barr Virus-Associated Lymphomas

Azzam, M.

1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis

Azzanelli, Y.

1471 - Real World Evidence of Efficacy of CPX-351 in Secondary Acute Myeloid Leukemia Defined According to Who 2022 Classification
1478 - High Risk Mutations in Critical Genes Do Not Significantly Affect Remission Rates and Minimal Residual Disease Clearance in Acute Myeloid Leukemia Patients Receiving CPX-351 Induction
1482 - Comparing Outcomes between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease
4239 - Excellent Outcome in NPM1-mutated Acute Myeloid Leukemia Patients Receiving Intensified Fludarabine-Based Induction Is Not Affected By Secondary Type Mutations and Other High Risk Aberrations

Azzi, J.

570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Azzi, J.

2088 - Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies

Azzimondi, C.

2916 - T/NK Cell-Associated Transcriptomic Profile Informs Response to FLT3 Inhibitors in Acute Myeloid Leukemia

Author Index: A